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Abstract 
Colon cancer is one of the most common cancers diagnosed in England. Despite the universal 
healthcare system, the most deprived groups of colon cancer patients have a poorer prognosis than 
the more affluent patients, particularly in the short-term following diagnosis.  
Comorbidity is considered to be a prognostic factor in cancer outcomes. Moreover, the presence of 
comorbidity tends to be associated with increased levels of socio-economic deprivation. In this thesis 
I investigated the role that comorbidity plays in socio-economic inequalities in ninety-day mortality 
after diagnosis with colon cancer. My research used population-based England national cancer registry 
data linked with Hospital Episode Statistics (HES), National Bowel Cancer Audit (NBOCA) and Route to 
Diagnosis data of approximately 100,000 patients diagnosed with colon cancer between 2009 and 
2013. 
This research emphasised the increased burden of comorbidity and multiple comorbidity among the 
most deprived cancer patients. The presence of comorbidity influenced the short-term mortality of 
the most deprived patients following diagnosis with colon cancer, but stage of diagnosis and the 
receipt of surgical treatment appeared to be influential factors in socio-economic inequalities in short-
term mortality. Accounting for time-varying proxy measures of comorbidity severity reduced some of 
the differences in ninety-day mortality between the most and least deprived patients with pre-existing 
diabetes, COPD and cardio-vascular conditions, but disparities in mortality still remained, suggesting 
other factors may be contributing towards inequalities between these groups of patients.  
The growing prevalence of multimorbidity and the comorbidity burden among cancer patients 
highlights a need for healthcare systems equipped and resourced for managing multiple chronic 
conditions simultaneously. Further investigation into healthcare utilisation and access to optimal care 
may provide insights into opportunities to improve outcomes of deprived patients living with chronic 
diseases who go on to develop cancer. Mechanisms to be explored include the interplay between 
deprivation, chronic disease burden, stage at cancer diagnosis and cancer treatment options.   
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Chapter 1 - Background 
 
The prevalence of chronic disease is increasing,1 as is the prevalence of people living with multiple 
chronic conditions, or multimorbidity.2-4 Non-communicable chronic diseases are responsible for 
considerable mortality and morbidity and thus represent an important public health issue.5 Among 
them, cancer is the second most common cause of death in the world after cardio-vascular diseases, 
and accounted for approximately 9.6 million deaths globally in 2018.6  
Colon cancer is one of the most commonly diagnosed cancers: approximately 8% of all cancers 
diagnosed in England in 2017 were cancers of the colon.7  Differences between socio-economic groups 
in terms of colon cancer prognosis are evident in England, with the most socio-economically deprived 
groups of patients having a poorer prognosis than the less deprived patients.8, 9 These inequalities 
have persisted despite government initiatives, such as the NHS Cancer Plan in England, that were 
designed to reduce them.10, 11 Moreover, socio-economic inequalities in colon cancer prognosis appear 
to be most apparent in the short-term following diagnosis.12  
Cancer patients living with additional chronic diseases, or comorbidities, may have poorer prognosis 
than those without,13 while the burden of living with multiple chronic diseases tends to be greater 
among the most deprived.14, 15 There is a lack of information in the scientific literature on the role of 
comorbidity in socio-economic inequalities in short-term cancer outcomes. More clarity in this will be 
informative for healthcare strategy and clinical guidelines to manage multiple chronic diseases 
simultaneously and to improve outcomes among more deprived groups of cancer patients.     
 




The colon, or large intestine, is made up of four parts - the ascending colon, the transverse colon, the 
descending colon and the sigmoid colon - and extends from the cecum to the rectum.16 It is the final 
part of the digestive system, and its function is to reabsorb fluids and to process waste products and 
prepare for their elimination from the body.16 Waste matter passes from the colon to the rectum for 
transportation or storage.17  
Approximately two-thirds of colorectal cancers originate in the colon.18, 19 Colon cancers and rectal 
cancers share similar aetiology. The majority of cases of colorectal cancer are sporadic,20 that is, they 
occur in people without a family history of colorectal cancer or an inherited change in their DNA that 
would increase their risk for developing this cancer.21  Non-hereditary risk factors for colorectal cancer 
include lifestyle factors and non-modifiable risk factors such as age and sex. Modifiable or lifestyle risk 
factors are responsible for up to 50% of the risk of colorectal cancer,18 and may include increased body 
weight22 and physical activity23, 24 or dietary factors such as increased consumption of red meat,18, 25, 
26 lower dietary fibre intake27 and excessive alcohol consumption.18, 28 There is evidence to suggest 
that tobacco smoking also increases the risk of developing colorectal cancer.22, 29, 30 Certain health 
conditions have been associated with an increased risk of developing colorectal cancer, such as 
Diabetes Mellitus.31 Inflammatory conditions, such as Crohn’s disease or ulcerative colitis, also carry 
some risk, but these conditions only account for 1-2 percent of all cases of colorectal cancers in the 
general population.20  
It is estimated that 10-30% of cases of colorectal cancer have a familial aetiology, in other words they 
occur in people who have biological relatives with a history of colorectal cancer or colorectal 
adenoma.18, 20  An additional 5% of colorectal cancers arise from inherited cancer susceptibility 





The incidence rate of colon cancer has historically been higher in developed countries than in less 
developed countries.25 This may be linked with dietary patterns,  given the prominence of the western 
diet (i.e. a diet with a high intake of fats and animal-source foods, refined carbohydrates and added 
sugars32) in many developed nations, and the association between this style of diet and incidence of 
colorectal cancer.33  The incidence of colon cancer typically increases with age,34 although recent 
evidence suggests colon cancer incidence has been increasing among younger people in England35  as 
well as in the United States36 and Europe.37 Incidence patterns according to age indicate that men may 
develop colorectal cancer earlier in their life than women.38 
The evidence regarding an association between colon (or colorectal) cancer incidence and socio-
economic position appears to be mixed. Some studies have reported measures of a lower socio-
economic position, for example income, education and occupation, as risk factors for colorectal 
cancers,39-42 while another reported the risk as being higher in affluent populations.43  The association 
between incidence and socio-economic position may be stronger in men, in comparison with 
women.39, 40, 43     
 
Prognosis 
Colorectal cancers are the fourth most common type of cancer diagnosed in England.44 One-year net 
survival (i.e. survival from cancer after accounting for death from other causes) among colon cancer 
patients is poorer than that among patients with other common cancers, such as cancer of the rectum. 
Among patients diagnosed with colon cancer in England, one-year age-standardised net survival from 
colon cancer was reported as approximately 75% in women and 77% in men, while it was 
approximately 82% from rectal cancer among both sexes.45 One-year net survival from colon cancer 
in England has been persistently poorer than in several comparable developed countries. For example, 
between 2005-2009, age-standardised one-year net survival was approximately 74% in England while 
in Canada, Sweden and Australia it ranged between 81% and 84% 46  
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Socio-economic inequalities and prognostic factors  
 
Patient characteristics, tumour characteristics and healthcare factors can all influence prognosis 
following colon cancer diagnosis. For example, factors such as patient age and tumour stage at 
diagnosis47 or comorbidity48 have been shown to be associated with one-year net survival from colon 
cancer. Socio-economic inequalities are found throughout the cancer continuum, from pre-diagnosis 
to receipt of palliative care.49 These inequalities are evident in colon cancer outcomes, and have been 
reported from 30-days following diagnosis12 up to one-year10, 11, 50 and beyond.12, 51-53  
Many of the studies investigating colon or colorectal cancer prognosis have focused exclusively on 
post-operative patients. Factors associated with thirty-day post-operative mortality following surgery 
include age,54 presence of comorbidity,55, 56 stage and operative urgency.57 A population-based study 
of colorectal cancer patients in England reported that the most deprived groups of patients had 32% 
increased odds of thirty-day post-operative mortality, even after adjusting for factors thought to differ 
between socio-economic groups, such as stage, comorbidity and emergency presentation.57 Age,58 
stage, and mode of surgery continued to be prognostic factors in mortality up to one year following 




The terms multimorbidity and comorbidity are widely, and often interchangeably, used in the scientific 
literature when discussing the prevalence of chronic health conditions or diseases. To distinguish 
between the two, multimorbidity is a general term that implies the existence of two or more diseases 
or conditions,60 while the term comorbidity describes the existence of a long-term health condition in 
the presence of a primary disease of interest.61  
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Risk factors for multimorbidity have not been widely researched.62 Multimorbidity within the general 
population tends to be most prevalent among older age groups, but there is also an association with 
socio-economic position.14, 15, 63 A study of 1.75 million patients in Scotland reported that onset of 
multimorbidity occurred 10-15 years earlier among people living in the most deprived areas, 
compared with those in the least deprived areas.64 Lifestyle factors such as tobacco smoking, dietary 
factors (such as lower intake of fruit, vegetables and whole grain foods), body mass index (BMI) and 
physical inactivity are potential risk factors for multimorbidity.65-68  
While the prevalence of multimorbidity is increasing,2-4 the management of these patients may be 
challenging within the confines of healthcare systems and guidelines that appear to be single disease 
focused.62, 64, 69 Therefore, the investigation of outcomes of patients with multiple chronic conditions 
is a pertinent topic for cancer research.   
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The overarching aim of this thesis is to investigate patterns in comorbidity in cancer patient 
populations, and to examine the role of comorbidity in the socio-economic inequalities in short-term 




1. Examine the influence of prognostic factors on socio-economic differences in ninety-day 
mortality among colon cancer patients 
2. Describe and evaluate the measurement of comorbidity prevalence in cancer patient 
populations, by deprivation  
3. Investigate the role of factors that could indicate severity of comorbid conditions, such as time 
with comorbidity and timing and duration of hospital visits since comorbidity diagnosis, on 





Population-based data used in this research 
 
The research conducted for this thesis used population-based National Cancer Registry data of up to 
102,216 patients diagnosed with colon cancer in England between the years of 2009 and 2013.70 These 
data were linked with electronic health records (Hospital Episode Statistics,71 HES), Route to Diagnosis 
data and with cancer-site specific clinical data (National Bowel Cancer Audit,72  NBOCA) compiled by 
clinicians working with patients in hospitals in multi-disciplinary teams. In addition, the research 
conducted for Chapter 4 of the thesis used the cancer registry data linked with HES records of patients 
diagnosed with cancer of the rectum (N = 56,342), lung (N=165,677) or with Hodgkin lymphoma (N= 
7,420) in England between 2009 and 2013.  Inclusion criteria were patients aged 15 years and over at 
cancer diagnosis, the diagnosis was of a primary or invasive tumour (i.e. the cancer originated at the 
respective cancer site or had spread into surrounding, healthy tissue), and there were at least six years 
of HES records prior to cancer diagnosis from which to obtain information on patient comorbidity.  
 
The data linkages were undertaken by Cancer Survival Group colleagues. The registry data was linked 
with HES and with NBOCA at the patient level using a hierarchical algorithm initially developed by 
Shack et al.73 and further developed internally. The algorithm was based upon availability of patient 
identifier variables (NHS number, postcode, date of birth and sex) and prioritised linkage of records 
according to the combination in which these patient identifier variables were available. Following this, 
tumour-level data were linked by patient variables, tumour site and diagnosis date.  
The registry data represented more than 99% of cancer registrations in England.70 Approximately 90% 
of these records linked with the HES records, while approximately 80% linked with NBOCA data. Route 
to Diagnosis information was linked with registry data using registry identifier and registry patient 
identifier variables present in both sources. Approximately 95% of registry records matched with 
known information on Route to Diagnosis.  
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National Cancer Registry data and Cancer Analysis System (CAS) 
Patients diagnosed with cancer in England are registered with the National Cancer Registry, which 
collects data about the patients and about the characteristics of the cancer or tumour. The cancer 
registry data used in this research provided information on date of diagnosis, vital status, date of last 
follow up and cancer site (based upon the coding system of the tenth version of the International 
Statistical Classification of Diseases and Related Health Problems, ICD1074). Cancer of the colon was 
identified by the ICD10 code C18, while cancers of the rectum or lung or Hodgkin lymphoma were 
identified by the ICD10 codes C19-C20, C34 and C81, respectively. Patient information obtained from 
the registry data included age at diagnosis, sex and residential postcode at the time of cancer 
diagnosis. Cancer Analysis System is a national database that combines cancer registry data with data 
from other sources. These data provided information on pathological and clinical staging components 
and summary stage at diagnosis (based on the Union for International Cancer Control (UICC) TNM 
classification of malignant tumours75).  
 
Hospital Episode Statistics (HES) 
The HES data provided information on inpatient admissions (Admitted Patient Care) and outpatient 
appointments at National Health Service hospitals pre- and post-cancer diagnosis. These data were 
available for hospital admissions or appointments occurring between 1st January 2003 and 31st 
December 2013. Inpatient admissions records are defined in terms of ‘episodes’ – an episode is a term 
given to define a period of care in hospital under one consultant, and is represented by one 
observation in these data. Single admissions to hospital (or ‘spells’) can be made up of multiple 
episodes. The outpatient data capture same-day appointments with healthcare practitioners in 
hospitals.   
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These data were used to obtain information on comorbidities diagnosed up to six years pre-cancer 
diagnosis. This six-year lookback was based on previous research on the optimal lookback period 
required to capture information on comorbidity.76 The diagnostic fields within inpatient records and 
outpatient records contained ICD10 codes, which provided information on the condition(s) the 
patients had. Hospital episode start and end date variables in the inpatient records, and appointment 
date variables in the outpatient records, were used to derive information on the (minimum) time with 
the comorbid condition. Episode date variables (and a variable defining the order in which multiple 
episodes occurred) were used to derive the frequency and duration of hospital admissions since the 
condition was first recorded in HES.  
Information on the type of surgical procedure received was available in the inpatient and outpatient 
data, and was based upon the coding of the Classification of Interventions and Procedures, fourth 
version - OPCS-4.77 These data also provided information on the date a surgery occurred, and whether 
it was performed as an emergency or an elective procedure.  
 
National Bowel Cancer Audit data (NBOCA) 
The NBOCA data are clinical data compiled by clinicians and other healthcare professionals working 
with colorectal cancer patients in hospitals as part of multi-disciplinary teams. These data were used 
to obtain information on the primary surgical treatment that the patient received (according to OPCS-
4 codes), the date of the surgery, and stage at diagnosis (obtained using the available information on 
TNM pathological and clinical staging components and summary stage). This information was used in 
the research conducted in Chapter 3 of this thesis.  
 
Route to Diagnosis  
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This is derived from an algorithm that uses information on patient pathways from HES, cancer registry 
data and other cancer-specific data sources (Cancer Waiting Times and cancer screening data) to 
categorise every case of cancer registered in England into one of eight Routes to Diagnosis.78 Routes 
include GP referrals, screening and emergency presentation. This variable was used to identify 
patients who had been diagnosed with colon cancer via emergency presentation. 
 
Income Deprivation domain of the Indices of Multiple Deprivation (IMD) 
The measure of socio-economic deprivation used in the research conducted for this thesis was the 
Income deprivation domain of the Indices of Multiple Deprivation (IMD).79 This is an ecological 
measure of deprivation, and represents the proportion of the population at the Lower layer Super 
Output Area (LSOA) (mean population 1,500) level experiencing deprivation due to low income.  
The Income Deprivation domain score represents the number of individuals with income deprivation 
within an LSOA as a proportion of all individuals within that LSOA. The number of income deprived 
individuals is calculated by summing the following five indicators:80 
i) Adults and children in Income Support families 
ii) Adults and children in Income-Based Jobseeker’s Allowance families 
iii) Adults and children in Pension Credit (Guarantee) families 
iv) Adults and children in lower income Child Tax Credit families (income below 60% of the 
median), and  
v) Asylum seekers in receipt of subsistence or accommodation support  
The domain score is used to rank all LSOAs from most to least deprived, and the order of these rankings 
determines the grouping of LSOAs into deprivation quintiles. My research used the quintiles of the 
Income Deprivation domain. Residential postcode at the time of cancer diagnosis was used to 
determine a patient’s LSOA and thus their deprivation quintile.  
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Development of algorithms  
 
During the course of the research conducted for this thesis, I worked on the development of 
algorithms to obtain robust information on key variables of interest from these data sources.  
 
Stage at diagnosis 
The CAS and clinical audit (NBOCA) data both provided information on stage at diagnosis. I assisted in 
the development of a hierarchical algorithm to derive the most robust definition of stage using 
information from both data sources, to manage discrepancies between the two sources, and to 
manage the scenario in which information is missing in one but not both sources. The algorithm 
provides a single stage category for each tumour based on a prioritisation of information according to 
data source and the various individual components of tumour stage. It follows a restrictive or non-
restrictive approach to summarising stage, according to the availability of information for each of the 
tumour (T), lymph nodes (N) and distant metastases (M) components, and is based upon the rules of 
the UICC TNM classification system.75 I was a co-author of a paper published in the British Journal of 
Cancer in 2016 detailing the methodology behind this algorithm.81 
In deriving the stage at diagnosis variable, the clinical audit data (NBOCA) were the preferred data 
source of T, N and M staging component information, while CAS supplemented missing NBOCA data.  
Within the NBOCA data it was possible to have multiple records for a single tumour, and thus 
potentially differing information on the T,N and M components. To address this, the algorithm 
prioritised the staging information on the date closest to the date of cancer diagnosis. In the rare event 
that there were multiple records for that tumour on that particular date, the record with the lowest 
values of individual T, N and M components was given priority, in line with general TNM classification 
rules.75  
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The following step of the algorithm was to select the individual T, N and M components from 
pathological, clinical or unknown (integrated) sources of information. The pathological information 
was prioritised over the clinical information for T and N because microscopic evidence was assumed 
to better determine tumour extent and nodal involvement than clinical sources.82 For M, clinical 
information was given priority over pathological information.82 Lastly, clinical or pathological data was 
prioritised over T, N or M information from an unknown source.  
The final part of the algorithm was to apply the TNM definitions75 for grouping of stage to obtain a 
summary TNM stage variable. The algorithm considers the values of M, N and then T to summarise 
stage into one of four classifications – from stage 1 (local) to stage 4 (metastatic). The summary stage 
variable used in the analyses conducted for this thesis had been derived using a restrictive approach 
– i.e. only considering observations of tumour stage in which valid information was available for all 
individual TNM components. The process followed by the algorithm to derive grouped TNM stage via 
the restrictive approach is illustrated in Appendix Figure 1. 
 
Comorbidity 
I assisted in the development of an algorithm to extract information on 17 of the conditions of the 
Charlson Comorbidity Index83 (Table 1.1) plus obesity, using information in the diagnostic fields of HES 
records. Each of the conditions was defined according to the grouping of ICD10 codes for that 
condition proposed by Quan et al.84 The algorithm generated binary variables for each condition for 
each six-month time interval up to ten years prior to cancer diagnosis, to indicate if it had been 
recorded during any hospital admissions occurring  during that interval. Using these binary variables, 
it was then possible to summarise the comorbidities present during any given timeframe up to ten 
years prior to cancer diagnosis. I was a co-author on a paper describing the methodology behind this 
algorithm, which was published in PLoS One in 2017.76 
21
 
Table 1-1  The seventeen conditions of the Charlson Comorbidity Index included in the algorithm 
Conditions 
Myocardial infarction Congestive Heart Failure  
Peripheral Vascular Disease  Cerebrovascular Disease 
Dementia Chronic Obstructive Pulmonary Disease 
Rheumatic Disease Peptic ulcer disease 
Mild liver disease Diabetes without chronic complications 
Diabetes with chronic complications Hemiplegia or paraplegia 
Renal disease Moderate or severe liver disease 
AIDS/HIV Any malignancy 
Metastatic solid tumours  
 
 
Receipt of major surgery  
Information on surgical treatment received was available from both the NBOCA and HES data. I 
developed an algorithm to extract information on the first major surgery received in the time window 
from 30 days prior to 90 days following cancer diagnosis. Major surgery was considered to be surgery 
with curative intent, and was categorised as such according to definitions agreed by National Cancer 
Intelligence Network Site Specific Clinical Reference Groups.85 The algorithm also defined whether the 
surgery was received as an elective procedure, or following emergency presentation, using 




Chapter 2 - Comorbidity and cancer 
 
The presence of additional chronic conditions can be influential at several points on the cancer patient 
pathway, from the time leading up to the diagnosis of cancer to ultimate cancer prognosis. 
Additionally, there is some evidence suggesting that these comorbidities may explain some of the 
social or socio-economic disparities in cancer prognosis. This is discussed in more detail in the 
following manuscript, “The role of comorbidities in the social gradient in cancer survival in Europe”, a 
chapter I drafted for a book entitled “Social environment and cancer in Europe: towards an evidence-
based public health policy” to be published by Springer.  
The research conducted for writing this book chapter involved reviewing the published scientific 
literature on studies investigating comorbidity as an explanatory factor in social or socio-economic 
inequalities in survival or mortality from any type of cancer. The literature search was undertaken 
using Medline, EMBASE and Pubmed databases using the keywords in Table 2.1 for articles published 
between January 1990 and November 2019. The review was restricted to articles written in English.  
 
Table 2-1: Topic and search terms for literature review 
Topic Search terms 
Primary disease cancer OR malig* 
Comorbidity comorbid* OR multimorbid* 
Social position  socio* OR social OR income OR educ* OR 
occuptation*  
Social gradient Inequal* OR inequit* OR gradient 
Survival Survival OR mortality OR prognosis 
 
The book chapter firstly examines the role of comorbidity as a prognostic factor in cancer outcomes, 
considering how it may influence stage at cancer diagnosis and the management of cancer following 
diagnosis. It then reports and summarises the findings of the published scientific studies from 
European countries examining the role of comorbidity in inequalities in cancer survival.  
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The chapter is included in this thesis in its entirety and in manuscript format, as submitted to the book 
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The role of comorbidities in the social gradient in cancer survival in Europe 
 
Helen Fowler, Pamela Minicozzi, Miguel Angel Luque-Fernandez and Bernard Rachet 
 
Social disparities in cancer survival in Europe are evident, as discussed in earlier chapters of this book. 
Survival is commonly worse among the more socio-economically deprived cancer patients, an issue 
that is pertinent for many different cancer types. The prognosis of cancer patients can be affected by 
the presence of additional diseases or comorbidities, with the more deprived patients tending to 
experience a higher prevalence of comorbid conditions. This chapter aims to examine the role played 
by comorbidities on the social gradient in cancer survival that is often observed in Europe.  
To illustrate the interconnections of comorbidity, and variables associated with comorbidity, with 
these social inequalities, the Directed Acyclic Graph (Fig. 22.1) depicts assumed causal relationships 
between social position and cancer survival. The chapter will discuss these relationships in turn, and 
will then summarise the findings of published scientific studies investigating comorbidity as an 





























Fig. 22.1 Directed Acyclic Graph (DAG) illustrating the interconnections of comorbidity in the 
relationship between social position and survival from cancer 
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22.1 Defining comorbidity 
 
The terms multimorbidity and comorbidity are frequently used in the literature when discussing 
disease prevalence. Multimorbidity is a broad term that refers to the presence of two or more chronic 
diseases, while comorbidity describes one or more other chronic diseases that co-exist with a primary 
disease of interest (Porta et al. 2014). Comorbidity is commonly considered as a prognostic factor in 
cancer outcomes (Sarfati et al. 2016). The distinction between multimorbidity, comorbidity and 
related terms is particularly timely with the ever-increasing number of studies examining the impact 
of multiple chronic conditions (Nicholson et al. 2019). Indeed, the Pubmed Medical Subject Headings 
(MeSH) were updated in January 2018 to include multimorbidity as a separate term from comorbidity.  
 
Although there are a variety of approaches to quantifying comorbidity within the scientific literature, 
there is no agreed gold standard for measuring comorbidity in the presence of cancer (Sarfati 2012). 
The lack of consensus in the best approach to defining and measuring multiple chronic diseases 
challenges the ability to compare findings across populations and draw upon this for the development 
of guidelines and interventions (Johnston et al. 2019). Studies of comorbidity and cancer outcomes 
may define comorbidity in terms of specific chronic conditions (Bare et al. 2017) or consider the 
patient’s full comorbidity burden based on a summary metric, such as the widely-used Charlson 
Comorbidity Index (CCI) (Charlson et al. 1987). Other metrics of comorbidity often used in the cancer 
patient setting include the Adult Comorbidity Evaluation – 27 (ACE-27) developed for adult cancer 
patients (Piccirillo et al. 2008), and the Elixhauser index (Elixhauser et al. 1998) or age-adjusted CCI 
(Charlson et al. 1994) which are not specific to cancer patients. Another variable in quantifying 
comorbidity relates to the time window during which the presence of comorbidities is considered 
relevant for defining the patient’s comorbidity status once the cancer has been diagnosed. Studies 
have investigated the overall lookback time period for comorbidities and / or the length of the time 
that is excluded prior to primary disease diagnosis (Preen et al. 2006; Shack et al. 2010; Maringe et al. 
2017), offering different perspectives on the most appropriate time period to use. It may not be 
possible to establish a universally agreed ‘optimal’ time window, given that this window may vary 
between studies, depending on the research question and underlying assumptions towards 
comorbidity. Another anomaly is whether summary metrics used for cancer comorbidity should 
consider previous malignancies as a comorbidity. Additionally, there are a variety of sources of 
patient-level information on cancer comorbidity ranging from information collected during cancer 
treatment clinical trials to routine, administrative sources such as primary or secondary care data. In 
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comparing data sources, the strengths and limitations of each can vary according to quality, reliability 
and generalisability (Geraci et al. 2005).  
 
22.2. Social gradient in comorbidity prevalence 
 
Comorbidity prevalence has been shown to be associated with socio-economic position, both in a 
general context (Macleod et al. 2004; McLean et al. 2014; Moffat and Mercer 2015)  - i.e. not specific 
to a nominated primary disease - and within the context of cancer (van Leersum et al. 2013; Aarts et 
al. 2015; Fowler et al. 2020). For example, one study found mixed physical and mental health 
multimorbidity was more common among more deprived than less deprived people at all ages under 
75 years (McLean et al. 2014). Furthermore, a low socio-economic position was observed to be 
associated with a higher risk of comorbidity, independently from the cancer under study (Louwman 
et al. 2010; Fowler et al. 2020). 
Additionally, many cancers and comorbid conditions share common aetiological risk factors, which in 
turn are associated with increasing levels of socio-economic deprivation. For example, the 
development of common cancers such as lung or colorectal cancers has been linked to tobacco 
smoking (Schottenfeld and Fraumeni 2006; Tindle et al. 2018), dietary habits and alcohol use (Danaei 
et al. 2005; Haggar and Boushey 2009). Tobacco smoking is also linked to conditions such as chronic 
obstructive pulmonary disease (Devereux 2006; Buist et al. 2007; Laniado-Laborín 2009) and Type 2 
diabetes (Hu et al. 2001; Wannamethee et al. 2001), and with socio-economic position (Cavelaars et 
al. 2000; Giskes et al. 2005; Huisman et al. 2005; Hiscock et al. 2012). Other risk factors such as poor 
dietary habits, lack of physical activity and obesity can also typically follow a social gradient (Alcaraz 
et al. 2020). The risk of excess alcohol consumption and binge drinking has been shown to be socio-
economically patterned (Fone et al. 2013), while alcohol consumption and raised body mass index are 
both associated with liver disease, with evidence of a synergistic interaction between the two (Hart et 
al. 2010). Moreover, health conditions that are typically most prevalent among people of a lower 
socio-economic position, such as diabetes (Fano et al. 2013; Grundmann et al. 2014; Kim et al. 2015), 
can be associated with an increased risk of a wide range of cancers (Dankner et al. 2016).  
 
22.2.1. Comorbidity prevalence among cancer patients in Europe 
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Within the epidemiological literature, studies investigating the role of comorbidity in cancer outcomes 
often summarise the overall comorbidity status of a patient. European studies providing detailed 
discussion of the prevalence of comorbid conditions among cancer patients are fairly limited in 
number, and the majority of the research has been conducted in the north rather than in the south of 
Europe. Several studies conducted in the Netherlands suggest that the prevalence of chronic disease 
has increased over time (Uijen and van de Lisdonk 2008; van Leersum et al. 2013; Aarts et al. 2015; 
van Oostrom et al. 2016). Moreover, the rise in chronic non-communicable diseases, including cancer, 
is likely to increase dramatically during the coming years in line with the changing demographic 
structure of the population due to the ageing phenomenon (Thun et al. 2010; World Health 
Organisation and US National Institute of Aging 2011). The annual number of new cancer cases 
worldwide is projected to rise to 17 million by 2020 and to reach 27 million by 2030 (Sutcliffe 2012). 
Although the population of Europe represents only one eighth of the total world population, currently 
one quarter of the global total of cancer cases are in Europe (World Health Organisation 2020).  
 
Among the studies of cancer comorbidity in Europe, a study of small-cell lung cancer (SCLC) patients 
(Aarts et al. 2015) and another of colorectal cancer patients (van Leersum et al. 2013) found low socio-
economic status was associated with increased odds of having one or more comorbidity or multiple 
comorbidities. Common conditions among the SCLC patients were pulmonary disease, cardiac disease 
and hypertension, while hypertension and cardiac diseases were also common among colorectal 
cancer patients. In a Spanish study of colorectal cancer patients in two provinces, congestive heart 
failure, diabetes and chronic obstructive pulmonary disease were the most common comorbidities 
among patients (Luque-Fernandez et al. 2020b), while hypertension, diabetes and chronic obstructive 
pulmonary disease were the three most common comorbid conditions among patients diagnosed with 
colorectal cancer or with lung cancer in England (Fowler et al. 2020). The prevalence of most of the 
comorbid conditions studied, and the probability of having the condition as one of multiple 
comorbidities, was associated with the highest level of socio-economic deprivation. The most frequent 
conditions in breast cancer patients in the south of the Netherlands were cardiovascular disease, 
diabetes mellitus and previous cancer (Louwman et al. 2005). Some of the studies of multimorbidity 
prevalence discuss comorbidity among cancer patients. In a Scottish study, chronic obstructive 
pulmonary disease (COPD) and diabetes were among the most frequent comorbid conditions present 
in cancer patients, and the prevalence of the comorbid conditions was higher among the most 
deprived group of cancer patients, compared with the least deprived group (Barnett et al. 2012).  
Similar findings to these were reported in a study of multimorbidity in Denmark (Schiotz et al. 2017).  
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In examining risk factors for development of certain comorbidities, studies of tobacco smoking 
prevalence in Europe suggest that socio-economic inequalities in smoking were increasing in many 
countries towards the end of the last century (Giskes et al. 2005). While in northern European 
countries smoking was more common in lower educated than in higher educated people at that time, 
the opposite pattern was reported in southern European countries, where smoking was more 
common in people with higher educational attainment (Cavelaars et al. 2000), particularly women 
(Huisman et al. 2005). Tobacco control policies introduced in European countries in the 2000s may 
have helped to reduce the prevalence of smoking in the total population, particularly in lower socio-
economic groups, but their effect on the extent of socio-economic inequalities is not clear (Hu et al. 
2017). Moreover, socio-economic inequalities in smoking cessation rates increased during the 2000s 
(Bosdriesz et al. 2015).  In a comparative study of forty-three European countries, the countries with 
the highest summary scores for health policy performance (summarising 10 areas of health policy 
contributing to major population health gains, including tobacco control) were Nordic countries 
(Sweden, Norway, Iceland and Finland, in respective order) (Mackenbach and McKee 2013). 
 
22.3. Role of comorbidity as a prognostic factor in cancer outcomes 
 
22.3.1. Comorbidity may influence stage of diagnosis 
 
Fleming posited four hypotheses to explain the relationship between comorbidity and stage at cancer 
diagnosis (Fleming et al. 2005), and similar ideas have also previously been discussed by others (Kiefe 
et al. 1998; Newschaffer et al. 1998; Vaeth et al. 2000). These are: 
 The ‘surveillance’ hypothesis: patients with other chronic diseases are likely to have sought 
medical assistance more often and had more opportunity for early cancer diagnosis.  
 The ‘physiological’ hypothesis: the presence of comorbidity is associated with a more 
advanced stage of disease. Certain types of comorbidity and cancer may interact at a cellular 
or physiological level to increase aggressiveness or metastasis of the tumour.  
 The ‘competing demands’ hypothesis: also relates to a more advanced stage of disease, where 
management of chronic types of comorbidity may divert patient and clinician attention from 
early symptoms of a tumour.  
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 The ‘death from other causes’ hypothesis: most applicable to patients with poor prognosis, 
such as those with a heavy comorbidity burden, where undergoing cancer screening and / or 
diagnostic testing would not represent a benefit to the patient.   
Although the presence of pre-existing comorbidity can be influential in the stage at which a cancer is 
diagnosed, this may vary according to the type of cancer, the individual comorbid condition, and the 
overall burden of the comorbidity (Sarfati et al. 2016). Research articles endorse the ‘surveillance’ 
hypothesis (Fleming et al. 2005; Sarfati et al. 2016; Salika et al. 2018; Renzi et al. 2019a) and the 
‘competing demands’ theory (Sarfati et al. 2016; Park et al. 2017). Others suggest that the presence 
of comorbidity may increase the likelihood of a patient not receiving a stage of disease at diagnosis 
(Gurney et al. 2015), supporting the ‘death from other causes’ hypothesis. In the case of colorectal 
cancer, a longer time to diagnosis has been observed in patients with pre-existing comorbid 
conditions, whether the comorbid condition represented a ‘competing demand’ or an ‘alternative 
explanation’ to colorectal cancer (Mounce et al. 2017).  
Emergency presentation for medical assistance with symptoms of cancer can be a factor in the 
relationship between comorbidity and stage of cancer diagnosis. Presentation via an emergency 
hospital admission is most common in patients with serious or complex pre-existing comorbidities 
(Renzi et al. 2019b) or a higher overall burden of comorbidity (McPhail et al. 2013). In turn, tumour 
diagnosis via emergency presentation may be associated with later stage of diagnosis (McPhail et al. 
2013).  
 
22.3.2. Comorbidity may Influence cancer management and therapeutic options 
 
Comorbid cancer patients may be less likely that those without other chronic diseases to receive 
curative treatment (Sarfati et al. 2016), although there is some evidence to suggest that patients with 
comorbidity who receive treatment have better prognosis for survival than those who do not (Sarfati 
et al. 2009). Decisions to offer treatment to patients may be made based on the type and severity of 
comorbidity. For example, there is evidence to suggest that the presence of COPD may influence 
receipt of surgical treatment among early stage non-small cell lung cancer patients (Belot et al. 2019) 
and influence receipt of adjuvant therapy in colon cancer patients (Gross et al. 2007). Treatment 
decisions made for comorbid patients may also be influenced by the attitude of physicians – for 
example, in one study, older physicians were less likely to recommend adjuvant chemotherapy to 
colon cancer patients compared with younger physicians (Keating et al. 2008). Older age 
(Mellemgaard et al. 2015), stage at diagnosis (Noer et al. 2017), and socio-economic position (Aarts et 
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al. 2013b) may influence treatment received by cancer patients with comorbidity, although socio-
economic inequalities in cancer management have also been related to age at diagnosis rather than 
comorbidity status (Rollet et al. 2018). 
 
22.3.2.1. Clinical management of comorbidities with cancer among European countries  
 
Despite the high prevalence of multimorbidity among cancer patients, cancer treatment guidelines 
generally focus on single-disease management (Guthrie et al. 2012; Tinetti et al. 2012). However, the 
effective management of multimorbidity is important in optimizing the cancer patient’s health status 
(McLean et al. 2014) and decisions regarding cancer treatment among the elderly cancer patients 
require careful consideration of comorbidities and multimorbidity (Gurney et al. 2015; Stairmand et 
al. 2015; Sarfati et al. 2016). Furthermore, postoperative complications occur more frequently in 
patients with multimorbidity (Søgaard et al. 2013) and certain comorbid conditions have been linked 
to adverse outcomes following surgery for cancer (Cauley et al. 2015; Sarfati et al. 2016). A challenge 
for clinicians and oncologists in managing comorbid cancer patients is that health care systems may 
not be designed for the simultaneous management of two or more chronic conditions (Boyd and Fortin 
2010; Barnett et al. 2012; Tinetti et al. 2012). In the United Kingdom, clinical guidelines are not 
adaptive to the cumulative impact of treatment recommendations on those with multiple chronic 
conditions, and do not facilitate a comparison of potential benefits or risks (Hughes et al. 2013). A 
study that investigated the influence of comorbidity on breast cancer treatment and outcomes in 9 
European countries concluded that women without comorbidities and of a younger age were most 
likely to receive prompt, standard treatment for breast cancer (Minicozzi et al. 2019). However, it is 
unclear from the literature whether the apparent under treatment reflects appropriate consideration 
of greater toxicity risk, poorer clinical quality, patient preferences, or poor adherence among patients 
with comorbidity (Søgaard et al. 2013). Ovarian cancer patients in Denmark with moderate or severe 
comorbidity may often experience longer health system delays then patients with no or mild 
comorbidity (Noer et al. 2017).  
    
22.4. Comorbidity and cancer survival in Europe 
 
Much of the research conducted in Europe towards understanding the influence the presence of 
comorbidity has on cancer survival, and on socio-economic inequalities in cancer survival, is based 
upon studies of patients in the north of Europe. Commonly studied cancers in this context are sex-
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specific cancers such as breast or ovarian cancers in women or prostate cancer in men. Within the 
literature on this topic, studies investigated all-cause survival, survival from the cancer, or both. This 
section discusses the available scientific literature on the role of comorbidity in cancer survival and 
also research that investigates how comorbidity may be an influential factor in social inequalities in 
cancer survival.  
 
22.4.1. Comorbidity and survival 
 
The role of comorbidity in survival following cancer diagnosis is complex. The presence and burden of 
comorbidity can impact or be impacted by other prognostic factors, such as whether the patient 
receives curative surgery (Sarfati et al. 2016). Thus, it is plausible to have a scenario where cancer 
survivors with comorbidities have worse survival than those cancer patients without comorbidities, 
but more evidence is needed regarding the presence of multimorbidity and cancer survival. Similarly, 
there are scenarios where cancer survivors with a particular comorbidity and cancer have a better 
relative survival than those with the same comorbidity yet without cancer, but these scenarios are 
underreported (Renehan et al. 2019). 
 
In respect to breast cancer prognosis, one study reported little difference in 1-year and 5-year survival 
between groups of women defined according to their Charlson Comorbidity Index (CCI)(Charlson et 
al. 1987) score (0, 1 and 2+) (Carlsen et al. 2008), while another reported differences between Charlson 
score groups and flagged that survival was poorer among patients with comorbid disease (Cronin-
Fenton et al. 2007). A study of women with early-stage breast cancer identified that patients with any 
comorbidities had an increased risk of dying from all causes, but only the presence of peripheral 
vascular disease, dementia, chronic pulmonary disease, liver disease and renal disease significantly 
increased the risk of dying due to breast cancer (Ewertz et al. 2018). In studies of women diagnosed 
with breast cancer in the Netherlands, comorbidity appeared to have an independent prognostic 
effect on survival (Louwman et al. 2005), except for tumours with poor prognosis (Janssen-Heijnen et 
al. 2005). Severity or burden of comorbidity was also associated with prognosis (Louwman et al. 2005; 
Houterman et al. 2004). In a Spanish study of three cancers including breast cancer, 5-year survival 
decreased as comorbidity burden increased, but stage of diagnosis was the strongest predictor of 
survival (Parés-Badell et al. 2017).   
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Among ovarian cancer patients in Denmark, there was evidence to suggest that women with 
comorbidity had a 17% higher risk of death compared to women without comorbidity, after adjusting 
for other prognostic factors such as age, stage, residual tumour, histology and performance status 
(Sperling et al. 2013). Similarly, in another study of ovarian cancer patients in Denmark and Sweden, 
comorbidity was associated with survival (Noer et al. 2018). Prognosis was poorer among the women 
in Denmark, although comorbidity did not explain survival differences between the two countries. 
Comorbidity was also an independent predictor of worse 5-year survival from cancer among surgically 
treated patients with vulvar carcinoma in Italy (Di Donato et al. 2019). 
 
Among non-small cell lung cancer patients in Denmark, patients with cardiovascular comorbidities 
(acute myocardial infarction or congestive heart failure) had a 30% excess mortality versus patients 
without comorbidity, whereas patients with diabetes and patients with cerebrovascular disorders had 
a 20% excess mortality (Iachina et al. 2015). Severity of comorbidity was prognostic of mortality among 
resected non-small cell lung cancer patients, and was associated with lower stage-specific 5-year 
survival in patients with early stage (pT1) disease (Luchtenborg et al. 2012). Conversely, Mellemgaard 
and colleagues only found comorbidity to have a limited effect on survival only among lung cancer 
patients treated with chemotherapy (Mellemgaard et al. 2015). In lung cancer patients in France, 
comorbidity was only associated with lower survival in patients with small cell cancers (Seigneurin et 
al. 2018).  
 
Severity of comorbidity was associated with lower cancer-related 1-year survival in colorectal cancer 
patients in England, even after adjusting for age and stage (Shack et al. 2010) and was associated with 
lower 1-year cancer-related survival in invasive bladder cancer patients in Denmark (Lund et al. 2010). 
Furthermore, recently it has been shown that multimorbidity significantly increased the time-to-
surgery among patients with colorectal cancer in Spain (Luque-Fernandez et al. 2020b). This is possibly 
because multimorbid patients need to be brought to a healthier status before undergoing a surgical 
treatment. Also, multimorbidity was a strong independent predictor of short-term mortality at 6 
months and 1 year among colorectal cancer patients in Spain (Luque-Fernandez et al. 2020a). 
Comorbidity was also prognostic of mortality in bladder cancer patients in the Netherlands, after 




22.4.2. Comorbidity and social inequalities in survival in Europe 
 
Conclusive information on the underlying causes of social inequalities in cancer survival is sparse. As 
discussed, comorbidity can interact with tumour characteristics and health care (e.g. receipt of 
treatment and cancer management) in determining patient prognosis. Furthermore, many studies 
consider comorbidity in combination with other prognostic factors when investigating social 
inequalities in cancer survival.  Different approaches to defining and measuring comorbidity, and 
variation in measures (or proxy measures) of social or socio-economic position can limit the 
opportunity to draw comparisons across the literature.  
 
We have summarised the published studies reporting on the potential role of comorbidity on the 
social gradient in cancer survival in European countries (Table 22.1). The results presented in many of 
these studies were in a format that showed differences in survival or mortality between social groups 
following progressive adjustment for comorbidity and other factors in the analysis models. Where 
possible, we calculated the percentage change of social inequalities in the outcome reported using 
the equation ([HRBasic model – HRBasic model + comorbidity])/[HRBasic model – 1] x 100, an approach used in a 
published review of socio-economic inequalities in prostate cancer survival (Klein and von dem 
Knesebeck 2015). Of the studies found (n=14), half of the studies were of female cancers: breast (Aarts 
et al. 2011; Larsen et al. 2015; Morris et al. 2016; Morris et al. 2017), cervical (Ibfelt et al. 2013), 
endometrial (Seidelin et al. 2016) or ovarian (Ibfelt et al. 2015) cancer. The remaining were prostate 
(Li et al. 2012; Aarts et al. 2013b), colorectal (Frederiksen et al. 2009a; Frederiksen et al. 2009b), or 
lung cancer (Dalton et al. 2015), or studies of more than one type of cancer (Aarts et al. 2013a; 
Louwman et al. 2010). The studies were undertaken in the north of Europe: in Denmark (n=7), England 
(n=2), Netherlands (n=4) and Sweden (n=1).  
The contribution of comorbidity in reducing social inequalities in breast cancer survival was similar 
among screen detected and non-screen detected patients in the Netherlands (Aarts et al. 2011) and 
in England (Morris et al. 2016): comorbidity was responsible for approximately 20% and 10% of socio-
economic inequalities in these groups, respectively, in both countries.   
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Table 22.1 Research articles discussing comorbidity and social inequalities in cancer survival or mortality, according to cancer type 













Percentage change of 
social inequalities in 
outcome due to 
comorbidity†◊ 
Findings 
Female cancers  
Aarts et al.  
(2011) 
Breast Netherlands Women invited 





1998 - 2006 Charlson Comorbidity 
Index (CCI) 

















(1.30 to 1.23) 
Interval cancer: -7% (1.72 to 
1.67) 
Not screened: -12% (1.42 to 
1.37) 
Comorbidity 






Larsen et al. 
(2015) 








1993 - May 
1997 
CCI: one year before 
cancer diagnosis 








lymph node status, 






Education: -6% (1.35 to 
1.33) 
Income: -89% (1.09 to 1.01)  
Comorbidity and 
other prognostic 
factors affected but 
did not explain the 
social gradient in 
death after breast 
cancer 
Morris et al. 
(2016) 
















Year of diagnosis 












women: -11% (1.44 to 1.39) 
Screen-detected: -18% 
(1.66 to 1.54) 
Adjustment for 
comorbidity 
resulted in a slight 
change in excess 
hazard of death in 
the most deprived 
women in both 
non-screened and 
screened groups  











1989 - 2006 CCI score (0, 1+) Deprivation 
(Income domain 




by each factor of 
interest in turn 
Net survival, 
% 
Calculation not possible as 
data not provided 
Persistent trend of 
lower net survival 




and other factors 
studied (obesity, 
alcohol intake and 
smoking status) 
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Percentage change of 
social inequalities in 
outcome due to 
comorbidity†◊ 
Findings 
Ibfelt et al.  
(2013) 
Cervical Denmark National: women 
diagnosed with 
cervical cancer 
2005 - 2010 CCI score (0, 1, 2, ≥3) 











adjusted for age 
and education 
Income adjusted 





Education: -4% (1.46 to 
1.44) 
Disposable income:  
ALL: +6% (1.32 to 1.34) 
Age <60: -5% (1.59 to 1.56) 
Cohabitation status: 
ALL: -88% (1.08 to 1.01) 




explained by stage 
and less by 
comorbidity 
Seidelin et al. 
(2016) 














Education: -4% (1.49 to 
1.47) 
Social inequalities 









Ibfelt et al.  
(2015) 
Ovarian Denmark National: women 
diagnosed with 
ovarian cancer 
2005 - 2010 CCI score (0, 1, 2, ≥3) 
up to one year before 
cancer diagnosis  










adjusted for age 
and education, 
Income adjusted 








Stage I + II: -4% (1.75 to 
1.72) 
Stage III + IV: -6% (1.17 to 
1.16) 
Cohabitation status: 
Stage I + II: +3% (1.38 to 
1.39) 
Stage III + IV: 0% (1.24 to 
1.24) 
Disposable income: 
Stage I + II: -10% (1.80 to 
1.72) 













Aarts et al.  
(2013b) 
Prostate Netherlands Men diagnosed 
with prostate 






1998 - 2008 CCI (adapted to 
include additional 
conditions) 






of house)  
Stage 
Age 









≤59 years: -21% (2.32 to 
2.04) 
60-74 years: -25% (1.81 to 
1.61) 
Advanced stage: 




year survival were 
related to treatment 
and comorbidity 
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Percentage change of 
social inequalities in 
outcome due to 
comorbidity†◊ 
Findings 
≥75 years: -15% (1.27 to 
1.23) 
Li et al.  
(2012) 
Prostate Sweden Male population 
of Sweden aged 
25 to 74 years 













Year of diagnosis 
Analysis stratified 
by age and stage 
Marital status 
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Calculation not possible for 
comorbidity in isolation: 
model adjustment made for 
hospitalisation for COPD 
plus marital status, family 
income, educational 
attainment, immigrant 
status, urban / rural status 
and mobility  
Men who were 
older, unmarried, 
with a low family 
income or low 
educational 
attainment, had 
moved or been 
hospitalised for 
COPD had highest 
odds of all cause 
mortality. 
Other cancers  
Frederiksen 
et al. (2009a) 
Colorectal Denmark Patients 
diagnosed with 
colon or rectal 
cancer, 
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i)medical treatment for 
cardiovascular 
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iv) medical treatment / 
hospitalisation for 
diabetes, 
v) medical treatment 
or hospitalisation for 
depression or 
schizophrenia,  
vi) medical treatment 
or hospitalisation for 


















adjusted for age, 
sex, year of 
operation 
Housing status is 
adjusted for age, 






Year of operation 
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cause), HR 
Education: -40% (0.80 to 
0.88)* 
Housing status: -30% (0.87 
to 0.91)*   
The association 







et al. (2009b) 
























Education: -37% (0.65 to 
0.78)* 
Housing status: -42% (0.76 
to 0.86)* 




accounted for by 
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social inequalities in 
outcome due to 
comorbidity†◊ 
Findings 
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iv) medical treatment / 
hospitalisation for 
diabetes, 
v) medical treatment 
or hospitalisation for 
depression or 
schizophrenia,  
vi) medical treatment 
or hospitalisation for 






lifestyle, but not by 
treatment and 
disease factors 
Dalton et al. 
(2015) 
Lung Denmark Patients 
diagnosed with 
lung cancer 















Calculation not possible for 
comorbidity in isolation: 
model adjustment made for 
comorbidity plus stage, first-









Studies of more than one cancer  
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Adjusting only for baseline 
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2.7) 
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cancer in the 
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of house)  
1.06) 
Lung: 
Males: 0% (1.11 to 1.11) 
Females: 0% (1.09 to 1.09) 
Prostate (males): 23% (1.47 
to 1.36) 
Breast (females): 18% (1.68 
to 1.56) 
All cancers studied 
combined: 
Males: -12.5% (1.40 to 






prostate or breast 
cancers. The 
gradient of more 
comorbidity from 
high to low SES 
was apparent for 
all tumour types 
studied. 
 
† Comparing low versus high measure of social position, unless otherwise indicated;  * Comparing high versus low measure of social position  
◊ Statistically significant results are in bold 
      







Some studies stratified their analyses by stage, reporting results for localised / stage I or II cancer and 
for advanced / stage III or IV cancer. Adjustment for comorbidity resulted in a larger reduction in socio-
economic inequalities in survival among prostate cancer patients (Aarts et al. 2013b) - and inequalities 
in survival according to income among ovarian cancer patients (Ibfelt et al. 2015) - with an earlier 
rather than later stage of diagnosis. For example, after adjustment for comorbidity, socio-economic 
inequalities reduced by 25% among patients aged 60-74 years with localised stage prostate cancer, 
while the reduction was 6% among patients of the same age with advanced stage of disease. 
Comorbidity appeared to account for more of the inequalities in survival according to disposable 
income and cohabitation status among cervical cancer patients aged under 60 years compared with 
patients of all ages (Ibfelt et al. 2013). However, among prostate cancer patients, the extent of the 
contribution of comorbidity toward socio-economic inequalities in survival appeared to increase with 
increasing age, particularly among patients with advanced stage of disease (15% of inequalities among 
patients aged 75 years or older compared with 6% of inequalities among patients aged 60-74 years) 
(Aarts et al. 2013b).   
There are limitations in drawing conclusions upon the role of comorbidity in social inequalities in 
cancer survival from the findings of these studies. Of the fourteen studies, only five explicitly stated 
that results provided were for cancer-specific mortality or survival due to cancer. Of the remaining 
studies, seven presented results for all-cause mortality and the other two did not specify (all-cause 
mortality was assumed in these instances). Another limitation is that, based on the methods of 
analysis used in these studies, the application of causal assumptions to the associations reported is 
not valid. In Fig. 22.1, the Directed Acyclic Graph illustrates assumed causal relationships between 
variables in the pathway between social position and cancer survival. To be able to examine and 
quantify the causal effect of comorbidity and associated variables in this pathway would require 
analytical approaches such as causal mediation analysis. 
 
22.5. Proposing the need for life tables by deprivation  
 
When interest is in survival from the cancer (e.g. net survival), competing risks of death from other 
causes need to be accounted for. As information on cause of death contained in routine, population-
based data is not considered to be robust and accurate enough, the risk of death from other causes is 
estimated from life tables of the general population with socio-demographics similar to the cancer 
patients. Life tables provide average mortality rates for a geographic area, most commonly according 
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to sex and age. However, when examining the role of comorbidities on social inequalities in cancer 
survival, it is important that the life tables reflect the social differential in mortality rates observed in 
the general population. General life tables systematically underestimate the expected mortality 
hazards among more deprived populations and overestimate these in less deprived. Using such 
general life tables can therefore result in underestimated net survival (i.e. survival from cancer) in 
deprived populations and overestimated net survival in less deprived populations (Dickman et al. 
1998; Maringe et al. 2008). Furthermore, a simulation-based study showed that the use of life tables 
lacking stratification by a variable present in the excess hazard model leads to measurement bias in 
both the effect of this variable and other variables included in the model (Graffeo et al. 2012).  
Some strategies have been proposed to compensate for insufficient stratification of life tables. 
Sensitivity survival analyses can be performed using modified life tables according to successive 
plausible scenarios regarding the social gradients in the studied population (Ito et al. 2014; Antunes 
et al. 2019). 
Rubio and colleagues developed models for the estimation of the excess mortality hazard that correct 
for possible misspecification of the expected mortality rate occurring due to mismatches in the life 
table (Rubio et al. 2019). Flexible population-based models were developed to account for cause-of-
death misclassification and for the effects of selection when estimating long-term net survival in the 
clinical trial setting (Goungounga et al. 2019).   
 
Similarly, life tables that do not account for comorbidities may overestimate the expected survival in 
populations with an important burden of comorbidities while underestimating expected survival in 
populations with a low prevalence of comorbidities. Life tables commonly include the deprivation 
dimension in the UK and in several countries of the North of Europe. Whether such life tables (which 
may also include ethnicity) are sufficient to adjust for social differential mortality associated with 
comorbidity is still debated. A study focussing on the specific lung and laryngeal cancers (for which 
most patients have comorbidities associated with tobacco smoking) concluded that not using life 
tables adjusted for tobacco smoking (and deprivation) led to notable under-estimation of cancer 
survival for all deprivation groups, but had a fairly small impact on the estimation of the deprivation 
inequalities in cancer survival (Ellis et al. 2014). Life tables adjusted for comorbidity may nevertheless 
be helpful to uncover the role of comorbidity in social inequalities in cancer survival. Such life tables 





Among the published studies on this topic in a European setting, the magnitude of the influence of 
comorbidity in social inequalities in cancer survival varied. The extent of the relationship also varied 
by measure of social position. The impact comorbidity had on inequalities in survival was also 
associated with other prognostic factors, such as tumour stage, patient age, and treatment received.  
Having one or more comorbid conditions at the time of cancer diagnosis is associated with socio-
economic position, and the prevalence of many comorbid conditions increases with increasing levels 
of socio-economic deprivation (Barnett et al. 2012; van Leersum et al. 2013; Aarts et al. 2015; Schiotz 
et al. 2017; Fowler et al. 2020). The most deprived groups of patients may be disproportionately 
impacted by clinical guidelines that focus on single disease management and by decision making that 
leads to non-treatment of cancer patients with comorbidity.  
Reviewing the treatment process of cancer patients with comorbidity may help to reduce socio-
economic inequalities in receipt of treatment, and ultimate prognosis. Clear guidelines that account 
for multiple management scenarios (depending on comorbidity severity and stage of cancer), together 
with the resources to robustly manage comorbid conditions during cancer treatment, could help 
reduce adverse outcomes occurring due to the comorbid disease, and limit the development of new 
comorbidities. Moreover, investigation of aspects of comorbidity management, such as the 
relationship between adherence to comorbidity medication and outcomes among cancer patients, 
may be informative. In a study of patients with diabetes and ischemic heart disease, cardioprotective 
medication adherence was associated with lower all-cause mortality (Ho et al. 2006). 
Further studies investigating comorbidity and social inequalities in cancer survival across multiple 
European countries, with representation of southern European countries, would provide a firmer 
foundation for comparison of inequalities between countries. Greater efforts in achieving a more 
consistent approach toward measuring comorbidity would help facilitate a like-for-like comparison.  
From the evidence presented, the need for a mechanistic understanding of the causes of socio-
economic inequalities in survival outcomes is apparent. The current lack of understanding illustrates 
the importance of using causal inference methods with routine medical data and population-based 
registries to disentangle the contributions of different pathways of cancer diagnosis and treatment to 
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Comorbidity and colon cancer outcomes 
 
Drawing from the scientific literature discussed in the book chapter, there is clear evidence to suggest 
comorbidity influences survival or mortality from many of the cancer types, including breast cancer,86-
89 ovarian cancer90 and non-small cell lung cancer.91, 92 This was also reported in studies of colon or 
colorectal cancer patients, both in Europe48, 52, 56, 93 and further afield. For example, studies of 
colorectal cancer patients in the United States94 and South Australia95 reported that comorbidity 
status was associated with 5-year cancer-related mortality. In the latter study, post-operative patients 
with multiple or severe comorbidities had a 21% increased risk of 5-year mortality compared with 
patients with no comorbidity.95 Comorbidity status was also associated with 5-year all-cause mortality 
in a study of colon cancer patients in New Zealand.96 In this study, patients with Chronic Respiratory 
Disease , Myocardial Infarction or with Congestive Heart Failure had approximately 20-25% increased 
risk of 5-year all-cause mortality of that of patients without the respective condition. Meanwhile 
patients with angina had a 12% reduced risk of mortality versus those patients without angina.  
Additionally, comorbidity status has been linked with shorter-term prognosis among colorectal cancer 
patients. In a study in England, patients with a Charlson Comorbidity Index (CCI) score of 3 or more 
had an 80% increased risk of mortality within one year of colorectal cancer diagnosis compared with 
patients with a score of 0, after adjusting for age, stage, deprivation and follow-up.48  Comorbidity 
level, measured in terms of number of comorbid conditions, was an independent predictor of one-
year mortality in a study of patients in the United States. Compared with patients with no comorbidity, 
patients with 2 comorbid conditions had a 32% increased risk and patients with 3 or more conditions 
a 48% increased risk of one-year mortality.97  Having more than one comorbidity was also a predictor 
of six-month and one-year mortality among colorectal cancer patients in a study conducted in Spain.98 
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Comorbidity and social or socio-economic inequalities in colon cancer mortality 
 
Published studies investigating the influence of comorbidity on social inequalities in cancer prognosis 
are scarce. Three studies reported results on differences in survival or mortality between social groups 
of colorectal cancer patients in European countries. Two were studies in Denmark, one of which 
focused on 30-day post-operative cancer-related mortality of patients undergoing elective surgery for 
colorectal cancer56 and the other all-cause mortality among colorectal cancer patients.52 The third 
investigated all-cause mortality for several cancers, including colorectal cancer, in the Netherlands.93 
The results presented in these studies are summarised in Table 22.1 within the book chapter. Among 
patients studied in Denmark, adjusting for comorbidity reduced the odds of thirty-day post-operative 
cancer-related mortality according to education status by 37% (from 35% to 22% increased odds of 
mortality among patients with short versus longer educational attainment) and according to housing 
status by 42% (from 24% to 14% increased odds of mortality among patients renting their home versus 
owning it).56 Adjusting for comorbidity reduced the hazard of all-cause mortality according to 
education status by 40% (from 20% to 12% increased hazard of mortality, short versus long education) 
and by 30% according to housing status (from 13% to 9% increased hazard of mortality among renters 
versus owners).52 There is also evidence from the Netherlands to suggest that adjusting for 
comorbidity reduced socio-economic differences in all-cause mortality by 23% among male colorectal 
cancer patients (from 13% to 10% increased hazard of mortality of patients with low versus high SES), 
although the evidence of comorbidity reducing SES inequalities among females was weak.93 All three 
studies concluded that comorbidity (together with lifestyle factors in the Danish studies) had partly 
mediated the association between social position and the respective mortality outcome.   
However, two studies of comorbidity and colorectal cancer survival from the United States do not 
support these conclusions. Robbins et al investigated insurance status, comorbidity and survival 
among black and white colorectal cancer patients. Comorbidity influenced survival but had little 
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impact on differences in survival according to various measures of social position, such as household 
income or attainment of a high school degree and survival, irrespective of race.97 Similarly, another 
study reported only weak evidence of an association between socio-economic status and colorectal 
cancer mortality, and adjusting for comorbidity did not have any effect on this association.99     
 
When estimating cancer survival, using lifetables adjusted for comorbidity would be useful to account 
for background mortality due to these comorbidities. Lifetables that do not adjust for comorbidity 
may overestimate the expected survival in populations with a higher burden of comorbidity and 
underestimate survival in populations with less comorbidity. As discussed in the book chapter, 
lifetables including deprivation may account for some of the differential distribution of comorbidity. 
The use of comorbidity-adjusted lifetables is not commonplace, partly as opportunities to construct 
these lifetables are dependent on the availability and reliability of information on comorbidity. In the 
United States, Mariotto and colleagues developed non-cancer lifetables by comorbidity score, but as 
comorbidity data was derived from Medicare claims data it was limited to people aged 66 years of age 
or older.100  
 
Given the scarcity of published studies, plus differing measures of social or socio-economic position 
and varying measures of outcome within the available scientific literature, there is a gap in the 
knowledge regarding the role that comorbidity plays in socio-economic inequalities in cancer 
outcomes. Further research into this topic is important and timely given the increasing prevalence of 
chronic disease and multimorbidity, the association between lower socio-economic position and 
chronic disease prevalence, and the persistence of socio-economic inequalities in cancer outcomes. 
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Chapter 3 - Influence of prognostic factors in socio-economic 
inequalities in short-term cancer mortality 
 
This chapter covers the research conducted to complete the first objective of this thesis: to examine 
ninety day mortality among colon cancer patients according to socio-economic position, and to 
investigate the extent to which prognostic factors such as age, stage at diagnosis, comorbidity and 
receipt of surgical treatment influence inequalities in ninety-day mortality. This work was published 
in the British Journal of Cancer in 2017.101 The chapter includes the publication and supplementary 
material, a background to the work, a description of the study, the main findings and conclusions, and 
a discussion explaining how this work fulfils the first objective of this thesis.  
 
Introduction to research paper 1 
 
Background 
Colon cancer is one of the most commonly diagnosed cancers in England among adults, but has a less 
favourable short-term prognosis than other common cancers.102 Additionally, wide socio-economic 
inequalities in survival from cancer of the colon have persisted for some time,8, 10, 11 with  inequalities 
most evident in the short-term after diagnosis.12  
Within the scientific literature, socio-economic position has been investigated alongside other factors 
that may influence colon or colorectal cancer mortality. For example, studies have focused on age103 
or stage at diagnosis12, 47 as prognostic factors, or have examined prognostic factors in short-term 
mortality following surgery for colon cancer.57, 58 However, few studies offer a comprehensive 
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assessment of prognostic factors influencing socio-economic inequalities in short-term colon cancer 
mortality among all patients.  
The aim of this study was to quantify differences in ninety-day mortality (i.e. death occurring within 
ninety days of cancer diagnosis) according to socio-economic position, and to investigate how the 
prognostic factors of patient comorbidity, age, stage at diagnosis, receipt of major surgery (curative 
intent assumed) and presentation for surgery contribute to the differences in mortality between 
socio-economic groups, according to sex.  
 
Materials and Methods 
To fulfil this aim I undertook a population-based study of patients diagnosed with colon cancer in 
England between 1st January 2010 and 31st March 2013 using National Cancer Registry data for 
England linked with National Bowel Cancer Audit data and Hospital Episode Statistics. In this study, 
the measure of socio-economic position was the deprivation group that the patient belonged to, 
based on their residential postcode at the time of cancer diagnosis. Deprivation group was defined 
using the Income domain of the English Indices for Multiple Deprivation 2010,79  which provides a 
relative measure of deprivation at the Lower layer Super Output Area (LSOA) level. Patient 
comorbidity was measured as a score, based on the presence of 17 conditions of the Charlson 
Comorbidity Index (CCI)83 and their assigned weightings. The four-category comorbidity score variable 
used in the analysis summarised this CCI score (i.e. according to whether it was 0, 1, 2 or 3 or more).  
For each sex (referred to as ‘gender’ in the paper published in the British Journal of Cancer) I used 
logistic regression models to estimate two different indicators of probability of death within ninety 
days of cancer diagnosis.  
The first indicator was the conditional probability of death, which provided the probability of death of 
each deprivation group at every possible combination of values of the prognostic factors. From this 
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indicator it was possible to compare the difference in the probability of death between the most 
deprived patients with that of the least deprived patients, according to specific values of patient age, 
comorbidity score, stage of diagnosis and surgical treatment received.  
The second indicator was the average predicted probability of death within ninety days of diagnosis. 
It was estimated for each deprivation group and was an average of the predicted probability of death 
of every patient in that group. In the first instance it was estimated based on the observed value of 
the deprivation group (i.e. between 1 and 5, depending on the relative deprivation level), with the 
distribution of prognostic factors among patients in that group remaining as observed. This indicator 
provided the means to calculate the difference in probability of death between the most and least 
deprived groups, after adjustment for the differential distribution of prognostic factors among 
patients in each group. 
The average predicted probability of death was then estimated again for each of the groups, but with 
the assumption the patients in each group belonged to the least deprived group (group 1), while the 
distribution of prognostic factors remained as observed. For each deprivation group, the resulting 
change in the probability of death gave an indication of the effect of deprivation within that group. 
This also allowed for comparison of the differences in probability of death of the most and least 
deprived groups, with and without accounting for the effect of deprivation. Further analyses explored 
prognostic factors contributing to residual differences in probability of death between the most and 





The research findings of this study were reported in the paper “Persistent inequalities in 90-day colon 
cancer mortality: an English cohort study”, published in the British Journal of Cancer in 2017.101 I also 
presented the research findings at scientific conferences (details provided in the Appendices). 
The results obtained from this study showed that the most deprived patients were more likely to die 
within ninety days of cancer diagnosis than the least deprived patients, even after adjusting for 
prognostic factors. Based upon the conditional probability of death, older age, advanced stage and 
the highest comorbidity score (3 or higher) were strong prognostic factors of ninety-day mortality, as 
was receiving major surgery via emergency presentation. The magnitude of the socio-economic 
differences in probability of death within ninety days varied according to the values of prognostic 
factors. Inequalities were wider among patients with older age, advanced stage, higher levels of 
comorbidity or who received emergency surgery.  
 
At the deprivation group level, after adjusting for the distribution of values of prognostic factors of 
patients within that group, the difference in the average predicted probability of death of the most 
deprived group and the least deprived group of male and of female patients was 5.3% and 6.5%, 
respectively. When the probability of death was estimated with the assumption that all patients were 
in the least deprived group (distribution of other prognostic factors remaining unchanged), the 
difference between the most and least deprived groups reduced. Among male patients, the difference 
between these groups reduced to 1.3% and among female patients the difference became 1.7%. 
Further analysis exploring the contribution of prognostic factors to these residual differences showed 
that stage and treatment in combination were the most influential factors: differences became 0.1% 




The most deprived patients consistently had poorer prognosis then the least deprived patients, 
regardless of the status of other prognostic factors at which probability of death was estimated. At 
the deprivation group level, accounting for the effect of deprivation reduced but did not completely 
remove the differences in ninety-day mortality between the most and least deprived groups. 
Differential distribution of prognostic factors in deprivation groups may account for some of the 
mortality differences between the most and least deprived groups. Stage and treatment appeared to 
be the prognostic factors that had the most influence on the remaining socio-economic inequalities 
after the effect of deprivation was taken into account.   
 
Fulfilment of the first objective of this thesis 
 
In this chapter I quantified the probability of death within ninety days of colon cancer diagnosis among 
the most and the least deprived groups of patients at every combination of values of the prognostic 
factors. I also estimated the probability of death at deprivation group level, adjusting for the 
distribution of the prognostic factors within that group. I have shown that socio-economic inequalities 
in ninety-day mortality among colon cancer patients exist, and while comorbidity score, stage, age 
and receipt of major surgery are all prognostic factors in ninety-day mortality, they did not fully explain 
differences in probability of death between the most and least deprived groups of patients.  
The results indicated that patient comorbidity, measured according to the CCI index score, was an 
influential factor in ninety-day mortality, particularly among the most deprived group of patients: 
those with the highest comorbidity score had a higher probability of ninety-day mortality than patients 
with no recorded comorbidity, and the presence of comorbidity appeared to have the greatest impact 
on ninety-day mortality amongst those in the most deprived groups. While the CCI is commonly used 
in epidemiological research of cancer outcomes, there is no one recommended measure of 
comorbidity in the cancer setting.104 One limitation of using a summary measure of patient 
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comorbidity is that it does not provide information on the comorbid condition(s) the patient has, nor 
their specific influence on the patient’s outcome.  In view of this limitation, the following chapters of 
this thesis investigate comorbidity at a more detailed level.  
In the next chapter I examine patterns in the prevalence of comorbidities among cancer patient 
populations according to socio-demographic characteristics, and evaluate hospital-based electronic 
health records as a source of information on chronic disease prevalence (Chapter 4). To further 
disentangle the role of comorbidity in socio-economic inequalities in short-term colon cancer 
mortality, I then investigate the influence of severity of comorbidity on ninety-day mortality by 
deprivation group. Time since specific comorbid conditions were recorded, and duration and 
frequency of hospital visits once the condition is present are used as proxies for comorbidity severity 
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Persistent inequalities in 90-day colon cancer
mortality: an English cohort study
H Fowler*,1, A Belot1, E N Njagi1, M A Luque-Fernandez1, C Maringe1, M Quaresma1, M Kajiwara1
and B Rachet1
1Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population
Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Background: Variation in colon cancer mortality occurring shortly after diagnosis is widely reported between socio-economic
status (SES) groups: we investigated the role of different prognostic factors in explaining variation in 90-day mortality.
Methods: National cancer registry data were linked with national clinical audit data and Hospital Episode Statistics records for 69 769
adults diagnosed with colon cancer in England between January 2010 and March 2013. By gender, logistic regression was used to
estimate the effects of SES, age and stage at diagnosis, comorbidity and surgical treatment on probability of death within 90 days from
diagnosis. Multiple imputations accounted for missing stage. We predicted conditional probabilities by prognostic factor patterns and
estimated the effect of SES (deprivation) from the difference between deprivation-specific average predicted probabilities.
Results: Ninety-day probability of death rose with increasing deprivation, even after accounting for the main prognostic factors.
When setting the deprivation level to the least deprived group for all patients and keeping all other prognostic factors as
observed, the differences between deprivation-specific averaged predicted probabilities of death were greatly reduced but
persisted. Additional analysis suggested stage and treatment as potential contributors towards some of these inequalities.
Conclusions: Further examination of delayed diagnosis, access to treatment and post-operative care by deprivation group may
provide additional insights into understanding deprivation disparities in mortality.
Colon cancer, the fourth most frequently diagnosed cancer in
England, has a less favourable 1-year prognosis in England when
compared with some other common cancers, such as cancers of the
rectum and breast (Exarchakou et al, 2015). One-year net survival
for colon cancer (i.e., the survival of colon cancer if the other
causes of death have been removed) was recently reported at
around 75%, while it was largely 480% for the other cancers
mentioned above (Exarchakou et al, 2015). Meanwhile, wide socio-
economic inequalities in survival from colon cancer have been
repeatedly reported in England (Mitry et al, 2008; Rachet et al,
2010), with worse prognosis for more deprived patients. These
inequalities are generally evident shortly after diagnosis (Møller
et al, 2012), with two-thirds of cancer deaths related to these
inequalities occurring within 6 months after diagnosis (Ellis et al,
2012). Socio-economic inequalities in colon cancer survival have
been reported in several countries (Wrigley et al, 2002; Aarts et al,
2010; Cavalli-Bjorkman et al, 2011; Ito et al, 2014) but have not
been found in others (Dejardin et al, 2013; Antunes et al, 2016),
which underlines the importance of understanding factors
contributing to inequalities and more particularly differential
short-term mortality in colon cancer patients in England.
Many published studies have focussed their attention exclusively
towards subgroups of colon cancer patients, such as postoperative
patients (Morris et al, 2011) or elderly postoperative patients
(Dekker et al, 2011), to explain differences in short-term survival.
A variety of indicators has been considered in studies examining
SES – from metrics such as patient occupation or education level to
deprivation indices. Common themes in the literature include
examining the relationship between age, stage at diagnosis and
short-term mortality (Gatta et al, 1998; Møller et al, 2012) and the
relationship between cancer treatment and short-term mortality
(Faivre et al, 2007). However, there was little discussion offered
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regarding the relationship between socio-economic status and risk
factors for short-term mortality, such as comorbidity or stage at
diagnosis. Awareness of factors contributing to different prognoses
for short-term survival across all patient populations is central to
the effective management of cancer care.
This study aims to quantify differences in 90-day mortality
following diagnosis of colon cancer according to patients’ socio-
economic status. We investigate to what extent these differences
are influenced by age, stage at diagnosis, patient comorbidity score,
whether the primary treatment received by the patient was a major
surgery and whether the patient received major surgery as an
elective or emergency procedure.
MATERIALS AND METHODS
Data. The analysis was undertaken on 69 769 adults aged 15–99
years diagnosed with colon cancer in England between 1 January
2010 and 31 March 2013 and followed up until 31 December 2014.
The data for these analyses were obtained from the national cancer
registry records (Office for National Statistics, 2014) linked with
Hospital Episode Statistics (HES) records (Health and Social Care
Information Centre, 2013) and national bowel cancer clinical audit
data (Health and Social Care Information Centre, 2014a) –
representing information collated from clinicians working in
multidisciplinary teams who have direct involvement with the
patients. The linkage of the registry data with clinical audit data
and HES records was undertaken using an algorithm developed by
the Cancer Survival Group at the London School of Hygiene and
Tropical Medicine (Shack, 2009), which prioritised linkage of
records according to the combination of patient identifier variables
(Office for National Statistics, 2014). The cancer registry data
represented 499% of cancer registrations in England (Office for
National Statistics, 2014) and provided information on gender, age
at diagnosis, socio-economic status, tumour stage and date of
diagnosis. The clinical audit data had a case ascertainment of 94%
(Health and Social Care Information Centre, 2014b) and captured
information on tumour stage and treatment. To obtain the most
robust information on stage at diagnosis from clinical audit and
registry data, we used an algorithm (Benitez-Majano et al, 2016)
that creates a composite stage at diagnosis variable, based on the
rules of the Union for International Cancer Control TNM
classification of malignant tumours. It combined available
information in individual tumour (T), nodes (N) and metastases
(M) stage components, prioritising information captured in the
clinical audit data and only using registry stage data where this was
not present, to derive a four-level ordinal stage variable, where
stage 1 represents localised stage cancer and stage 4 indicates
metastatic stage cancer (Benitez-Majano et al, 2016).
HES records were used to supplement treatment information
gathered from the clinical audit data and to derive information on
comorbidity prevalence. We devised an algorithm to derive the first
major surgical treatment received by each patient within a time
window of between 30 days prior and 90 days following cancer
diagnosis. Treatment information was derived from data coded
according to the Office of Population Censuses and Surveys
(OPCS) Classification of Interventions and Procedures (fourth
version, ‘OPCS-4’) (Health and Social Care Information Centre,
2017). The OPCS-4 codes represent an information standard used
by clinical coders within National Health Service hospitals in Great
Britain. In the clinical audit data, we used the sole OPCS-4-coded
treatment variable describing the patient’s primary procedure. In
HES up to 12 fields (among a total of 20) capturing OPCS-4-coded
treatment information had been completed for each hospital
episode. Major surgery was categorised using the definition of
major treatment devised by the Site-Specific Clinical Reference
Groups of the National Cancer Intelligence Network (National
Cancer Intelligence Network, 2013), which sought extensive input
from clinicians and oncologists. Supplementary Table 1 defines
OPCS-4 codes representing major surgery for colon cancer.
Surgery presentation was defined as either ‘emergency’ or ‘elective’,
according to the method of admission recorded in HES.
Information on the presence of comorbidities and other
conditions were derived from the historical records of diagnosis
fields in HES between 2003 and 2013, allowing the capture of
information up to 6.5 years prior to cancer diagnosis. Each hospital
spell record can contain up to 20 diagnostic fields in which
coexisting conditions could be recorded. We extracted information
on the prevalence of the 17 comorbidities of the Charlson Index
(Charlson et al, 1987) plus obesity by applying an algorithm
(Maringe et al, 2017) that created a binary variable to flag the
presence of each of the comorbidities of interest prior to the date of
cancer diagnosis recorded in the registry data. We considered
comorbidities recorded during a retrospective 6-year period from
0.5 to 6.5 years prior to cancer diagnosis in the analysis. Cancer
registry data were the source of information for the two Charlson
Index comorbidities relating to cancer (i.e., ‘any malignancy’ and
‘metastatic solid tumours’). However, stage information was largely
missing for many cancers and, where available, we found only 11
colon cancer patients with a metastatic tumour (i.e., TNM stage 4
tumour) prior to the diagnosis of their colon cancer. We therefore
considered any prior cancer diagnosis as ‘any malignancy’ in the
context of the Charlson Index. Each patient’s Charlson Comor-
bidity Index score was calculated based on Charlson’s weighted
index of comorbidity (Charlson et al, 1987). A weighted score was
derived for each patient based on whether any of the comorbidities
had been diagnosed, as confirmed from the binary comorbidity
indicators. The Charlson Comorbidity Index scores were then
summarised by creating a four-category comorbidity score
variable, indicating whether the Charlson Comorbidity Index
score was 0, 1, 2 or X3.
We defined socio-economic status as deprivation, which was
measured using the Income Domain from the 2011 England
Indices of Multiple Deprivation (Department for Communities and
Local Government, 2011) defined at the Lower Super Output Area
level (mean population 1500). Patients were allocated to one of the
five deprivation categories according to their area of residence at
the time of their cancer diagnosis. This ecological, five-level ordinal
variable represents a scale of deprivation, where ‘1’ represents the
least deprived and ‘5’ represents the most deprived category of
patients, based on the quintiles of the distribution areas in England.
Analysis. All analyses were conducted using Stata 14 (StatCorp
LP, College Station, TX, USA) (StataCorp, 2015).
Information on patient characteristics was investigated using
cross tabulations to explore the distribution and completeness of
variables of interest for each gender.
The first step was to quantify the role of key variables on the
90-day mortality, which then enabled us to derive a series of
indicators with public health relevance, discussed in the next
subsection. Prior to conducting our analyses, the relationships
between the prognostic factors (age, stage at diagnosis, treatment
received and comorbidity score), our primary exposure of
interest (deprivation) and the outcome of interest (90-day
mortality) were considered. A directed acyclic graph depicting
the assumed relationships between these variables is provided in
Supplementary Figure 1.
We used multivariable logistic regression models to estimate the
associations between the probability of death occurring within 90
days of colon cancer diagnosis (our outcome of interest) and
deprivation as well as age at diagnosis, stage at diagnosis,
comorbidity score and treatment received, separately for each
gender. The possible nonlinear effect of age at diagnosis was
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modelled using a quadratic regression spline with one knot at 70
years (near the mean age of the patients, 72.2 years). Furthermore,
because the association between deprivation and 90-day mortality
might vary by stage, comorbidity and treatment, the initial multiple
logistic regression model included, in addition to the variables
mentioned above, the corresponding interactions. Similarly,
interactions between stage and age, stage and treatment, stage
and comorbidity and comorbidity and treatment were initially
considered on a priori clinical grounds. A backward elimination
method (Agresti, 2013) was then applied to select the most
parsimonious model to predict 90-day mortality. This final analysis
model was used to predict our outcome – probability of death
within 90 days of diagnosis. As a further step, to examine the
contribution stage and treatment made towards this outcome, we
performed additional analysis removing in turn from our final
analysis model, stage, treatment and both stage and treatment.
Multiple imputations accounted for 30% missing composite
stage, assuming a missing at random mechanism (Little and Rubin,
1987) – that is, that the probability of stage being missing
depended on the observed data. Given that the logistic regression
model included (i) interactions between stage and other variables
(and stage had missing information), and (ii) a nonlinear effect of
age, multiple imputation by the substantive-model compatible fully
conditional specification (SMC–FCS) method (Bartlett et al, 2015;
Bartlett and Morris, 2015) was employed to ensure compatibility
between the imputation model and the analysis model (Carpenter
and Kenward, 2013). Separately for each gender, a multinomial
logistic regression model was used to impute stage, including as
predictor variables, (i) all the variables in the analysis model
mentioned above, (ii) the vital status within 90 days, (iii) the
tumour grade (a four-level ordinal variable indicating the level of
differentiation of the tumour), and (iv) a variable representing the
Nelson–Aalen estimate (an estimator of the cumulative hazard of
death) (Falcaro et al, 2015). In this model, age was also included as
a nonlinear effect, to ensure compatibility (Carpenter and
Kenward, 2013) with the analysis model. Tumour grade was used
as an auxiliary variable in the imputation model, and as it also had
missing information (20% missing grade), a multinomial logistic
regression model was also used to impute it within the SMC–FCS
framework. It is important to mention that ordinal logistic
regression models, rather than multinomial logistic regression
models, could be employed to impute stage and grade, provided
that care is taken to test for the usually made proportional odds
assumption (Agresti, 2013; Carpenter and Kenward, 2013).
The Stata ‘smcfcs’ command (StataCorp, 2015) was used to
generate 30 imputed data sets, using the imputation model and
imputation strategy above. The initial multiple logistic regression
model was fitted to the 30 imputed data sets and Rubin’s Rules
(Little and Rubin, 1987) used to combine the analysis results. The
backward elimination model selection method was applied using
the ‘mi test’ command (StataCorp, 2015) to perform a multivariate
Wald test, dropping the most insignificant interaction term one at
a time; refitting the reduced model to the data imputed as above
and testing again for the remaining interactions, until all remaining
interactions were significant (P-valuep0.05). All interactions were
tested on the same set of imputed data: retaining the data imputed
using the most complex imputation model and testing all
subsequent reduced models on these same set of data ensures
valid estimation of all the reduced models (Carpenter and
Kenward, 2013; Bartlett and Morris, 2015).
Indicators produced. Using the final model selected for each
gender, we predicted two sets of probabilities of dying within 90
days of diagnosis. The first consisted of conditional probabilities,
that is, given specific values of the prognostic factors. This was
performed using the ‘mi estimate’ command (StataCorp, 2015).
The second set included average predicted probabilities estimated
for each deprivation group in turn; we predicted the probability of
death within 90 days of diagnosis for each patient, adjusting for
prognostic factors, and averaged these probabilities on all patients
in the subgroup (Muller and Maclehose, 2014). This meant the
probability of death was predicted for each patient in the
deprivation group – adjusting for the patient’s prognostic factor
values – and used to derive the average predicted probability of
death of all patients in that deprivation group. By way of
comparison, the average predicted probabilities were then
recalculated separately for each of the deprivation groups but
setting the level of deprivation as the least deprived group and with
all other prognostic factors remaining as observed. This gave an
estimate of the probability of death as if patients had been in the
least deprived group. The difference between those two probabil-
ities quantified the effect of deprivation. This was performed using
the ‘mimrgns’ command. In the additional analysis, we reiterated
this calculation of average predicted probabilities as if patients had
been in the least deprived group but using the final model without
stage, then without treatment and finally without both.
RESULTS
A total of 69 769 adults were diagnosed with colon cancer in
England between January 2010 and March 2013; 36 685 (52.6%) of
these adults were males. Table 1 shows the characteristics of the
patients in this study overall and for the 14.7 and 16.6% males and
females, respectively, who died within 90 days after a colon cancer
diagnosis. As deprivation increased the percentage of patients in
each deprivation group decreased in both genders (22.3 in
deprivation group 1 versus 15.2% in deprivation group 5 in males
and 21.4 versus 15.3% in females). However, by deprivation group,
the percentage of patients who died in 90 days increased with
deprivation: in the least deprived group, the percentage was 12.4 in
males and 13.3% in females; and in the most deprived group, the
percentages were 17.7 and 19.9 in males and females, respectively.
Both male and female elderly patients were highly represented,
especially the 80þ patients, in the patients who died within 90
days. Stage at diagnosis was missing for almost a third of the
patients but for 38.1% and 44.3% of males and females who died
within 90 days, respectively. Early stages (1 and 2) represented a
third of the patients with observed stage but about 13% of those
who died within 90 days. Only 74 males and 54 females diagnosed
with stage 1 died within 90 days, compared with 42000 diagnosed
with the most advanced stage 4 (representing three-quarters of the
patients who did not survive). The patients with no recorded
comorbidity were about three-quarters of all patients but were two-
thirds of those who died within 90 days, illustrating an over-
representation of those with no recorded comorbidity among the
group who died within 90 days. About one-third of the patients did
not receive any major surgery, but this group with no treatment
represented over three-quarters of those who died within 90 days.
By contrast, o10% of the patients who did not survive received a
major elective surgery while they represented nearly half of all
patients. We provide the distribution of stage at diagnosis in
patients receiving a major emergency, major elective surgery or no
major surgery in Supplementary Table 2. Of the 14 810 patients with
known tumour stage who did not have a major surgery, 11.1% had a
stage 1 diagnosis, whereas 66.6% had a stage 4 diagnosis.
Supplementary Table 3 shows the distribution of patients who
underwent major surgery via either emergency or elective presenta-
tion – and those who did not have major surgery – by comorbidity
score. The majority of patients (51%) with the highest comorbidity
score of 3 did not undergo major surgery while 34% of these patients
had a major elective surgery. By contrast, 49% of patients with no
BRITISH JOURNAL OF CANCER Persistent inequalities in 90-day mortality
1398 www.bjcancer.com | DOI:10.1038/bjc.2017.295
66
recorded comorbidity had a major elective surgery and 33% no major
surgery.
In building the multivariable model for obtaining the predic-
tions of probability of death within 90 days, the model selection
strategy identified significant interactions in both male and female
patients, that is, the association between age and 90-day mortality
was modified by stage, comorbidity and treatment. There was also
an interaction between treatment and stage. In males only, one
additional interaction was retained between comorbidity score and
treatment.
Probability of death within 90 days of colon cancer diagnosis
Conditional probabilities by prognostic factor patterns. In both
male and female patients, the conditional (i.e., conditional to
specific values of factors) probability of death within 90 days rose
with increasing level of deprivation, whatever the age and stage at
diagnosis. To investigate this at a more granular level, the
deprivation groups were split into subgroups of patients, according
to the presence of comorbidities and the treatment they received.
Therefore, for each sex, probability of death within 90 days was
assessed in terms of each level of deprivation, age, stage,
comorbidity score and treatment.
Table 2 presents the probability of death within 90 days for male
and female patients in the most and least deprived patients,
according to their age at diagnosis (60, 70 and 80 years), stage at
diagnosis, comorbidity (no recorded comorbidity and the highest
score of 3) and their treatment (major emergency surgery, major
elective surgery or no major surgery). The most deprived patients
were systematically more likely to die within 90 days than the least
deprived patients, irrespective of age, stage, comorbidity and
treatment status. For example, in males aged 70 years, with stage 2
diagnosis, comorbidity score 3 and who underwent a major
emergency treatment, the probability of dying within 90 days was
11.7% (95% confidence interval (CI) 8.3, 16.3%) in the most
deprived compared with 7.9% (95% CI 5.5, 11.2%) in the least
deprived patients. Similarly, among those who underwent a major
elective surgery, the probabilities of death were 3.8% (95% CI 2.7,
5.4%) and 2.5% (95% CI 1.7, 3.6%) in the most and least deprived,
respectively. The probability of death varied by deprivation even
among patients with no recorded comorbidity, regardless of their
treatment. We observed very similar patterns in females.
By contrast, stage-2 patients with no recorded comorbidity
experienced comparable 90-day mortality whether they had no
major surgery or a major emergency surgery (Figure 1, Table 2).
This was the case across all deprivation groups. For example, the
probability of 90-day mortality among the most deprived female
patients aged 70 years was 6.4% (95% CI 4.6, 8.8%) if not receiving
any major surgery and 6.2% (95% CI 4.6, 8.3%) when receiving a
major emergency surgery. These probabilities were much lower
among females receiving a major elective surgery (1.0%, 95% CI
0.7, 1.6% with the same combination of factors). Among men only,
the effect of comorbidity on the probability of 90-day mortality
according to treatment differed: highest in those receiving
Table 1. Patient characteristics – patients diagnosed with colon cancer 2010–2013a in England
Males Females
Total Died within 90 days Total Died within 90 days
N % n %b N % n %b
Deprivation (Income Indices of Multiple Deprivation)
Least deprived (1) 8180 22.3 1018 18.9 7078 21.4 946 17.2
2 8231 22.4 1124 20.9 7241 21.9 1109 20.2
3 7629 20.8 1114 20.7 7048 21.3 1195 21.8
4 7072 19.3 1132 21.1 6649 20.1 1232 22.4
Most deprived (5) 5573 15.2 989 18.4 5068 15.3 1006 18.3
Age (years)
15–40 643 1.8 29 0.5 736 2.2 20 0.4
41–50 1182 3.2 68 1.3 1202 3.6 50 0.9
51–60 3386 9.2 283 5.3 2966 9.0 232 4.2
61–70 9889 27.0 840 15.6 7226 21.8 638 11.6
71–80 12 171 33.2 1674 31.1 9785 29.6 1333 24.3
81–99 9414 25.7 2483 46.2 11169 33.8 3215 58.6
Stage
Missing 11 186 30.5c 2049 38.1c 10 531 31.8c 2430 44.3c
1 (localised) 3355 13.2d 74 2.2d 2647 11.7d 54 1.8d
2 7084 27.8d 368 11.1d 6571 29.1d 338 11.1d
3 6667 26.1d 388 11.7d 6006 26.6d 401 13.1d
4 (metastatic) 8393 32.9d 2498 75.1d 7329 32.5d 2265 74.1d
Comorbidity score
0 26 314 71.7 3380 62.9 24 982 75.5 3600 65.6
1 3780 10.3 697 13.0 3552 10.7 772 14.1
2 3558 9.7 631 11.7 2521 7.6 542 9.9
3þ 3033 8.3 669 12.4 2029 6.1 574 10.5
Treatment
No major treatment 13 390 36.5 4056 75.4 11 811 35.7 4290 78.2
Major emergency treatment 5749 15.7 794 14.8 5962 18.0 868 15.8
Major elective treatment 17 546 47.8 527 9.8 15 311 46.3 330 6.0
Total 36 685 100.0 5377 14.7 33 084 100.0 5488 16.6
a2013 data represent diagnosis between 1 January 2013 and 31 March 2013.
bRepresenting the percentage of patients within each gender who died within 90 days.
cRepresenting the percentage of patients with missing stage information.
dCalculated as a percentage of patients with complete stage information.
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emergency surgery, lowest in those receiving elective surgery, and
intermediate in those with no surgery, regardless of their
deprivation.
We provide graphs illustrating probability of death within 90
days of colon cancer diagnosis against age at diagnosis for each
treatment type in both males and females, at each of the four stages
of diagnosis (Figure 1, Supplementary Figures 2–4). The graphs
contrast probability of death in the most and least deprived groups
in patients with no recorded comorbidities and those with the
maximum comorbidity score of 3. The general pattern was that
more deprived patients were associated with higher 90-day
mortality, regardless of the combination of other prognostic
factors. Figure 1 presents these probabilities for stage-2 patients.
Average predicted probabilities by deprivation. In both males
and females, the average predicted probabilities of death within 90
days of diagnosis identified a clear gradient across the observed
deprivation groups, highest among the most deprived patients and
lowest among the least deprived patients (Table 3, second and
fourth columns). The existence of a difference in the average
predicted probability of death between the most deprived and least
deprived patient groups can be termed a ‘deprivation gap’. The
largest deprivation gap was in females, with 6.5% fewer deaths
predicted within 90 days for the least deprived group compared
with the most deprived (least deprived: 13.4%, 95% CI 12.7, 14.0%;
and most deprived: 19.9%, 95% CI 19.0, 20.7%). In males, this gap
was 5.3% (least deprived: 12.4%, 95% CI 11.8, 13.1%; and most
deprived: 17.7%, 95% CI 16.9, 18.6%).
To explore the deprivation gap further, the probability of death
was recalculated for each of the deprivation groups by predicting
each group’s probability of death as if it were the least deprived
group, while all other prognostic factors remained as observed
(Table 3, third and fifth columns). The results showed a shrinkage
in the difference in probability of death between the most and least
deprived groups, the difference became 1.7% and 1.3% in females
and males, respectively. As expected, we observed the largest
reduction in probability of death in the most deprived group: in
females the reduction was 4.8% and in males the reduction was 4%.
In the additional analysis, when stage, treatment or both stage
and treatment in combination were excluded from the final model
and when the average predicted probability of death was calculated
as if patients belonged to the least deprived group, there was a
further reduction in the mortality difference between the most and
least deprived patients from the one seen in the full analysis model
(Supplementary Table 4). When stage alone was excluded from the
model, the difference in probability of death between the most and
least deprived patients reduced by approximately 30% (absolute
difference of 0.9% compared with 1.3% with the final full model in
males and 1.2% compared with 1.7% in females). For treatment
alone, this percentage was 25% (absolute difference of 1%
compared with 1.3% in males, and 1.3% compared with 1.7% in
females). This suggested that, after accounting for the effect of
deprivation, stage (or treatment) contributed to approximately
one-third (or a quarter) of the remaining difference. When both
stage and treatment were removed from the model, the remaining
difference was close to 0%, indicating that in combination stage
and treatment appear to contribute to most of the remaining
difference in 90-day mortality once the effect of deprivation has
been accounted for.
DISCUSSION
We found a very wide overall range of short-term mortality
probabilities: for example, among female patients aged 60 years,
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Figure 1. Probability (%) of death within 90 days of stage 2 colon cancer diagnosis according to age at diagnosis, among patients with
(i) comorbidity score of 0 or 3 and (ii) from the least or the most deprived group.
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a major elective surgery had a 90-day mortality probability near
0%, compared with a probability between 25% and 55%
(depending on their deprivation group and comorbidity) for those
with a stage-4 diagnosis who did not receive a major surgery.
Deprivation differences in 90-day mortality were seen despite
adjusting for major prognostic factors.
In our patient population, when calculating the average
predicted probability of death within 90 days by deprivation
group, and assuming that patients belong to the least deprived
group, the differences between the probability of death in the least
deprived group and the other deprivation groups became smaller.
It translated to a total of 209 fewer deaths within 90 days of
diagnosis per year in females and 168 fewer deaths per year in
males (about 4% of the number of deaths observed in deprivation
groups 2–5). Furthermore, when considering only the most
deprived group of patients, it equated to approximately 74 and
Table 2. Conditional probabilities of death within 90 days of colon cancer diagnosis
Male Female
Age at diagnosis, years Age at diagnosis, years


















No major treatment 0 Least 0.2 (0.1; 0.6) 0.7 (0.4; 1.3) 1.9 (1.2; 2.9) 1.4 (0.8; 2.3) 3.8 (2.7; 5.4) 8.0 (6.2; 10.2)
Most 0.4 (0.1; 1.0) 1.1 (0.7; 2.0) 2.9 (1.8; 4.5) 2.3 (1.4; 3.9) 6.4 (4.6; 8.8) 12.9 (10.1; 16.2)
3 Least 0.5 (0.2; 1.3) 0.9 (0.5; 1.6) 1.9 (1.2; 3.0) 2.8 (1.5; 5.5) 7.0 (4.7; 10.3) 11.3 (8.5; 14.9)
Most 0.7 (0.3; 2.0) 1.4 (0.8; 2.4) 2.9 (1.8; 4.6) 4.8 (2.5; 9.0) 11.4 (7.8; 16.4) 17.9 (13.8; 22.9)
Major emergency treatment 0 Least 0.3 (0.1; 1.4) 1.2 (0.4; 3.8) 3.6 (1.2; 10.4) 1.2 (0.7; 2.1) 3.7 (2.7; 5.0) 8.1 (6.5; 10.0)
Most 0.5 (0.1; 2.2) 1.8 (0.6; 5.8) 5.4 (1.8; 15.2) 2.1 (1.3; 3.5) 6.2 (4.6; 8.3) 13.1 (10.7; 16.0)
3 Least 1.1 (0.3; 4.7) 2.4 (0.7; 7.6) 5.9 (1.9; 16.6) 2.6 (1.4; 4.9) 6.8 (4.7; 9.7) 11.6 (9.0; 14.8)
Most 1.7 (0.4; 7.1) 3.6 (1.1; 11.3) 8.9 (3.0; 23.7) 4.3 (2.3; 8.0) 11.1 (7.8; 15.4) 18.3 (14.5; 22.8)
Major elective treatment 0 Least 0.2 (0.1; 0.5) 0.5 (0.3; 0.8) 1.5 (1.0; 2.3) 0.1 (0.1; 0.3) 0.5 (0.4; 0.8) 1.4 (1.0; 1.8)
Most 0.3 (0.1; 0.7) 0.8 (0.5; 1.3) 2.4 (1.6; 3.5) 0.2 (0.1; 0.4) 0.9 (0.6; 1.3) 2.3 (1.8; 3.0)
3 Least 0.6 (0.2; 1.8) 1.1 (0.6; 1.9) 2.9 (1.8; 4.5) 0.3 (0.1; 0.6) 1.0 (0.7; 1.6) 2.0 (1.5; 2.7)
Most 1.0 (0.3; 2.7) 1.7 (1.0; 3.0) 4.4 (2.8; 6.7) 0.5 (0.2; 1.0) 1.7 (1.1; 2.6) 3.4 (2.5; 4.6)
Stage 2
No major treatment 0 Least 1.2 (0.7; 1.9) 3.8 (2.8; 5.1) 7.1 (5.5; 9.3) 1.4 (0.8; 2.3) 3.8 (2.7; 5.4) 8.0 (6.2; 10.2)
Most 1.9 (1.2; 3.0) 5.7 (4.2; 7.7) 10.7 (8.2; 13.8) 2.3 (1.4; 3.9) 6.4 (4.6; 8.8) 12.9 (10.1; 16.2)
3 Least 2.3 (1.3; 4.1) 4.5 (3.2; 6.4) 7.2 (5.4; 9.7) 2.8 (1.5; 5.5) 7.0 (4.7; 10.3) 11.3 (8.5; 14.9)
Most 3.6 (2.1; 6.1) 6.8 (4.9; 9.5) 10.8 (8.1; 14.2) 4.8 (2.5; 9.0) 11.4 (7.8; 16.4) 17.9 (13.8; 22.9)
Major emergency treatment 0 Least 1.2 (0.7; 1.9) 4.1 (3.1; 5.3) 9.1 (7.3; 11.2) 1.2 (0.7; 2.1) 3.7 (2.7; 5.0) 8.1 (6.5; 10.0)
Most 1.8 (1.2; 2.9) 6.2 (4.7; 8.0) 13.4 (10.9; 16.4) 2.1 (1.3; 3.5) 6.2 (4.6; 8.3) 13.1 (10.7; 16.0)
3 Least 3.8 (2.1; 6.7) 7.9 (5.5; 11.2) 14.5 (10.8; 19.1) 2.6 (1.4; 4.9) 6.8 (4.7; 9.7) 11.6 (9.0; 14.8)
Most 5.8 (3.3; 10.0) 11.7 (8.3; 16.3) 20.8 (15.9; 26.8) 4.3 (2.3; 8.0) 11.1 (7.8; 15.4) 18.3 (14.5; 22.8)
Major elective treatment 0 Least 0.4 (0.2; 0.6) 1.1 (0.9; 1.4) 2.6 (2.1; 3.2) 0.1 (0.1; 0.3) 0.5 (0.4; 0.8) 1.4 (1.0; 1.8)
Most 0.6 (0.4; 0.9) 1.7 (1.3; 2.2) 4.0 (3.2; 5.0) 0.2 (0.1; 0.4) 0.9 (0.6; 1.3) 2.3 (1.8; 3.0)
3 Least 1.4 (0.8; 2.4) 2.5 (1.7; 3.6) 4.9 (3.6; 6.6) 0.3 (0.1; 0.6) 1.0 (0.7; 1.6) 2.0 (1.5; 2.7)
Most 2.1 (1.2; 3.7) 3.8 (2.7; 5.4) 7.4 (5.5; 9.9) 0.5 (0.2; 1.0) 1.7 (1.1; 2.6) 3.4 (2.5; 4.6)
Stage 3
No major treatment 0 Least 3.2 (2.3; 4.5) 5.8 (4.6; 7.3) 9.8 (7.9; 12.1) 2.6 (1.7; 3.8) 4.7 (3.5; 6.2) 7.3 (5.8; 9.3)
Most 4.9 (3.5; 6.9) 8.8 (6.9; 11.0) 14.5 (11.8; 17.7) 4.3 (2.9; 6.4) 7.7 (5.8; 10.2) 11.9 (9.4; 14.9)
3 Least 6.1 (3.9; 9.4) 6.9 (5.2; 9.2) 9.9 (7.7; 12.7) 5.2 (3.0; 9.0) 8.5 (6.0; 11.9) 10.5 (8.0; 13.5)
Most 9.2 (6.0; 13.8) 10.4 (7.9; 13.5) 14.6 (11.5; 18.4) 8.6 (5.1; 14.4) 13.7 (9.9; 18.7) 16.6 (13.0; 21.1)
Major emergency treatment 0 Least 2.0 (1.4; 2.9) 4.0 (3.1; 5.1) 8.1 (6.5; 10.1) 3.0 (2.1; 4.2) 5.7 (4.6; 7.2) 9.4 (7.8; 11.4)
Most 3.1 (2.2; 4.4) 6.1 (4.8; 7.6) 12.0 (9.7; 14.8) 5.0 (3.5; 7.0) 9.4 (7.5; 11.7) 15.1 (12.5; 18.0)
3 Least 6.3 (3.9; 10.1) 7.7 (5.5; 10.7) 13.0 (9.7; 17.3) 6.1 (3.6; 10.0) 10.3 (7.6; 13.9) 13.3 (10.5; 16.7)
Most 9.4 (5.9; 14.8) 11.5 (8.3; 15.7) 18.8 (14.3; 24.4) 9.9 (6.0; 16.0) 16.4 (12.3; 21.5) 20.8 (16.8; 25.4)
Major elective treatment 0 Least 0.5 (0.4; 0.8) 0.9 (0.7; 1.2) 2.0 (1.5; 2.6) 0.3 (0.2; 0.6) 0.9 (0.6; 1.2) 1.6 (1.3; 2.2)
Most 0.8 (0.6; 1.2) 1.4 (1.1; 1.9) 3.1 (2.4; 4.0) 0.6 (0.4; 0.9) 1.5 (1.1; 2.0) 2.8 (2.1; 3.7)
3 Least 2.0 (1.2; 3.3) 2.1 (1.5; 3.0) 3.7 (2.6; 5.2) 0.7 (0.4; 1.4) 1.6 (1.1; 2.4) 2.4 (1.8; 3.3)
Most 3.0 (1.8; 5.0) 3.2 (2.2; 4.6) 5.7 (4.1; 7.9) 1.2 (0.6; 2.3) 2.8 (1.9; 4.0) 4.1 (3.0; 5.5)
Stage 4
No major treatment 0 Least 24.9 (22.7; 27.2) 33.2 (31.0; 35.4) 46.0 (43.4; 48.7) 24.4 (22.0; 27.0) 34.2 (31.8; 36.7) 49.1 (46.3; 51.9)
Most 33.9 (31.2; 36.8) 43.5 (40.9; 46.1) 57.0 (54.2; 59.7) 35.6 (32.4; 38.9) 47.1 (44.2; 49.9) 62.3 (59.4; 65.0)
3 Least 39.4 (31.6; 47.7) 37.5 (32.6; 42.6) 46.3 (41.8; 50.9) 40.5 (30.3; 51.6) 49.5 (42.9; 56.2) 58.8 (53.8; 63.6)
Most 50.2 (41.8; 58.6) 48.2 (42.9; 53.4) 57.3 (52.7; 61.7) 53.8 (42.7; 64.5) 62.7 (56.3; 68.7) 70.9 (66.6; 74.9)
Major emergency treatment 0 Least 11.9 (9.8; 14.4) 18.1 (15.9; 20.6) 31.4 (27.9; 35.2) 11.1 (9.0; 13.6) 17.6 (15.3; 20.1) 29.6 (26.2; 33.2)
Most 17.3 (14.5; 20.6) 25.6 (22.7; 28.7) 41.6 (37.3; 45.9) 17.5 (14.4; 21.2) 26.7 (23.5; 30.2) 41.8 (37.6; 46.1)
3 Least 30.7 (22.1; 40.9) 30.9 (24.4; 38.2) 43.7 (36.3; 51.4) 20.8 (13.9; 29.9) 28.7 (23.0; 35.2) 38.3 (32.8; 44.1)
Most 40.8 (30.6; 51.8) 41.0 (33.4; 48.9) 54.6 (46.9; 62.2) 31.0 (21.7; 42.1) 40.8 (33.9; 48.0) 51.5 (45.5; 57.5)
Major elective treatment 0 Least 3.8 (2.9; 5.0) 5.3 (4.4; 6.4) 10.4 (8.6; 12.6) 1.9 (1.3; 2.8) 4.1 (3.2; 5.2) 8.5 (6.9; 10.5)
Most 5.8 (4.4; 7.5) 7.9 (6.6; 9.5) 15.3 (12.7; 18.3) 3.2 (2.2; 4.6) 6.8 (5.3; 8.5) 13.7 (11.2; 16.7)
3 Least 12.7 (8.3; 19.0) 11.2 (8.2; 15.1) 18.1 (13.8; 23.4) 3.9 (2.2; 6.7) 7.4 (5.4; 10.2) 12.1 (9.4; 15.5)
Most 18.5 (12.4; 26.6) 16.4 (12.3; 21.5) 25.6 (19.9; 32.2) 6.5 (3.7; 11.0) 12.1 (8.8; 16.2) 19.0 (15.0; 23.8)
Abbreviations: CI¼ confidence interval; PoD¼probability of death.
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69 fewer deaths in females and males, respectively. These results
suggested that the differential distribution of the prognostic factors
in deprivation groups may account for some of the outcome
differences observed.
In the additional analysis, when we explored the role stage and
treatment may be having in 90-day mortality differences between
the most and least deprived patients, we found that stage and
treatment appeared to contribute towards almost all of the
remaining difference between the most and least deprived patient
groups. When the average predicted probability of death was
calculated assuming all patients were in the least deprived group
and after removing both stage and treatment from the model, the
average predicted probabilities were almost the same between the
most and least deprived patient groups.
Differential access of treatment by deprivation may explain
some of the inequalities in mortality. The percentage of colon
cancer cases diagnosed during an emergency admission was as
high as 31.4% in England for diagnoses made between 2006 and
2010 (Abel et al, 2015). In Scotland, the most deprived patients
were more likely to present as an emergency and undergo palliative
surgery (Oliphant et al, 2013). The same study also found higher
postoperative mortality among more deprived colorectal patients,
after adjusting for comorbidity and stage. These findings are in line
with ours, where the socio-economic differences in 90-day
mortality were evident in both nonoperative and postoperative
colon cancer patients. Comorbidity and stage provide some
contribution towards differences in short-term cancer mortality,
but the socio-economic inequalities in 90-day mortality probability
persisted even within any given treatment category, after control-
ling for stage and comorbidity. In the context of randomised
clinical trials, where stage, comorbidity and also treatment are well
controlled, we did not find evidence of a deprivation gap in 1-year
colorectal cancer survival (Nur et al, 2008).
In a broader context, other work discussed differences in the
quality of postoperative care and availability of beds in high
dependence and intensive care units in the institution where
treatment is received as potential factors influencing short-term
postoperative mortality (Morris et al, 2011). This is especially
pertinent in the presence of a high prevalence of postoperative
complications. Previous research in Australia found that patients
from higher socio-economic areas had a lower risk of developing
postoperative complications (Beckmann et al, 2016), reinforcing
the need for adequate postoperative care facilities in the most
deprived areas. Comparing postoperative care resourcing between
institutions in more and lesser deprived areas could provide some
explanation behind socio-economic differences in 90-day colon
cancer mortality and should be examined in more detail. Our study
included surgical treatment received up to 90 days after diagnosis
but did not account for the time to surgical treatment. Other
research has shown more deprived patients were more likely to
receive late treatment, that is, later than a month since diagnosis
(Lejeune et al, 2010).
The results of this study provided some insight into an existing
dynamic between treatment, comorbidity and short-term mortal-
ity. This relationship has some complexity, as comorbidity affects
survival and influences cancer management (Faivre et al, 2007).
This complexity is more pronounced in the elderly: the frequency
of comorbidity is often higher in the elderly (Colorectal Cancer
Collaborative Group, 2000), they tend to have more advanced
disease stage (Dekker et al, 2011), and postoperative mortality
increases with age (Morris et al, 2011). Additionally, patients
undergoing emergency major surgery had a higher 90-day
probability of death than patients who had received elective major
treatment. This concurs with previous research indicating
emergency surgery in comorbid patients to be a risk factor for
short-term mortality in postoperative colon cancer patients
(Gooiker et al, 2012).
Some challenges were faced when conducting analyses for this
study, in particular owing to the use of population-based data. We
employed a robust imputation strategy to mitigate the disadvan-
tage of having missing information on stage (Bartlett et al, 2015).
This approach allowed us to select the most parsimonious model as
the final model to predict probability of death within 90 days, while
taking proper account of the missing data. The overall probability
of 90-day mortality was estimated as 14.7% (95% CI 14.4, 15.0%)
for males and 16.6% (95% CI 16.3, 16.9%) for females. These
predictions closely align with the observed proportion of deaths
occurring within 90 days in our study population, confirming the
goodness of fit of the analysis model on the observed data.
Information on treatment received by patients in our study was
obtained using records from public hospitals. Some patients in our
study may have received treatment in private facilities, which is not
captured in our study. However, the proportion of cancer patients
receiving surgical treatment outside the National Health Service
has historically been small (Lawrence, 2013).
Our method for deriving patient comorbidity information
was dependent on patients visiting the hospital and being
diagnosed with the comorbidity in the time period of interest.
We acknowledge the possibility that some comorbid adults may
not have attended hospital nor had a comorbidity diagnosis
recorded in this time, and therefore their comorbidity score
would be 0. When available, including nonsurgical treatment
in the analysis may provide additional insight into disparities
in 90-day mortality between colon cancer patient groups,
although surgery remains the primary curative treatment for
colon cancer.
In conclusion, this study gives a full picture of 90-day
probability of death according to the main prognostic factors
and highlights persistent socio-economic inequalities in short-term
mortality, even after accounting for the main prognostic factors,








Average predicted probability, adjusted
as if patients belonged to the deprivation





Average predicted probability, adjusted
as if patients belonged to the deprivation
group 1b (95% CI)
Least deprived (1) 12.4 (11.8; 13.1) 12.4 (11.8; 13.1) 13.4 (12.7; 14.0) 13.4 (12.7; 14.0)
2 13.7 (13.0; 14.3) 12.9 (12.2; 13.5) 15.3 (14.7; 16.0) 14.1 (13.4; 14.8)
3 14.6 (13.9; 15.3) 13.3 (12.6; 14.0) 17.0 (16.3; 17.6) 14.8 (14.0; 15.5)
4 16.0 (15.3; 16.7) 13.6 (13.0; 14.3) 18.5 (17.8; 19.3) 15.5 (14.7; 16.2)
Most deprived (5) 17.7 (16.9; 18.6) 13.7 (13.0; 14.3) 19.9 (19.0; 20.7) 15.1 (14.4; 15.9)
Abbreviation: CI¼ confidence interval.
aProbability predicted for each deprivation group based on the observed value of the deprivation group, with the distribution of all prognostic factors remaining as observed.
bProbability predicted for each deprivation group adjusted to assume patients in each group belong to the least deprived group (group 1), with the distribution of all prognostic factors
remaining as observed.
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including prediagnosis comorbidities that could be derived from
hospital attendance records and cancer registry data. Indeed, these
socio-economic differences in 90-day mortality were especially
apparent in the older patients, as probability of 90-day mortality
increased with age. The provision of treatment involves considera-
tion as to whether patients can withstand the trauma of surgery,
particularly where patients have comorbid conditions. This is
especially true in older patients more vulnerable to the aftermath of
surgery. The planning of cancer treatment and care would need to
focus decisions to treat patients on patient performance status and
comorbidities, rather than their chronological age (Lawler et al,
2014). Socio-economic inequalities in 90-day mortality being
found even among non-vulnerable patients suggest that resources
for optimal treatment planning and postoperative care facilities
may not be equally accessible to all patient deprivation groups.
This study has identified a need to focus on understanding what is
driving the effect of deprivation on 90-day mortality, including
differences in health-care-seeking behaviours. Based on the
findings of this population-based study, beneficial health policy
initiatives could include targeted screening programmes to
facilitate earlier-stage diagnosis in vulnerable patient groups,
improved preoperative planning, including evaluation of comorbid
patients, and more stringent postoperative monitoring of the
patients.
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Supplementary Table 1: Major surgery, as defined using OPCS-4 codes
Code Description
H011 Emergency excision of abnormal appendix and drainage HFQ
H012 Emergency excision of abnormal appendix NEC
H013 Emergency excision of normal appendix
H018 Other specified emergency excision of appendix
H019 Emergency appendicectomy NEC, unspecified
H021 Interval appendicectomy
H022 Planned delayed appendicectomy NEC
H023 Prophylactic appendicectomy NEC
H024 Incidental appendicectomy
H028 Other specified other excision of appendix
H029 Appendicectomy NEC, unspecified
H041 Proctocolectomy NEC, panproctocolectomy and ileostomy 
H042 Panproctocolectomy and anastomosis of ileum to anus and creation of pouch HFQ 
H043 Panproctocolectomy and anastomosis of ileum to anus NEC 
H048 Other specified total excision of colon and rectum 
H049 Panproctocolectomy NEC, total excision of colon and rectum, unspecified
H051 Total colectomy and anastomosis of ileum to rectum 
H052 Total colectomy and ileostomy and creation of rectal fistula HFQ 
H053 Total colectomy and ileostomy NEC 
H058 Total excision of colon, other specified 
H059 Total excision of colon, unspecified 
H061 Extended right hemicolectomy and end to end anastomosis 
H062 Extended right hemicolectomy and anastomosis of ileum to colon 
H063 Extended right hemicolectomy and anastomosis NEC 
H064 Extended right hemicolectomy and ileostomy HFQ 
H068 Other specified extended excision of right hemicolon 
H069 Extended excision of right hemicolon, unspecified, excision of right colon and surrounding tissue 
H071 Right hemicolectomy and end to end anastomosis of ileum to colon, ileocaecal resection 
H072 Right hemicolectomy and side to side anastomosis of ileum to transverse colon 
H073 Right hemicolectomy and anastomosis NEC 
H074 Right hemicolectomy and ileostomy HFQ 
H078 Other specified other excision of right hemicolon 
H079 Other excision of right hemicolon, unspecified; right hemicolectomy NEC 
H081 Transverse colectomy and end to end anastomosis 
H082 Transverse colectomy and anastomosis of ileum to colon 
H083 Transverse colectomy and anastomosis NEC 
H084 Transverse colectomy and ileostomy HFQ 
H085 Transverse colectomy and exteriorisation of bowel NEC 
H088 Other specified excision of transverse colon 
H089 Excision of transverse colon, unspecified 
H091 Left hemicolectomy and end to end anastomosis of colon to rectum 
H092 Left hemicolectomy and end to end anastomosis of colon to colon 
H093 Left hemicolectomy and anastomosis NEC 
H094 Left hemicolectomy and ileostomy HFQ 
H095 Left hemicolectomy and exteriorisation of bowel NEC 
H098 Excision of left hemicolon, other specified 
H099 Left hemicolectmy NEC, excision of left hemicolon, unspecified 
H101 Sigmoid colectomy and end to end anastomosis of ileum to rectum
H102 Sigmoid colectomy and anastomosis of colon to rectum
H103 Sigmoid colectomy and anastomosis NEC
H104 Sigmoid colectomy and ileostomy HFQ
H105 Sigmoid colectomy and exteriorisation of bowel NEC
H108 Other specified excision of sigmoid colon
H109 Unspecified excision of sigmoid colon
H111 Colectomy and end to end anastomosis of colon to colon NEC
H112 Colectomy and side to side anastomosis of ileum to colon NEC
H113 Colectomy and anastomosis NEC
H114 Colectomy and ileostomy NEC
H115 Colectomy and exteriorisation of bowel
H118 Other excision of colon, other specified
H119 Hemicolectomy NEC; colectomy NEC,  other excision of colon, unspecified 
H121 Excision of diverticulum of colon
H122 Polypectomy NEC, excision of lesion NEC
H123 Destruction of lesion of colon NEC
H128 Other specified extirpation of lesion of colon
H129 Unspecified extirpation of lesion of colon
H291 Subtotal excision of colon and rectum and creation of colonic pouch and anastomosis of colon to anus
H292 Subtotal excision of colon and rectum and creation of colonic pouch NEC
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Code Description
H293 Subtotal excision of colon and creation of colonic pouch and anastomosis of colon to rectum
H294 Subtotal excision of colon and creation of colonic pouch NEC
H298 Subtotal excision of colon, other specified 
H299 Subtotal excision of colon, unspecified 
H331 Abdominoperineal excision of rectum and end colostomy
H332 Proctectomy and anastomosis of colon to anus
H333 Anterior resection of rectum and anastomosis of colon to rectum using staples
H334 Anterior resection of rectum and anastomosis NEC
H335 Hartmann procedure, rectosigmoidectomy and closure of rectal stump and exteriorisation of bowel
H336 Anterior resection of rectum and exteriorisation
H337 Perineal resection of rectum HFQ
H338 Anterior resection of rectum NEC, rectosigmoidectomy and anastomosis of colon to rectum, excision of rectum, other specified
H339 Rectosigmoidectomy NEC, excision of rectum, unspecified 
H341 Open excision of lesion of rectum: open removal of polyp; Yorke Mason
H342 Open cauterisation of lesion of rectum, Diathermy
H343 Open cryotherapy to lesion of rectum
H344 Open laser destruction of lesion of rectum
H345 Open destruction of lesion of rectum NEC
H348 Open removal of lesion of rectum, other specified
H349 Open removal of lesion of rectum, unspecified
H401 Trans-sphincteric excision of mucosa of rectum
H402 Trans-sphincteric excision of lesion of rectum
H403 Trans-sphincteric destruction of lesion of rectum
H404 Trans-sphincteric anastomosis of colon to anus
H408 Other specified operations on rectum through anal sphincter
H409 Unspecified operations on rectum through anal sphincter
X141 Total exenteration of pelvis
X142 Anterior exenteration of pelvis
X143 Posterior exenteration of pelvis
X148 Other specified clearance of pelvis
X149 Clearance of pelvis, unspecified
Abbreviations: NEC, Not elsewhere specified; HFQ, however further qualified 
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n % n % n % n %
Total missing stage 10,391 47.8* 3,344 15.4* 7,982 36.8* 21,717 31.1
1 1,649 11.1** 287 3.4** 4,066 16.3** 6,002 8.6
2 1,472 9.9** 2,609 31.2** 9,574 38.5** 13,655 19.6
3 1,828 12.3** 2,831 33.8** 8,014 32.2** 12,673 18.2
4 9,861 66.6** 2,640 31.6** 3,221 12.9** 15,722 22.5
TOTAL 25,201 36.1 11,711 16.8 32,857 47.1 69,769 100.00
Stage
Supplementary Table 2: Distribution of stage at diagnosis by treatment received in patients diagnosed with  colon cancer 2010-2013† in England 
* Representing the proportion of all patients in this group
** Representing the proportion of patients with complete stage information in this group
† 2013 data represents diagnosis between 1st January 2013 and 31st March 2013
No major treatment Major emergency treatment Major elective treatment TOTAL
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n % n % n % n % n %
No major surgery 17,088 33.3 3,062 41.8 2,452 40.3 2,599 51.3 25,201 36.12
Major emergency surgery 8,979 17.5 1,151 15.7 859 14.1 722 14.3 11,711 16.79
Major elective surgery 25,229 49.2 3,119 42.5 2,768 45.5 1,741 34.4 32,857 47.09
TOTAL 51,296 73.5 7,332 10.5 6,079 8.7 5,062 7.3 69,769 100.00
Treatment
Supplementary Table 3: Distribution of treatment received by comorbidity score in patients diagnosed with colon cancer 2010-2013† in England
† 2013 data represents diagnosis between 1st January 2013 and 31st March 2013
Comorbidity Score
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Supplementary Figure 4
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Deprivation group Final analysis model Model excludes stage Model excludes treatment Model excludes stage and treatment
Least deprived (1) 12.4 [11.8; 13.1] 12.4 [11.8; 13.1] 12.4 [11.8; 13.1] 12.4 [11.7; 13.1]
2 12.9 [12.2; 13.5] 12.8 [12.1; 13.5] 12.8 [12.1; 13.5] 12.9 [12.2; 13.7]
3 13.3 [12.6; 14.0] 13.0 [12.3; 13.7] 13.2 [12.5; 13.9] 12.8 [12.1; 13.5]
4 13.6 [13.0; 14.3] 13.3 [12.6; 14.0] 13.4 [12.7; 14.1] 12.7 [11.9; 13.4]
Most deprived (5) 13.7 [13.0; 14.3] 13.3 [12.6; 14.0] 13.4 [12.7; 14.1] 12.5 [11.8; 13.2]
Least deprived (1) 13.4 [12.7; 14.0] 13.4 [12.7; 14.1] 13.4 [12.7; 14.0] 13.4 [12.6; 14.1]
2 14.1 [13.4; 14.8] 13.9 [13.2; 14.7] 14.1 [13.4; 14.9] 13.9 [13.1; 14.7]
3 14.8 [14.0; 15.5] 14.4 [13.7; 15.2] 14.8 [14.1; 15.6] 14.2 [13.4; 15.0]
4 15.5 [14.7; 16.2] 15.1 [14.3; 15.8] 15.4 [14.6; 16.2] 14.5 [13.7; 15.3]
Most deprived (5) 15.1 [14.4; 15.9] 14.6 [13.8; 15.4] 14.7 [13.9; 15.4] 13.7 [12.9; 14.5]
CI, confidence interval 
* Probability predicted for each deprivation group adjusted to assume patients in each group belong to the least deprived group (group 1), with the distribution of all prognostic factors remaining as observed 




Supplementary Table 4: Average predicted probability of death (%) within ninety days: by deprivation - additional analyses
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Chapter 4 - Comorbidity prevalence among cancer patient populations 
 
This chapter describes the research undertaken to achieve both parts of the second objective of this 
thesis: to i) describe and ii) evaluate the measurement of comorbidity prevalence in the cancer patient 
population. The research conducted for the first part of the objective resulted in a research paper 
which describes a population-based study of the prevalence of comorbidity among four cohorts of 
cancer patients. This paper was published in BMC Cancer in January 2020 and is referred to as research 
paper 2. The first section of this chapter provides the background, description, summary of main 
findings and conclusions of this descriptive study, together with a copy of the research paper.  
The second section of the chapter explains the research conducted to address the second part of the 
objective: to evaluate the measurement of cancer comorbidity. This study examined sources of 
information on chronic disease prevalence in other cancer patient cohorts and in the general 
population. The background, methods, results and conclusions from this study have been written up 
in this chapter.  
At the end of the chapter is a discussion of how this work fulfils the second objective and informs the 
research conducted in next chapter.   
 
Introduction to research paper 2 
 
Background 
The presence of comorbidity can influence the care of cancer patients,13, 105, 106 and is considered a 
prognostic factor in cancer outcomes.87, 107-109 This has been highlighted in studies of colon or 
colorectal cancer patients,48, 57, 110-112 including the study I conducted of ninety-day mortality among 
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colon cancer patients that was described the previous chapter of this thesis (Research Paper 1).101 A 
study of cancer patients in the United States reported that patients with localised stage colon cancer 
and moderate or severe comorbidity (based on the Adult Comorbidity Evaluation Index (ACE-27)113) 
had almost 2.5 times the hazard of dying within one year of diagnosis as compared with colon cancer 
patients with localised stage and no comorbidity (HR 2.48; 95% CI: 1.67, 3.68).110 Similarly, a study of 
colorectal cancer patients in the North West of England reported that patients with a Charlson 
comorbidity score of 3 or more had 1.8 times the hazard of death within one year, after adjusting for 
stage and other prognostic factors.48 In the study of colon cancer patients described in Research Paper 
1, those with a Charlson comorbidity score of 3 or more consistently had a higher probability of death 
than those without any recorded comorbidity, regardless of sex, age, stage at diagnosis, receipt of 
major surgery and deprivation group.101  
 
Multimorbidity and comorbidity are associated with age114, 115 but also with socio-economic position, 
with a greater burden of multimorbidity falling among the most deprived members of the 
population.14, 15, 64 Moreover, the prevalence of various comorbid conditions among cancer patients is 
not very well known. A study in New Zealand investigated the prevalence of 50 conditions among 
14,096 cancer patients, including 3,999 patients with cancer of the colon, based upon hospital 
admissions data. The most common conditions among the cohort of colon cancer patients included 
hypertension (17%), coagulopathy and blood disorders (12%), metabolic disorders (9%) and cardiac 
diseases (8%).116 By comparison, a study of 1,061 colorectal cancer patients in two regions of Spain 
found common conditions to be diabetes (24%), chronic obstructive pulmonary disease (17%) and 
congestive heart failure (15%).117 However, there is limited information available on the prevalence of 
comorbidity among cancer patients in England, or on how the prevalence of these conditions varies 
according to factors such as socio-economic deprivation. Further research to investigate patterns of 
comorbidity prevalence among cancer patients, particularly among the more deprived groups, may 
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help to increase our understanding of which groups of comorbid patients have a higher risk of dying 
soon after cancer diagnosis.  
The first aim of this study was to estimate the prevalence of comorbid conditions among cancer 
patients in England using population-based electronic health records of hospital admissions. The 
second aim was to describe patterns of comorbidity according to patient characteristics, such as socio-
economic position.  
 
Description 
This study examines comorbidity prevalence among patients diagnosed with cancer of the colon, 
rectum or lung, or with Hodgkin lymphoma in England between 2009 and 2013. 118, 119 The choice of 
these cancers was based on their aetiology. The development of colon, rectal or lung cancers is 
associated with environmental or lifestyle risk factors such as poor diet, excessive alcohol use and 
tobacco smoking.120 The risk factors for these cancers are also associated with the development of 
other chronic diseases. For example, smoking is associated with developing chronic obstructive 
pulmonary disease,121 while poor diet122, 123 and smoking124  increase the risk of developing diabetes. 
It was therefore anticipated that the prevalence of conditions such as these would be higher among 
patients with these cancers. As a contrast, Hodgkin lymphoma was studied as it tends to have an 
infectious rather than an environmental aetiology.118 Prior exposure to the Epstein Barr virus has been 
shown to increase the risk of developing Hodgkin lymphoma.118, 125 Additionally, the development of 
the other three cancers tends to be associated with older age,126 while Hodgkin lymphoma has a 
bimodal age distribution, most commonly occurring in children and younger adults or in older 
adults.125     
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The study uses national cancer registry data linked with electronic health records of hospital visits, 
and investigates the prevalence of conditions recorded in these data up to six years prior to cancer 
diagnosis. Information on non-cancer comorbidities was extracted from hospital admissions records 
using an algorithm initially published in a research paper in PLoS One76 and further described earlier 
in this thesis. Information on previous malignancies was obtained from cancer registration data. The 
choice of comorbid conditions to study followed a thorough exploration of these data to ascertain the 
prevalence of approximately fifty conditions. The fourteen selected conditions of interest were 
conditions of the Charlson Comorbidity Index83 and other highly prevalent conditions that may 
influence cancer treatment or prognosis, either in isolation or in combination with other conditions. 
The analyses conducted for this descriptive study firstly involved estimation of both the crude and 
age-sex prevalence of each of these conditions. Logistic regression was then used to estimate the odds 
of having each condition, adjusting for age, sex and deprivation, to look for associations between these 
variables and each of the comorbid conditions. Cross tabulations of the data provided relative 
frequencies in which five of the common conditions were present in combination with other 
conditions. Multinomial logistic regression was used to estimate the probability of having each 
condition as a single comorbidity or as one of multiple comorbidities, according to whether patients 
were in the most or the least deprived socio-economic deprivation groups.   
 
Main findings 
The findings from this study were reported in the research paper entitled “Comorbidity prevalence 
among cancer patients: a population-based cohort study of four cancers” published in BMC Cancer in 
January 2020.127 These findings were also presented at scientific conferences, listed in the Appendices 
to this thesis.  
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Among the four cohorts of cancer patients studied, up to two thirds of the lung cancer patients and 
approximately half the colon cancer patients (56%) and the rectal cancer patients (47%) had at least 
one long-term health condition when their cancer was diagnosed. Comorbidity was less prevalent 
among the cohort of patients with Hodgkin lymphoma (30%), which had a younger age demographic 
than the other cancers studied. The most prevalent comorbid conditions among all four cohorts of 
cancer patients studied were hypertension, chronic obstructive pulmonary disease (COPD) and 
diabetes. Among colon cancer patients the age-sex adjusted prevalence of these conditions was 17.4% 
(95%CI: 17.0%, 17.8%), 10.8% (10.2%, 11.3%) and 5.7% (5.4%, 5.9%) for hypertension, COPD and 
diabetes, respectively. Almost all of the conditions studied were associated with socio-economic 
deprivation, with increasing odds of the condition being present as deprivation level increased, after 
adjusting for age and sex. For example, the most deprived male colon cancer patients aged 70 years 
had twice the odds of having COPD (OR 2.01; 95%CI: 1.89, 2.12) and 75% increased odds (OR 1.75; 
1.64, 1.87) of having diabetes compared with the least deprived group of male patients of the same 
age. To put these results into context, among the cohort of colon cancer patients the age-sex adjusted 
prevalence of COPD was approximately 11% (prevalence: 10.8%; 95% CI: 10.2%, 11.3%) and the 
adjusted prevalence of diabetes approximately 6% (prevalence 5.7%; 5.4%, 5.9%). The most prevalent 
of the conditions studied was hypertension, with an adjusted prevalence of 17% (17.4%; 17.0%, 17.8%) 
among the colon cancer patient cohort. Only 29% of the patients with COPD and 14% of the patients 
with diabetes had these conditions as a single comorbidity, while the prevalence of multiple 
comorbidity was commonly highest in the most deprived groups of patients. Among the colon cancer 
patient cohort, a difference between the most and least deprived groups in the probability of having 
hypertension, COPD and diabetes as one of multiple comorbidities was established even by the age of 
45 years. This gap widened with increasing age. These patterns described among the colon cancer 




The study findings have illustrated sociodemographic factors influencing the presence of comorbidity 
among cancer patients. Over half of the colon cancer patient cohort studied had at least one comorbid 
condition and over one quarter had two or more comorbid conditions. This population-based study 
highlights an association between socio-economic deprivation and comorbidity among cancer 
patients in England. It also underlines the prevalence of multiple comorbidity, particularly among the 
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Abstract
Background: The presence of comorbidity affects the care of cancer patients, many of whom are living with
multiple comorbidities. The prevalence of cancer comorbidity, beyond summary metrics, is not well known.
This study aims to estimate the prevalence of comorbid conditions among cancer patients in England, and
describe the association between cancer comorbidity and socio-economic position, using population-based
electronic health records.
Methods: We linked England cancer registry records of patients diagnosed with cancer of the colon, rectum,
lung or Hodgkin lymphoma between 2009 and 2013, with hospital admissions records. A comorbidity was
any one of fourteen specific conditions, diagnosed during hospital admission up to 6 years prior to cancer
diagnosis. We calculated the crude and age-sex adjusted prevalence of each condition, the frequency of
multiple comorbidity combinations, and used logistic regression and multinomial logistic regression to
estimate the adjusted odds of having each condition and the probability of having each condition as a single
or one of multiple comorbidities, respectively, by cancer type.
Results: Comorbidity was most prevalent in patients with lung cancer and least prevalent in Hodgkin
lymphoma patients. Up to two-thirds of patients within each of the four cancer patient cohorts we studied
had at least one comorbidity, and around half of the comorbid patients had multiple comorbidities. Our
study highlighted common comorbid conditions among the cancer patient cohorts. In all four cohorts, the
odds of having a comorbidity and the probability of multiple comorbidity were consistently highest in the
most deprived cancer patients.
Conclusions: Cancer healthcare guidelines may need to consider prominent comorbid conditions, particularly
to benefit the prognosis of the most deprived patients who carry the greater burden of comorbidity. Insight
into patterns of cancer comorbidity may inform further research into the influence of specific comorbidities
on socio-economic inequalities in receipt of cancer treatment and in short-term mortality.
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Comorbidity refers to the existence of a long-term
health condition in the presence of a primary disease of
interest [1]. Having one or more comorbidities may in-
fluence the patient’s prognosis for a primary disease
such as cancer. Comorbidity may influence the timing of
cancer diagnosis, in either a positive or a negative way.
For example, the symptoms of comorbidity may drive a pa-
tient to seek medical care sooner, potentially leading to an
earlier diagnosis. Alternatively, cancer symptoms may be
mistakenly considered as symptoms of a pre-existing health
condition, and could delay diagnosis [2–4]. Following diag-
nosis, the presence of comorbidity may also influence tim-
ing, receipt, or outcome of treatment, with clear evidence
that those with comorbidity are less likely to receive curative
treatment than those without, despite increasing evidence
that many patients with comorbidity benefit from such
treatment [3]. Although the presence of multiple co-existent
health conditions is commonplace, the guidelines, funding
and structures of primary care may not support the care of
more patients with multiple conditions [5], and care in sec-
ondary and tertiary centres is typically highly siloed [3].
Methods used in the scientific literature to describe,
measure and quantify the status of comorbidity as an ex-
planatory factor in adverse disease outcomes are varied.
Many summarised metrics of comorbidity have been
proposed, providing an overall picture of a patient’s co-
morbidity status, some specific to a primary disease
while others are more general. For example, a widely
used metric of comorbidity in epidemiological studies is
the Charlson Comorbidity Index (CCI) [6], which
weights 19 long-term health conditions according to
their relative risk of one-year mortality, to produce an
overall index score.
In this study, we firstly aimed to examine the preva-
lence of comorbid conditions in cancer patients using
English population-based electronic health records of
patients diagnosed with cancer of the colon, rectum, or
lung or with Hodgkin lymphoma (HL). An association
between comorbidity (not specific to any primary disease
of interest) and socio-economic position has been widely
reported: the prevalence of certain specific comorbid
conditions [7–10] and general comorbidity prevalence
being higher in deprived groups of patients [11–13]. Our
second aim was to describe patterns of comorbidities
and multiple comorbidity in these cancer patient co-
horts, according to patient characteristics such as socio-
economic position (deprivation).
Methods
We defined a comorbid condition as one of the follow-
ing fourteen health conditions: myocardial infarction
(MI), congestive heart failure (CHF), peripheral vascular
disease (PVD), cerebrovascular disease (CVD), dementia,
chronic obstructive pulmonary disease (COPD), rheum-
atological conditions, liver disease, diabetes, hemiplegia
or paraplegia, renal disease, previous malignancy, obesity
or hypertension. The conditions, selected following a
systematic search of the data, included conditions of the
Charlson Comorbidity Index [6] and any highly preva-
lent conditions that may influence cancer management
alone or in combination with another condition.
Data
This study used England National Cancer Registry data
of 331,655 patients aged 15–90 years at diagnosis with
cancer of the colon, rectum, lung or Hodgkin’s lymph-
oma, between 2009 and 2013. Registry data provided in-
formation on patient sex, age at diagnosis, site of cancer,
date of cancer diagnosis and area of residence at time of
diagnosis, which was used to derive socio-economic pos-
ition, based on deprivation quintiles of the Income Do-
main of the Indices of Multiple Deprivation [14]. The
five-level, ordinal variable indicates the level of
deprivation from 1 (least deprived) to 5 (most deprived).
Areas of residence are defined at the Lower Super Out-
put Area level (mean population 1500).
Inpatient, outpatient and emergency hospital admis-
sions records (Hospital Episode Statistics, HES) [15]
were successfully linked with over 99% of the cancer
registry records, using common unique variables present
in both data sources. The International Statistical Classi-
fication of Diseases and Related Health Conditions tenth
edition (ICD-10) [16] codes captured within the diagnos-
tic fields of HES records provided information on health
conditions recorded during hospital admissions. We
used the ICD-10 code groupings of health conditions
proposed by Quan and colleagues for defining comor-
bidities using administrative data (see Additional file 1)
[17], and used an algorithm [18] to identify whether
these conditions had been recorded in the six-year
period prior to cancer diagnosis. In contrast to the ap-
proach of Maringe and colleagues [18], we included
diagnoses of conditions recorded up to 6 months prior
to cancer diagnosis. We anticipated that first-time diag-
noses of the conditions could occur in this period, and
wanted to obtain the most complete picture of patient
comorbidity. We used cancer registry data to identify
whether a patient had been diagnosed with an unrelated
malignancy up to 6 years before their diagnosis with the
cancer of interest.
Descriptive data analysis
We calculated the prevalence of a comorbid condition
within each of the four patient cohorts defined by cancer
site, firstly as a crude measure, calculating the percent-
age of patients who had a recorded diagnosis of the co-
morbidity in HES records, and secondly adjusting for
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age and sex to account for the older age demographic of
cancer patient populations. Weights for this adjustment
were obtained from 2011 UK census published popula-
tion estimates of persons living in England [19].
Statistical analysis
Logistic regression models were used to estimate the
odds ratio (OR) of having each comorbidity by cancer
site, adjusting for sex, age at cancer diagnosis and
deprivation group. The binary outcome variable indi-
cated the presence of the comorbidity. To account for a
non-linear association between increasing age and the
presence of comorbidity, age was modelled as a continu-
ous variable using a restricted cubic spline with one knot
fixed at 70 years in analyses conducted for cancers of the
colon, rectum and lung and at 45 years for HL (the knot
position was chosen as to be close to the mean age of
the patients in each of these cancer cohorts). To reduce
the risk of unstable models, we ensured there were at
least ten or more occurrences of a comorbidity within
the specific cancer patient cohort for every parameter of
the model (events per variable, EPV) [20].
Multinomial logistic regression was used to estimate
the probability of having a given comorbidity, either in
isolation, or as one of multiple comorbidities, according
to cancer site. The three-category outcome variable indi-
cated whether the patient did not have the given comor-
bidity, only had this comorbidity, or had this
comorbidity with other comorbidities. Models were ad-
justed for age, sex and deprivation, and were run for
each cancer site and comorbidity combination with at
least ten EPV.




The characteristics of patients diagnosed with cancer of
the colon (N = 102,216), rectum (N = 56,342), lung (N =
165,677) or with HL (N = 7420) between 2009 and 2013,
stratified by comorbidity status, are shown in Table 1.
The majority of patients in each cohort were male: ap-
proximately 55% of colon, lung and HL patients and
63% of rectal cancer patients. At least 80% of colon, rec-
tum and lung cancer patients were in the two oldest age
group categories, while 50% of the HL patients were
within the two youngest age groups. There was an even
distribution of patients among each of the deprivation
groups, except among lung cancer patients, where the
percentage of patients in each group increased with
deprivation level.
Comorbidity was over twice as prevalent in lung can-
cer patients than in patients with HL: 67% of lung can-
cer patients had one or more comorbidities versus
almost 30% of HL patients. Similar patterns in comor-
bidity prevalence were seen in males and females. The
prevalence of either single or multiple comorbidity rose
with increasing age. Single comorbidity was more com-
mon than multiple comorbidity in the younger age
groups, whereas in the older patients the opposite was
observed. For example, approximately 29.2% of lung can-
cer patients aged 15–29 years had one comorbidity and
3.4% had multiple comorbidities, while in lung cancer
patients aged 75–90 years the percentage of patients
with one comorbidity or with multiple comorbidities
were 26.9 and 49.9%, respectively.
The prevalence of multiple comorbidity increased with
deprivation level in colon, rectum and lung cancer pa-
tients, but there was no pattern with deprivation in HL
patients or in the prevalence of one comorbidity. For ex-
ample, from 24.7 to 25.7% of rectal cancer patients had
one comorbidity, while 17.7 to 27.6% of patients had
multiple comorbidities.
Crude and adjusted prevalence of comorbidities at the
time of cancer diagnosis
Across all cancer patient cohorts, hypertension, COPD,
diabetes, CVD, CHF and PVD were among the most
commonly recorded comorbid conditions. Adjusting for
age and sex strongly impacted the prevalence of some
comorbid conditions in colon, rectum and lung cancer
patients (Fig. 1). The three most prevalent comorbidities
in all four cancer patient cohorts were hypertension,
COPD and diabetes. The adjusted prevalence of hyper-
tension and of diabetes was similar among patients in
each of the four cohorts (approximately 15–20% of pa-
tients had hypertension while approximately 5% of pa-
tients had diabetes). However, the adjusted prevalence of
COPD was markedly higher in patients with lung cancer:
approximately 25% of lung cancer patients had COPD
versus 10% of patients in the other patient cohorts. Simi-
larly, in comparison between the four cohorts, the preva-
lence of several other conditions (CVD, CHF, PVD or
previous malignancy) was highest among the lung cancer
patients.
Combinations of multiple comorbidity
The relative frequency (%) in which five of the most
common conditions (COPD, diabetes, CVD, CHF and
PVD) are present either as a single comorbidity or in
combination with ten other common comorbid condi-
tions is shown in Fig. 2. For a given cancer (identified by
colour), the denominator is the number of patients with
the comorbid condition, as represented on the y-axis,
and the numerator is the number of those patients who
had the condition as a single comorbidity or who had
another condition, as depicted by the x-axis. Patients
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with two or more of the x-axis conditions are repre-
sented in the numerator for each condition.
Approximately one third of colorectal and lung cancer
patients with COPD, and over half of HL patients with
COPD, had this condition as a single comorbidity. By
comparison, under one fifth of patients with diabetes,
CVD, CHF and PVD had these conditions as a single co-
morbidity. CHF was the condition least frequently ob-
served as a single comorbidity across all four cancer
sites (89% or more of patients with CHF had additional
comorbidities).
Hypertension was the condition most commonly
present with each of comorbidities for which cross
tabulations were investigated. In each of the cancer
cohorts, approximately three-quarters of patients with
CHF, and a similar proportion with CVD, also had
hypertension. COPD was most commonly seen in
combination with diabetes, CVD, CHF or PVD in
lung cancer patients: while over 50% of lung cancer
patients with CHF also had COPD, around one third
of patients with HL, colon or rectal cancers with
CHF also had COPD.
Multivariate analysis
The odds ratios derived from logistic regression of each
comorbid condition being present at the time of cancer
diagnosis, by cancer site, for females relative to males,
age (relative to age 70 in colon, rectal and lung cancer
patients, and relative to age 45 in HL patients) and in-
creasing deprivation, adjusted for the other listed vari-
ables, are shown in Table 2. Analyses conducted for
patients with HL were restricted to the comorbidities of
diabetes, hypertension and COPD, as the prevalence
counts of the other conditions did not adhere to the
minimum of ten EPV required for the analyses.
Female patients with colon, rectal or lung cancer had
up to 29% increased adjusted odds of having dementia
(rectal cancer: OR 1.29; 95%CI 1.13, 1.48), up to 34% in-
creased adjusted odds of having a previous malignancy
(rectal cancer: OR 1.34; 1.23, 1.47) and approximately
twice the adjusted odds of having rheumatological con-
ditions (colon cancer: OR 2.16; 1.98, 2.36) compared to
male patients. Conversely, compared with male patients
in their respective cohort, females had significantly re-
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Fig. 1 Crude and adjusted prevalence (%) of fourteen comorbidities among cancer patients in England, by cancer
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paraplegia, CVD, renal disease, MI, CHF or PVD. Across
all four cancer cohorts, female patients had up to 38%
reduced odds of having diabetes (HL: OR 0.62; 95%CI
0.50, 0.77).
The adjusted odds of dementia, CVD, hypertension,
renal disease, MI and CHF being present at diagnosis
consistently increased with age. For example, with 70-
year old patients as the reference, colon cancer patients
aged 45 had 87% reduced adjusted odds of CVD (OR
0.13; 0.13, 0.13) and 88% reduced adjusted odds of CHF
(OR 0.12; 0.12, 0.12), while 90-year old patients had over
three times the adjusted odds of CVD (OR 3.27; 2.69,
3.99) and over four times the adjusted odds of CHF (OR
4.72; 3.63, 6.13). There was no trend with age in colon,
rectal or lung cancer patients for liver disease, having
had a previous malignancy, diabetes or obesity. In lung
cancer patients, no trend was observed with age for hav-
ing COPD.
For at least eleven of the fourteen conditions, the ad-
justed odds of having the comorbid condition increased
with the level of deprivation in colon, rectal or lung can-
cer patients. Obesity, dementia, hemiplegia, CVD, hyper-
tension, renal disease, MI, COPD, CHF and PVD were
associated with deprivation level in all three cancer co-
horts. For example, the most deprived groups of lung
cancer and colon cancer patients had approximately
twice the adjusted odds of having COPD compared with
the least deprived groups (OR 1.96; 1.89, 2.03 and OR
2.01; 1.89, 2.12 in the most deprived patients with lung
or colon cancer, respectively). No trend with deprivation
was seen with rheumatological conditions or with having
a previous malignancy.
Probability of having single or multiple comorbidity at
the time of cancer diagnosis
The graphs depicted in Fig. 3 show the adjusted prob-
ability of patients having one of the nine most common
comorbid conditions recorded (hypertension, COPD,
diabetes, CHF, CVD, PVD, MI, obesity or rheumato-
logical conditions) at the time of colon cancer diagnosis,
either as a single comorbidity, or as one of multiple co-
morbidities, according to age at cancer diagnosis and
deprivation group (the least and most deprived groups),
as derived from multinomial logistic regression.
With the exception of COPD, there was little differ-
ence between the most and least deprived groups in the
probability of having each of the conditions as a single
comorbidity. Among those patients with COPD as a
single comorbidity, the difference in probability between
Fig. 2 Relative frequency (%) of five common conditions as a single comorbidity or with another comorbidity, by cancer
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the most and least deprived groups decreased with age.
The most deprived patients had a higher probability of
having each of the conditions as one of multiple comor-
bidities compared with the least deprived group, with
one exception (rheumatological conditions). Generally,
the difference in probability between the two deprivation
groups was greatest in older age: it peaked at approxi-
mately 80 years for hypertension, COPD, diabetes, PVD
and obesity, while in patients with CHF, CVD, and MI
the difference continued to increase with age. Having
rheumatological conditions was not associated with in-
creasing age or deprivation level.
Similar patterns in the probability of having a comor-
bid condition according to deprivation group were ob-
served for patients with rectal or lung cancers
(Additional files 2 and 3).
Discussion
Our study is, to our knowledge, the first large-scale,
population-based study describing comorbidity preva-
lence in cancer patient populations. Up to two-thirds of
patients had at least one long-term health condition at
the time of their cancer diagnosis, and around half of
these comorbid cancer patients had multiple long-
term conditions. There was evidence that many of the
comorbid conditions we investigated were associated
with socio-economic deprivation, and the most de-
prived groups of patients had a higher probability of
having multiple comorbidities compared with the less
deprived groups.
The choice of cancer sites we studied was based on
aetiology of the cancer: three of the cancer sites (colon,
rectum and lung) were associated with environmental
risk factors including tobacco smoking [22, 23], alcohol
use and diet [24, 25]. Furthermore, tobacco smoking is
associated with certain conditions, such as COPD [26–28]
and Type 2 diabetes [29, 30], and is also associated with
socioeconomic position [31]. HL is linked to infection ra-
ther than environmental factors [22].
Hypertension, COPD and diabetes were the three most
prevalent comorbidities in all four cancer patient co-
horts, with a higher prevalence in the most deprived pa-
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Fig. 3 Probability (%) of condition present as single or multiple comorbidity, by deprivation group (colon cancer)
Fowler et al. BMC Cancer            (2020) 20:2 Page 11 of 15
100
most deprived group of lung cancer patients (compared
with being in the least deprived group – the ‘deprivation
gap’) was 10% more than the deprivation gap in the ad-
justed odds of having COPD in the Hodgkin lymphoma pa-
tients. This may be reflective of the role of smoking in the
aetiology of both lung cancer and COPD, and the higher
prevalence of smoking in the more deprived population.
The association between smoking status and deprivation is
not quantifiable in the cancer patient cohorts as we did not
have information on smoking prevalence.
Similar work using administrative data to describe co-
morbidity in cancer populations has been undertaken in
New Zealand [32] and in Spain [33]. In the study of pa-
tients diagnosed with colon, rectal, breast, ovarian, uter-
ine, stomach, liver, renal or bladder cancers in New
Zealand (N = 14,096), commonly diagnosed comorbidi-
ties among colon and rectal cancer patients were hyper-
tension, cardiac conditions and diabetes. In the Spanish
cohort of colorectal cancer patients from the cancer
registries of Girona and Granada (N = 1061), diabetes,
COPD and CHF were the most common comorbidities.
Comparing our study with the study in New Zealand,
there were similarities among colon cancer patients in
the age-sex adjusted prevalence of hypertension, while
diabetes prevalence was higher in New Zealand. The ad-
justed prevalence of hypertension was 16.6%, uncompli-
cated diabetes was 5.9% and diabetes with complications
was 5.0% among patients in New Zealand, while in our
study the adjusted prevalence of hypertension was 17.4%
and diabetes (with and without complications) was 5.7%.
This supports our earlier assumption that less severe
diabetes may be underreported in hospital admissions
records. Given the ‘gatekeeper’ structure and functioning
of the healthcare system in the UK [34] and the focus on
managing diabetes within primary care [35], cases of dia-
betes recorded in hospital admissions are possibly those
that are not controlled within available primary care re-
sources [36] or present with complications. The Spanish
study reported the crude prevalence of conditions
among colorectal cancer patients, which were generally
higher than the crude prevalence of conditions observed
in our study. Diabetes was prevalent in 23.6% of colorec-
tal cancer patients in this study, while in our study the
crude prevalence of diabetes was 11.4% or 9.4% among
colon or rectal cancer patients, respectively. Nonetheless,
there was consistency between our study and both of
these other studies in terms of common comorbid con-
ditions among the patient cohorts.
In our study, approximately 13% of the HL cohort,
over 21% of the colorectal cancer cohorts and over 39%
of the lung cancer cohort had multiple comorbidities,
while from 17 to 28% of patients in each cohort had a
single comorbidity at the time of their cancer diagnosis.
These findings are important given the impact
comorbidity may have on cancer care, particularly where
care is provided within the constraints of healthcare
guidelines that are not designed for the simultaneous
management of two or more chronic conditions or mor-
bidities (i.e. “multimorbidity”). Scientific studies indicate
that multimorbidity is regularly observed in the popula-
tion [37–39] and poses a challenge to health care sys-
tems, particularly those geared towards single disease
management [5, 40, 41]. Clinical guidelines in the United
Kingdom are not accommodating to the cumulative im-
pact of treatment recommendations on those with mul-
tiple morbidities, and do not facilitate a comparison of
potential benefits or risks [42]. Patients with multiple
chronic conditions have higher rates of healthcare con-
sultations than those without [38, 43, 44]. Managing and
treating comorbid conditions places an additional eco-
nomic burden on healthcare systems. In one study of the
costs per capita of several comorbid conditions, renal
disease was identified as one of the most costly condi-
tions to manage among cancer patients (approximately
174% of the costs of the cancer), while the cost of dia-
betes or heart disease was substantially lower (approxi-
mately 20% or 6% of cancer costs, respectively) [45]. The
increase in costs also depends on the number and com-
bination of comorbid conditions: among the cancer pa-
tients with diabetes in our study, between 10 and 15% of
these patients also had renal disease.
In cancer patients, the presence of comorbidity can be
influential on cancer management and therapeutic op-
tions. Patients with comorbidity may be less likely than
those without comorbidity to receive curative treatment
[3]. Treatment decisions made by clinicians may be
weighted by the type and severity of comorbidity, for ex-
ample, CHF has been reported to influence receipt of
surgery for non-small cell lung cancer [46], receipt of
adjuvant chemotherapy for colon cancer [47] and receipt
of any treatment for prostate cancer [48]. The presence
of COPD influenced receipt of surgical treatment in
non-small cell lung cancer patients [46] and adjuvant
therapy in colon cancer patients [47]. However, there is
also evidence that comorbid patients who receive treat-
ment have better prognosis for survival than those who
do not receive treatment, as shown with the receipt of
adjuvant therapy for colon cancer [47, 49]. Moreover,
older cancer patients and patients with comorbidity have
historically been under-represented in cancer clinical tri-
als. This limits the applicability of cancer clinical trial
results to a younger and healthier cohort of patients
than clinicians are actually treating, meaning that while
there is evidence suggesting that patients with comor-
bidity as a group are not receiving optimal cancer treat-
ment, specific information required for clinical decision-
making is often lacking [50]. We found a non-negligible
increase in the prevalence of comorbidities when we
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included diagnoses in the six-months prior to cancer
diagnoses. While some of these conditions may have
arisen in these months because of the cancer, their pres-
ence will be as relevant when considering treatment, ir-
respective of the timing of their diagnosis.
Our study showed socio-economic position to be an
important factor associated with having one or more co-
morbid conditions at the time of cancer diagnosis, with
comorbidity prevalence increasing with deprivation. It is
possible that mechanisms within clinical guidelines and
decision-making that lead to non-treatment of cancer
patients with comorbidity disproportionately impact the
more deprived patients. An existence of socio-economic
inequalities in receipt of treatment has been identified
[51, 52]. Reviewing the treatment process of cancer pa-
tients with comorbidity may therefore have a beneficial
effect in reducing the socioeconomic inequalities in re-
ceipt of cancer treatment. Moreover, because cancer
data contains mainly cancer-related outcomes, how the
cancer and related treatments impact patient comorbid-
ity and prognosis is not well known [3]. Having the re-
sources and guidelines within which to manage patient
comorbid conditions robustly during cancer treatment is
one strategy for mitigating the risk of adverse patient
outcomes occurring from comorbid disease. In England,
socio-economic inequalities in cancer survival have nar-
rowed little, despite the implementation of government
strategies that intended to reduce these inequalities [53].
Focusing on the management of comorbidity in cancer
patients could be one potential pathway to addressing
socio-economic inequalities in cancer outcomes.
There are a variety of metrics of comorbidity in the
scientific literature that are used to study the relation-
ship between comorbidity on cancer outcomes, although
no consensus has been reached on a gold standard
measure of comorbidity within the context of cancer
[54]. Many of the approaches provide a summary meas-
ure of the patient’s comorbid conditions and the severity
of these conditions. However, the prognostic impact of
comorbidity can depend on the type and stage of the
cancer [55]. In addition, the presence of comorbidity -
particularly certain comorbid conditions - adds com-
plexity to the provision of treatment for cancer. When
investigating the relationship between comorbidity and
cancer outcomes, a more granular approach investigat-
ing specific comorbid conditions in turn, rather than
using a summary measure of comorbidity, could be
more appropriate and insightful.
We acknowledge potential limitations in this study.
We capture comorbidity information based on diag-
noses of health conditions recorded during hospital
admission(s) prior to cancer diagnosis, and are there-
fore reliant on patients requiring hospital-based med-
ical attention for their health condition(s) in order to
obtain this information. The potential for measure-
ment error from the information recorded in the
diagnostic fields of hospital admissions records should
also be acknowledged. However, we assume that the
more severe conditions are likely to be captured
within the diagnostic fields. Underreporting may
occur in less severe conditions, such as obesity, that
are unlikely to be the primary reason for the hospital
admission, and may occur more frequently with eld-
erly patients or patients with more severe comorbidi-
ties, due to competing demands. Conditions such as
less severe type II diabetes are possibly underreported.
Further work comparing the prevalence of the condi-
tions we studied in the cancer cohorts with the
prevalence of these conditions in the general popula-
tion in England, as reported in government publica-
tions and scientific literature, would be useful step in
validating our results.
Our study of over 300,000 patients is one of the largest
population-based studies of comorbidity prevalence
among cancer patients, and one of the first such studies
of patients in England. Using data from well-established
sources, we were able to describe the prevalence of four-
teen chronic health conditions among these cancer pa-
tients, and highlight an association between socio-
economic position and prevalence of most of these
conditions.
Conclusion
This study underlines that many comorbid cancer pa-
tients are living with multiple comorbidities, and that
the most deprived patients carry the greater burden of
comorbidity. Healthcare guidelines may not always en-
compass the simultaneous management of multiple
chronic conditions, but guidelines for the management
of cancer may need to consider some prominent comor-
bid conditions. Insight into patterns of cancer comorbid-
ity informs further research into the influence of
comorbidity - particularly the influence of specific co-
morbid conditions - on outcomes following cancer diag-
nosis, including socio-economic inequalities in receipt of
treatment and short-term mortality.
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Additional file 1. Definition of the fourteen conditions, according to
ICD-10 code classification. Table of the fourteen conditions and the ICD-
10 code groupings used to define them.
Additional file 2. Probability (%) of condition present as single or multiple
comorbidity, by deprivation group (lung cancer). Additional results in
complement to those presented in Fig. 3: graphs representing the probability
of having any of nine comorbid conditions in lung cancer patients.
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Additional file 3. Probability (%) of condition present as single or
multiple comorbidity, by deprivation group (rectal cancer). Additional
results in complement to those presented in Fig. 3: graphs representing
the probability of having any of nine comorbid conditions in rectal
cancer patients.
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Additional file 1: Definition of the fourteen conditions, according to ICD-10 code classification
Condition ICD-10 codes
Liver disease B18,  I850, I859, I864, I982, K700, K701, K702, K703, K704, K709, K711, 
K713, K714, K715, K717, K721, K729, K73, K74, K760, K762, K763, K764, 
K765, K766, K767, K768, K769, Z944 
Previous malignancy CXX, excluding related same site malignancy
Diabetes E100, E101, E102, E103, E104, E105, E106, E107, E108, E109, E110, E111, 
E112, E113, E114, E115, E116, E117, E118, E119, E120, E121, E126, E128, 
E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149, E122, 
E123, E124, E125, E127, E132, E133, E134, E135, E137, E142, E143, E144, 
E145, E147
Obesity E66
Dementia F00, F01, F02, F03, F051, G311, G30
Hemiplegia or paraplegia G041, G114, G801, G802, G81, G82, G830, G831, G832, G833, G834, G839
Cerebrovascular disease G45, G46, H340, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69
Hypertension I10, I119, I129, I139
Renal disease I120, I131, N032, N033, N034, N035, N036, N037, N052, N053, N054, N055, 
N056, N057, N18, N19, N250, Z490, Z491, Z492, Z940, Z992
Myocardial infarction I21, I22, I252
Chronic obstructive pulmonary diseaseI278, I279, J40, J41, J42, J43, J44, J45, J46, J47, J60, J61, J62, J63, J64, J65, J66, 
J67, J684, J701, J703
Congestive heart failure I43, I50, I099, I110, I130, I132, I255, I420, I425, I426, I427, I428, I429, P290
Peripheral vascular disease I70, I71, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z959
Rheumatological conditions M05, M06, M315, M32, M33, M34, M351, M353, M360
Abbreviations - ICD: International Classification of Diseases and Related Health Problems;
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Evaluating the measurement of comorbidity prevalence 
 
Background 
As previously discussed in this thesis, the impact of comorbidity across the cancer patient pathway is 
wide-reaching. Patients with comorbidity are, generally, more likely to have been diagnosed with 
cancer via emergency presentation,128 and less likely to receive curative cancer treatment than 
patients without comorbidity.13 Comorbidity is a prognostic factor in cancer survival,92, 109 the extent 
to which depends on the type of comorbidity and cancer116 and stage of disease.110 Additionally, 
comorbidity is more prevalent among the older population, in which the majority of cancers occur.129 
The prevalence of comorbidity tends to be higher among the most socio-economically deprived;14, 130 
which was also observed in the population-based study of cancer patients described in Research Paper 
2.127 These elements have important implications on cancer care in these populations. 
The availability of reliable data on comorbidity in cancer patients facilitates the effective investigation 
of the role of comorbidity in cancer patient outcomes.104 Sources of information on cancer 
comorbidity vary, from administrative data sources to information collected during prospective cohort 
studies of cancer patients or cancer treatment clinical trials, or information contained within health 
survey data. In the scientific literature, information on cancer comorbidity is commonly sourced from 
routine, administrative data, such as primary or secondary care data. By their nature, these data 
potentially cover the largest cancer patient populations, and therefore offer greater generalisability 
to all cancer patients, as compared with other sources of information on cancer comorbidity.131 
However, there has been concern regarding possible under-recording of some conditions in 
administrative data sources.131, 132  
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In Research Paper 2, information from hospital admissions records (Hospital Episode Statistics, HES71) 
was used to estimate the crude and adjusted prevalence of thirteen chronic conditions among England 
cancer registry cohorts of patients, retrospective to their cancer diagnosis. The study described here 
draws upon this work undertaken for Research Paper 2, with the aim of evaluating hospital admissions 
data as a source of information on cancer comorbidity prevalence, based upon the prevalence of the 
conditions among England cancer registry cohorts of colorectal cancer, lung cancer and Hodgkin 
lymphoma patients prior to their cancer diagnosis.  
 
The first objective of this study was to undertake a review of the scientific literature to find studies 
that reported information on the prevalence of these thirteen conditions among population-based 
cohorts of colorectal cancer patients. This was done in order to compare and contrast sources of 
comorbidity prevalence information from these studies with the prevalence of the comorbidities 
among the England cancer registry cohort of colorectal cancer patients. The second objective was to 
undertake a review of the grey literature (including government web-based resources) and scientific 
literature to obtain information on the national prevalence of these conditions among the general 
population in England, as a reference point with which to compare the prevalence of these conditions 
among the three England cancer registry cohorts of patients. The hypothesis for this second objective 
was that the prevalence of many of the conditions could reasonably be higher among pre-cancer 
cohorts of patients than among the general population, given that certain types of cancer share similar 
aetiological risk factors with some of the conditions studied.  
 
Methods 
The health conditions of interest included non-cancer conditions of the Charlson Comorbidity Index 
(CCI),83 or any non-CCI conditions that were highly prevalent in our data and that may impact 
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treatment for cancer. The thirteen conditions that were investigated were: myocardial infarction (MI), 
congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular disease (CVD), 
dementia, chronic obstructive pulmonary disease (COPD), rheumatological conditions, liver disease, 
diabetes, hemiplegia or paraplegia, renal disease, obesity and hypertension. 
 
Cancer patient data 
The patient data that were used to estimate the prevalence of these thirteen conditions were the 
same data used in the study described in Research Paper 2.127 Data were analysed as three separate 
patient cohorts (according to cancer type), using national cancer registry records of 331,655 patients 
aged 15-90 years diagnosed with either colorectal cancer (N=158,588), lung cancer (N=165,677) or 
Hodgkin lymphoma (HL) (N=7,420) between 2009 and 2013, linked with HES data of Inpatient, 
Outpatient and Accident & Emergency hospital admissions.  
 
Data analysis 
The crude and adjusted prevalence of each condition was estimated using the same methods 
described in Research Paper 2.127  Crude prevalence was based on the percentage of patients that had 
been diagnosed with the condition. The age-sex adjusted prevalence, and corresponding 95% 
confidence intervals, were estimated using weights for each year of age and sex based on published 
population estimates from the 2011 UK census.133 Adjustment for age and sex facilitated the 
comparison of the prevalence of comorbid conditions in the cancer patient cohorts with the observed 
or estimated prevalence of these conditions in the general population (derived from the literature 
search). 
 
Literature search  
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The literature search strategy for the first objective was to search the EMBASE, MEDLINE and PUBMED 
databases for studies published in the scientific literature reporting the prevalence of the conditions 
of interest among colorectal cancer patients (Table 4.1). For the second objective, the strategy was to 
search government websites, the grey literature and the published scientific literature for information 
on the national prevalence of the conditions in England. For the latter, where information was 
available from multiple sources, priority was given to that representing official national prevalence 
statistics (such as information available from government sources). The intention of the study was to 
report the prevalence information obtained from the literature, and to compare it with the prevalence 
among the England cancer registry cohorts (i.e. based on information derived from the HES data).    
 
Table 4-1: Search criteria to obtain information on prevalence 
Objective Databases / sources Search criteria 
1. Prevalence of conditions 




- Adult cancer patients; 
- Colorectal cancer diagnosis from 
2000 onwards 
- Population-based studies 
2. Prevalence of conditions 
among the general population in 
England 
- Government web-based 
sources, including:  
    - Public Health England,  
    - Office for National Statistics 






- Reported from 2000 onwards 






Data sources of prevalence information 
Objective 1 – Prevalence among colorectal cancer patients  
From the literature search it was possible to find prevalence information on all thirteen conditions 
(Appendix Table 1). Six studies reported information on nine or more of the thirteen conditions of 
interest. These studies were undertaken in England,48 Spain,117, 134 New Zealand116 or the United 
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States.135, 136 With the exception of the cross-sectional study by Luque-Fernandez and colleagues,117 
these studies were retrospective cohort studies. Other studies undertaken in the United States,137-139 
Iran, 140 Denmark,52 Canada141 and Australia142 reported information on one or two of the conditions. 
The majority of these studies were population-based, with study populations derived from cancer 
registration data, while three studies were based upon the data of patients attending clinics or 
treatment centres,137, 139, 140 and the Australian study was based on people (both with and without a 
cancer diagnosis) recruited to a prospective cohort study of diet and lifestyle in Melbourne. The 
reported age range of patients varied between studies: some studies focused on older age groups 
only, or others studied different age ranges of adult populations (e.g. one study had a lower age range 
of 15 years while in another the youngest patients were 25 years old). 
 
Information on comorbidity was commonly obtained from administrative data sources, such as 
hospital records or primary care data. Several United States-based studies derived this information 
from Medicare claims data. Medicare is the United States federal government’s health insurance 
programme for people who are 65 years or older or for people with certain disabilities or End-Stage 
Renal Disease.143 Prospective cohort studies captured information on the comorbidity via diagnostic 
testing or examination at the time of recruitment. In some of the articles the presence of certain 
comorbidities, such diabetes, was obtained from reviewing medical notes. These data sources are 
summarised in Table 4.2. Timing within which the information on comorbidity was captured varied 
between studies and ranged from pre-cancer diagnosis only (up to a maximum of 5 years prior to 
cancer diagnosis) to pre- and post-cancer diagnosis (up to 6 months after cancer diagnosis).   
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Table 4-2 Data sources of comorbidity information for colorectal cancer patient cohorts 
Data source Data type Examples 
Primary care data Routinely collected 
administrative data 
- Medicare claims data of patient 
consultations with physicians (United 
States) 
Secondary care data  




- Hospital Episode Statistics (England) 
- Medicare claims data of hospital 
admissions (United States) 
Diagnostic testing / 
examination 
Ad hoc, collected for specific 
purpose 
- Blood tests for diabetes 
- Recording of weight and height for Body 





- Register of Medicinal Product Statistics 
(Denmark) 
Medical notes Record of patient medical 
history and care with one 
healthcare provider 
- Data from specialist clinics or centres  
 
 
Objective 2 – National prevalence in England 
Within the literature, the availability of information on the prevalence of the thirteen conditions of 
interest in the general population was variable (Appendix Table 2).   
Prevalence information was directly available from government agency resources (Public Health 
England, PHE) for six conditions: diabetes, CHF, obesity, dementia, renal disease (but only for 
moderate or severe chronic kidney disease) and hypertension. For some conditions, the only available 
information on prevalence was for a certain aspect of that condition rather than the general condition. 
For example, information was available for stroke (one aspect of CVD), peripheral arterial disease 
(peripheral vascular disease) and rheumatic arthritis (a rheumatological condition). Information on 
the incidence (but not prevalence) of liver disease, based on hospital records, was available from the 
PHE data tools website.144  
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Information on the prevalence of COPD145, 146 and the incidence of (but not prevalence of people with 
a history of) MI147 was available within the scientific literature. In addition, the scientific literature 
provided prevalence information on obesity,148 dementia,149 CHF,150 symptomatic peripheral arterial 
disease (PVD)151 and certain rheumatological conditions.152, 153 No information was found from 
government sources, the grey literature or the scientific literature on the national prevalence of 
hemiplegia or paraplegia. 
PHE prevalence information data sources were generally from: a) the National Health Service’s Quality 
and Outcomes Framework (QOF);154 or b) the Health Survey for England (HSE)155 (Table 4.3).  
National prevalence information in the scientific literature was ultimately sourced from the HSE or 
primary care sources. Primary care databases included the Clinical Practice Research Datalink 





Table 4-3: Data sources of national prevalence information for England or the United Kingdom 
Data from which prevalence was 
derived  
Data source and description Information source  
(depending on the condition) 
Quality and Outcomes Framework 
(QOF) 
Primary care – health indicators 
derived from data supplied by 
participating General Practices.  
Government web-based sources: 
-  Public Health England 
-  NHS England 
Health Survey for England  
(HSE) 
Annual cross-sectional survey 
focusing of several aspects of 
health. Nationally representative 
sample selected based on 
residential postcode. 
Government web-based sources: 
-  Public Health England 
-  NHS Digital 
Scientific literature 
Clinical Practice Research Datalink 
(CPRD) 
Primary care data – completed by a 
network of General Practices 
across the UK 
Grey literature: 
-  National Chronic Kidney Disease 
Audit± 
Scientific literature 
Royal College of General 
Practitioners Research and 
Surveillance Centre  
(RCGP RSC) 
Primary care data collected from 
over 1,700 General Practices across 
England and Wales 
Scientific literature 
International Diabetes Federation 
Atlas 
Four unspecified UK data sources Grey literature: 
- Organisation for Economic Co-
operation and Development 
(OECD) report 
The Health Improvement Network 
(THIN)* 
Primary care data – database of 
longitudinal patient records of 
approximately 6% of the UK 
population 
Scientific literature 
Hospital Episode Statistics 
(HES)◊ 
Routinely collected administrative 
secondary care data 
Government web-based sources: 
- Public Health England 
Grey literature: 
- British Heart Foundation 
Scientific literature 
English Longitudinal Study of 
Ageing+ 
Multi-wave prospective cohort 
study of a sample of people aged 
50 and over living in England 
(sample selected from three years 
of HSE samples) 
Scientific literature 
Whitehall II Study* Multi-wave prospective cohort 
study, sample of UK participants 
aged between 35-55 years at time 
of recruitment to study 
Scientific literature 
±Reported prevalence of moderate to severe chronic kidney disease; *Provided information on the prevalence of peripheral arterial disease;  
◊ HES provided information on incidence but not prevalence of liver disease and myocardial infarction;  
+Provided information on the prevalence of dementia among people aged 50 years and over;  
Abbreviations: NHS – National Health Service 
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Results 
Data analysis: prevalence of the thirteen health conditions among the England cancer registry 
cohorts 
Among the England cancer registry cohorts of colorectal cancer, lung cancer and Hodgkin lymphoma 
patients, the prevalence of comorbidity (having one or more of the conditions of interest) increased 
with age and with increasing deprivation (Table 4.4). There was little difference in comorbidity 
prevalence between males and females, although prevalence was slightly higher among males in each 
cohort.    
 
In the six-year period prior to cancer diagnosis, hypertension, COPD, diabetes, CVD, CHF and PVD were 
among the most commonly recorded health conditions in hospital records (Appendix Table 3). The 
three most prevalent conditions in all three of the cancer patient cohorts were hypertension, COPD 
and diabetes. The age-sex adjusted prevalence of hypertension was highest in lung cancer patients – 
approximately 19% (18.7%; 95%CI: 18.1%, 19.2%) - and lowest in HL patients at approximately 15% 
(15.2%; 14.3%, 16.1%). Lung cancer patients also had a higher adjusted prevalence of COPD than the 
other cancer patient cohorts: 24.6% (23.6%, 25.6%), versus a prevalence of around 10% in patients 
with colorectal cancers or HL. Diabetes was prevalent in 5.4% (5.1%, 5.7%) of lung cancer patients, 
with similar adjusted prevalence across the other two cohorts of cancer patients.  The adjusted 
prevalence of each of liver disease, obesity, CVD, renal disease, MI, CHF, PVD and of rheumatic 
conditions was approximately 1.5-3.0%, while the prevalence of dementia or of hemiplegia / 
paraplegia was lower (<1.0%).  
 
Prevalence of chronic health conditions among colorectal cancer patients 
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The crude prevalence of each of the thirteen conditions of interest among the England cancer registry 
colorectal cancer patient cohort, and the prevalence of these conditions among colorectal cancer 
patient cohorts described in the scientific literature is shown in Figure 4.1. The prevalence reported in 
the scientific literature is illustrated according to the data source(s) from which it came: hospital 
records, hospital and primary care records, hospital and pharmaceutical records, clinic medical notes, 
diagnostic testing / physical exam, or via Medicare claims records (either hospital records only or 
hospital and physician records).  
As would reasonably be expected, the prevalence of conditions reported tended to be higher where 
information was obtained from multiple sources, such as hospital records plus primary care data. This 
was the case for almost all of the conditions, excluding obesity.  The prevalence of obesity assessed 
from physical exam (measuring of body mass index) was 25%, while it was less than 5% based upon 
hospital records or information sourced from Medicare claims-based hospital and physician records. 
The  widest variation in prevalence reported for one condition was for hypertension: one study of 
patients aged ≥65 years reported 76% of patients were hypertensive, while the crude prevalence 
among the England cancer registry cohort of patients was approximately 40%, and the prevalence was 
less than 15% in a study where presence of hypertension was ascertained via testing. The reported 
prevalence of conditions such as dementia and hemiplegia or paraplegia was low among colorectal 
cancer patients, and this varied little between the data sources. 
There were eleven articles reporting diabetes prevalence among colorectal cancer patients, and 
between them these articles covered several of the data sources. The highest prevalence among 
cohorts of colorectal cancer patients was from hospital and primary care records combined 
(approximately 24%), and from clinic medical notes (approximately 22%). By contrast, among the 
cohort of England cancer registry colorectal cancer patients, the crude prevalence was approximately 
10%.   
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National prevalence of chronic health conditions in England 
There were variations in the reported prevalence of hypertension, diabetes, obesity and renal disease 
among the general population (Figure 4.2, Appendix Table 2). The reported prevalence of obesity 
(26%, according to the HSE158 and ~24% in males or females according to the scientific literature148) 
and renal disease (4.0-6.0% according to the HSE,159 National Chronic Kidney Disease Audit 
(information sourced from CPRD)160 and QOF161, 162) was higher than the age-sex prevalence estimated 
among the England cancer registry patient cohorts. The reported prevalence of hypertension varied 
according to the source (13.9% according to the QOF163 while the expected prevalence per total 
population was estimated as 23.6% using QOF and Health Survey for England data164). The adjusted 
prevalence of hypertension among each of the three England cancer registry patient cohorts fell 
somewhere between these two estimates, the most similarity being between the HL patient cohort 
and the lower of the two general population estimates. The reported prevalence of diabetes in the 
general population varied from 5% to almost 7% based on source (QOF165 or International Diabetes 
Federation Atlas / OECD report,166 respectively), the former estimate being closest to the adjusted 
prevalence estimates within the England cancer registry patient cohorts. 
The prevalence of COPD or CHF among each of the England cancer registry cohorts was higher than 
that reported in the general population. In primary care sources (RCGP RSC) the prevalence of COPD 
was reported as ~2.6%146 and based on data from the HSE, the expected prevalence was 3.5%.145 The 
prevalence of CHF in the general population was 0.8% according to the QOF167 or 1.4% according to 
primary care data (CPRD),150 and ranged from 2.5% (2.3%, 2.8%) in lung cancer patients to 1.4% (1.4%, 
1.5%) of colorectal cancer patients.  
According to CPRD / QOF, the reported prevalence of dementia was 4.3% of people aged 65+ years in 
England164 (not shown in Figure 4.2), while data obtained from the English Longitudinal Study of Ageing 
estimated that approximately 767,000 people in England and Wales had dementia149 (i.e. about 1.3% 
of this population). The adjusted prevalence of dementia among each of the three England cancer 
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registry cohorts was <1%.  There was no information directly available for the prevalence of CVD or 
rheumatological conditions among the general population in England.  
 
Discussion 
Hospital admissions records were used to derive the prevalence of thirteen chronic health conditions 
among three England cancer registry cohorts of patients in the six-year time window prior to their 
cancer diagnosis. The work undertaken in this section of the thesis aimed to evaluate the use of 
hospital records for capturing information on chronic disease prevalence. This was investigated in two 
ways: firstly comparing the crude prevalence of the thirteen conditions among the England cancer 
registry cohort of colorectal cancer patients with the prevalence of these conditions among cohorts 
of colorectal cancer patients described in the scientific literature, and secondly comparing the age-sex 
adjusted prevalence of the conditions among the England cancer registry cohorts of colorectal cancer, 
lung cancer and Hodgkin lymphoma patients with the reported prevalence of these conditions among 
the general population in England. This allowed insight into alternative sources of information on 
chronic disease prevalence.   
 
Comorbidity among colorectal cancer patients 
Among the studies retrieved from the literature review, hospital data were commonly used as a source 
of information of cancer comorbidity, either independently or with primary care (i.e. General Practice 
/ physician) data. Patterns in terms of the conditions most prevalent among colorectal cancer patients 
were fairly consistent where comorbidity information was captured from these data sources. 
Hypertension, COPD and diabetes were the three most common conditions based on retrospective 
cohort or cross-sectional studies using these routine administrative data sources. The variation in 
prevalence of certain conditions may be due to these conditions being underreported in hospital data. 
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Less severe comorbidities, such as obesity, may be underrepresented in hospital data of older patients 
and in patients with more severe comorbidities, due to competing demands from other health 
conditions requiring clinical treatment. Diabetes may also be underreported in hospital records as it 
can be well managed through primary care.168   
In comparison with the prevalence information I obtained using the HES data, the prevalence of many 
of the conditions, such as COPD, CHF, PVD and rheumatological conditions tended to be higher where 
hospital data were used in conjunction with primary care data. However, comparisons between the 
colorectal cancer patient cohorts should be drawn with extreme caution. Due to heterogeneity in 
patient characteristics of the different cohorts of colorectal cancer patients in these studies, and 
differences in the timeframes within which information on comorbidity was considered relative to 
time of cancer diagnosis, it cannot be assumed that differences in prevalence are solely due to 
differences between data sources of information on comorbidity. For example, information on 
comorbidity prevalence available from Medicare claims from hospital and / or physician appointments 
represents comorbidity among patients aged 65 years and above, i.e. people who are eligible for 
Medicare health insurance. It is generally anticipated that the prevalence of comorbidity would 
increase with increasing age,14 so cohorts of older cancer patients would have a higher prevalence of 
comorbidity than cohorts of adult patients of all ages.       
 
Chronic disease in the general population 
This study highlighted a lack of available information on the national prevalence of some health 
conditions in England. Where information on a condition was available from multiple sources, there 
was sometimes inconsistency between the sources. These findings were unexpected.  
Much of the available information was sourced from the Health Survey for England (HSE) or the Quality 
of Outcomes Framework (QOF). The HSE began in 1991 and is completed annually, with participants 
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selected to be nationally representative of people living at private addresses. Between the period 
1994 to 2009, the annual estimated adult interview response rate ranged from 58% to 75%.169 The 
QOF was introduced in 2004, and provides reward and financial incentive to volunteering general 
practices for the quality of care they provide to patients.154 Up to 25% of general practitioners’ income 
is linked to the achievement of quality targets for several chronic conditions. Such financial incentives 
may benefit patients with the relevant conditions, but might also be detrimental to patients with other 
conditions or for whom quality targets are seen as more difficult to achieve.170 Whether the design 
and participation of both the HSE and QOF are optimal for capturing information on the national 
prevalence of a broad range of health conditions is not clear. Both are open to sources of potential 
bias. Financial incentive could influence the reporting for the QOF. With the HSE, non-response bias 
could occur if the characteristics of those invited but not participating were different from those that 
participated, while data collected from survey questionnaires is liable to responder bias.171 Systematic 
registration has been implemented for some of the conditions of interest, such as diabetes, in 
countries like the United States and Sweden, although this practice does not occur in the UK.  
I estimated the prevalence of thirteen chronic health conditions among three cohorts of cancer 
patients in England from well-established data sources: cancer registration data linked with HES. I 
hypothesised that, of the three cohorts of patients, the prevalence of conditions among the HL patient 
cohort would be the most similar to the reported prevalence among the general population, given 
that HL traditionally has an infectious rather than environmental or behavioural aetiology. I expected 
that the prevalence of some chronic conditions would be higher in the other two cancer patient 
cohorts than in the general population, particularly where cancer and chronic condition share 
common risk factors. For example, as tobacco smoking is strongly associated with developing both 
lung cancer118 and COPD,172, 173 we assumed COPD prevalence would be higher among this cohort of 
cancer patients. Likewise, we would expect both diabetes and obesity to be highly prevalent among 
colorectal cancer patients, as both conditions share similar risk factors with colorectal cancer,174 175 
and diabetes is in itself a risk factor for colorectal cancer.31 The reported prevalence of renal disease 
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(moderate to severe chronic kidney disease) among the general population was 3-4% higher than the 
prevalence among the cancer patient cohorts. The sources of general population prevalence were the 
HSE, a Chronic Kidney Disease Audit report and the QOF. The lower prevalence of renal disease among 
pre-diagnosis cancer patients, obtained from hospital data, may be reflective of certain patients 
electing not to receive treatment (such as dialysis) for this condition. For example, untreated kidney 
failure appears to be more common among older people.176  
 
Using hospital data as a source of information on comorbidity 
It would have been useful to have more than one source of information on comorbidity for the cancer 
patients we studied, in order to compare the prevalence obtained using hospital data with prevalence 
information from alternative sources for the same study population. Studies conducted outside of the 
United Kingdom comparing available information from different data sources have considered 
medical charts to be the ‘gold standard’ of information on comorbidity. Two Australian studies 
comparing administrative hospital data with clinical medical charts found the prevalence of some 
comorbid conditions studied to be lower in hospital administrative data versus medical charts.132, 177 
In similar studies conducted in Singapore,178 Canada179, 180 and the United States181 the results were 
more mixed, some conditions were better recorded in the hospital charts while others were more 
prevalent based on information from hospital administrative data. The underreporting of some 
conditions in the administrative data, as compared with hospital medical charts, may arise as 
comorbidity is less important to report for hospital admission than for any complications arising while 
the patient is in hospital.132  Moreover, one of the Australian studies was investigating comorbidity 
among patients with heart disease. The importance of capturing information on specific comorbidities 
may vary according to the primary disease being treated, for example, placing priority upon reporting 
the presence of comorbid conditions that may interact with the primary disease to cause adverse 
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patient outcomes. Additionally, as previously discussed, recording of certain comorbid conditions may 
take priority over others, based upon the severity of the condition.  
 
There are some limitations with using hospital records for estimating the prevalence of chronic health 
conditions. The information available is limited to conditions diagnosed during a time of hospital visit.  
In addition, information derived from the diagnostic fields of the hospital records may be subject to 
measurement error and misclassification, arising either during collation or during the coding of 
information. In England, the Hospital Episode Statistics (HES) database of admissions at National 
Health Service hospitals incorporates both clinical information about diagnoses and operations and 
administrative information such as dates and methods of admission.71 The coding of clinical diagnoses, 
including comorbidities, is undertaken by highly trained clinical coders, but these coders are working 
independently from front line clinicians often using unstructured and unstandardized clinical notes.182 
It is unclear exactly what impact this may have on the level of detail extracted from the notes from 
medical charts, and the integrity of the information transferred to the HES records. A study in England 
using data from the Clinical Practice Research Datalink (CPRD) primary care database linked with HES 
secondary care data reported that, based on the comorbid conditions of the Charlson Index, more 
comorbidity was recorded in primary care data than secondary care data. With the exception of 
metastatic solid tumour and hemiplegia, the recorded prevalence of each of the Charlson Index 
conditions was higher based upon primary care data than secondary care data.183 However, the CPRD 
database covers approximately 7% of the UK population184 while the HES database contains all 
admissions, A&E attendances and outpatient appointments at NHS hospitals in England.185 For the 
data used in our study, the linkage between cancer registry data and HES data was over 99%.   
Moreover, we assumed that the more severe conditions will require medical assistance in a hospital 
and will be documented in patient records. 
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When drawing comparisons between countries in respect to the recording of chronic diseases in 
hospital records, differences between healthcare systems in terms of the procedures for diagnosing 
and managing these conditions should be acknowledged. In the UK, the healthcare system is designed 
so that most investigations and diagnostic procedures are performed within the National Health 
Service hospitals, where patients attend the hospital as an outpatient following a referral to a 
specialist. In the UK, specialists work in the secondary care setting while in many other countries, 
specialist doctors are numerous within primary care, and investigations may be made in that setting, 
without the need for the patient to visit a hospital. Therefore, in theory, comorbidities should be well 
captured from UK hospital records relative to comorbidities captured from hospital records in these 
other countries.   
 
An advantage of using population-based administrative data sources to capture information on cancer 
comorbidity is their generalisability, and their low cost relative to other methods of data collection.131 
The prospective cohort studies of colorectal cancer patients retrieved from the literature search used 
testing or physical examinations at the time of enrolment to ascertain the presence of the chronic 
health conditions. Such studies may offer more opportunity and flexibility in respect to the type and 
scope of data collected, but can be costly and time consuming to undertake.131 In a similar way to 
prospective cohort studies, cancer patient clinical trial data may provide detailed information on 
participants, including information on their comorbidities. However, older patients and patients with 
comorbidity have been historically underrepresented in cancer clinical trials,186 which compromises 
the extent of the generalisability of these data. No studies of comorbidity among colorectal cancer 
clinical trial patients were found during the search of the literature. Cancer registration databases do 
not commonly include information on patient comorbidities due to limitations in the scope of the data 
that can be collected. However, many cancer registries endeavour to collect information on 
comorbidities that are relevant for the patient care through linkage with other clinical datasets.187  
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From our data sources, we were able to investigate the prevalence of comorbidities in over 300,000 
cancer patients in England. The benefit of a large study population is that it improves the stability of 
prevalence estimates, particularly in the case of rarer conditions.188  
 
There was limited information on the national prevalence of the conditions that we investigated, with 
which to compare the prevalence estimates obtained from HES. Additionally, the prevalence of some 
cancer comorbidities was higher when information was sourced from a combination of primary care 
and secondary care data.  Nonetheless, from the hospital data we used we were able to establish that, 
according to type of cancer, between 30-67% of the cancer patients we studied had at least one 
recorded comorbidity. These data can inform further research into the influence of comorbidity on 
cancer outcomes. Within epidemiological studies in the scientific literature, hospital admissions data 
are a widely used source of information on cancer comorbidity. Although some health conditions 
could be under-recorded or under-reported within these data, this only serves to highlight that the 
burden and consequences of comorbidity on cancer patient outcomes may be underestimated.  
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Table 4-4: Characteristics of patients aged 15-90 years diagnosed with colorectal cancer, lung cancer or Hodgkin lymphoma in England between 2009 and 2013 
  
      
 Colorectal Lung Hodgkin lymphoma 
 All patients 
Patients with 
comorbidity All patients 
Patients with 
comorbidity All patients 
Patients with 
comorbidity 
 N %* n %** N %* n %** N %* n %** 
Sex 
Male 90,055 56.8 47,818 53.1 91,568 55.3 62,235 68.0 4,163 56.1 1,256 30.2 
Female 68,503 43.2 36,120 52.7 74,109 44.7 49,448 66.7 3,257 43.9 950 29.2 
Age (years) 
15-29 976 0.6 135 13.8 178 0.1 58 32.6 2,111 28.5 226 10.7 
30-44 4,218 2.7 765 18.1 1,757 1.1 545 31.0 1,660 22.4 248 14.9 
45-59 21,568 13.6 6,390 29.6 19,923 12.0 9,155 46.0 1,461 19.7 460 31.5 
60-74 67,396 42.5 32,627 48.4 75,085 45.3 49,112 65.4 1,398 18.8 747 53.4 
75-90 64,400 40.6 44,021 68.4 68,734 41.5 52,813 76.8 790 10.6 525 66.5 
Deprivation (IMD income) 
Least deprived 34,290 21.6 16,587 48.4 23,066 13.9 14,477 62.8 1,339 18.0 359 26.8 
2 34,845 22.0 17,551 50.4 28,411 17.1 18,498 65.1 1,428 19.2 415 29.1 
3 33,341 21.0 17,662 53.0 32,822 19.8 21,842 66.5 1,462 19.7 444 30.4 
4 31,206 19.7 17,442 55.9 39,220 23.7 26,864 68.5 1,618 21.8 486 30.0 
Most deprived 24,876 15.7 14,696 59.1 42,158 25.4 30,002 71.2 1,573 21.2 502 31.9 
TOTAL 158,558 100.0 83,938 52.9 165,677 100.0 111,683 67.4 7,420 100.0 2,206 29.7 
Abbreviations - IMD: Indices of Multiple Deprivation; 
*Percentage of patients with cancer type 
** Percentage according to patient characteristic and cancer type 
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NOTE: The prevalence reported for each cohort is the percentage of patients with the respective condition
Prevalence among cohorts in the scientific literature presented according to data source
Abbreviations:
COPD - Chronic obstructive pulmonary disease; HES - Hospital Episode Statistics; PVD - Peripheral vascular disease; Rheum - Rheumatological
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NOTE: Prevalence reported for the England cancer registry cohorts is the age-sex adjusted prevalence with 95% confidence intervals (prevalence information sourced from Hospital Episode Statistics data)
General population prevalence reported by data source
Abbreviations:
COPD - Chronic obstructive pulmonary disease; CPRD - Clinical Practice Research Datalink; CI - Confidence interval; HSE - Health Survey for England;
IDF - International Diabetes Federation; PVD - Peripheral vascular disease; QOF - Quality and Outcomes Framework; Rheum - Rheumatological;
RCGP RSC - Royal College of General Practitioners Research and Surveillance Centre; UK - United Kingdom
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Fulfilment of the second objective of this thesis 
 
The study described in Research Paper 2 investigated the prevalence of fourteen comorbidities among 
population-based cohorts of cancer patients and showed that the most deprived groups of patients 
carried the greatest burden of comorbidity and multiple comorbidity. While it is acknowledged that 
comorbidity in general terms can influence cancer prognosis, it would be useful to understand 
whether certain conditions have a greater influence that others on the poorer short-term prognosis 
experienced by the most deprived groups of cancer patients. 
The study I described in the second part of this chapter aimed to evaluate the measurement of 
comorbidity and the use of hospital data for this purpose. The findings from this study suggested that 
some conditions may be underreported in hospital data, and that access to additional sources of data 
(such as primary care data) to compliment hospital data may allow a more complete picture of cancer 
comorbidity. Nonetheless, the English hospital data provide a population-based insight into common 
comorbidities, and an indication of the (minimum) burden of comorbidity, among cancer patients.  
The most common conditions among the cohort of colon cancer patients were COPD, diabetes, 
hypertension, and cardio-vascular conditions such as CHF, MI, PVD and CVD. The age-sex adjusted 
prevalence of diabetes among the colon cancer patients was similar to the prevalence reported among 
the general population in England, while the age-sex adjusted prevalence of COPD among colon cancer 
patients was higher than the prevalence among the general population. Socio-economic deprivation 
was associated with the presence of each of the common conditions among colon cancer patients. In 
the next chapter of my thesis I investigate whether time living with COPD, diabetes or the cardio-
vascular conditions and frequency of hospital admissions prior to cancer diagnosis are an explanatory 
factor in the socio-economic inequalities in ninety-day mortality described in Chapter 3.   
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Chapter 5 - The role of time with comorbidity and timing and duration 
of hospital admissions pre-cancer diagnosis on socio-economic 
inequalities in short-term colon cancer mortality 
 
This chapter describes the research study undertaken to achieve the third objective of this thesis: to 
investigate whether timing of comorbidity and timing and duration of hospital visits pre-cancer 
diagnosis influence socio-economic inequalities in short-term colon cancer mortality. This work has 
been written up as a research article for peer-review publication. The chapter includes the 
background, description, main findings and conclusions of the study, a copy of the manuscript and a 
summary of how this work fulfils the third objective of the thesis.  
 
Introduction to research paper 3 
 
Background 
The study of prognostic factors influencing socio-economic inequalities in ninety-day mortality 
(Research paper 1)101 showed that comorbidity was a strong prognostic factor of ninety-day mortality 
among colon cancer patients. It also showed that socio-economic inequalities in ninety-day mortality 
were wider among patients with comorbidity than among patients with no recorded comorbidity. My 
study of comorbidity prevalence among cancer patients (Research paper 2)127 showed that the most 
deprived colon cancer patients tend to carry a greater burden of comorbidity. To further evaluate the 
role of comorbidity in socio-economic inequalities in ninety-day mortality, the next step of the 
research conducted for this thesis was to investigate comorbidity in more detail. Rather than use a 
summary metric of comorbidity, I focused on specific comorbidities that were either notably prevalent 
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among colon cancer patients or were a known risk factor for mortality. The impact of pre-existing 
comorbidities on patient health may be influenced by the time since the comorbidity first occurred 
and on the cumulative effect of living with the condition over a period of time. To investigate this 
further, I investigated time living with specific comorbidities prior to cancer diagnosis and 
hospitalisations occurring during this time, which I considered as time-varying proxy measures of the 
severity of the comorbidity and patient health status. An earlier study of comorbidity (not specific to 
a primary disease) as a prognostic factor in patient mortality concluded that models incorporating 
measures of duration, recency and severity of comorbidity offered a better model fit than models only 
including the presence of comorbidity.189   
 
The aim of this study was to investigate socio-economic inequalities in ninety-day mortality among 
colon cancer patients with comorbidity, and examine whether the time-varying proxy measures of 
comorbidity severity, plus other prognostic factors, explain some of the differences in the risk of short-
term mortality between the most and least deprived patients. My hypothesis was that patients with 
longer-term pre-existing comorbidities and more frequent hospital admissions (i.e. greater 
comorbidity severity) would be more at risk of dying within ninety days of colon cancer diagnosis.  
 
The three comorbidities studied were diabetes, chronic obstructive pulmonary disease (COPD) and 
the cardio-vascular conditions of the Charlson Comorbidity Index (CCI)83 – myocardial infarction or 
congestive heart failure, cerebrovascular disease and peripheral vascular disease. These comorbidities 
were selected due to their prevalence among the cohort of colon cancer patients127 and because their 
presence may impact upon mortality among colorectal cancer patients.   
Some risk factors for developing Type 2 diabetes are similar to those for developing colon cancer,  i.e. 
poor diet,122 lack of exercise122 and tobacco smoking.190 Diabetes may also develop due to non-
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modifiable risk factors such as genetic predisposition191 and ethnicity.192 Adverse outcomes among 
patients with diabetes are more common among male patients and older patients,193 and among those 
of lower socio-economic position.194 Diabetes can increase the risk of cardiovascular events and 
mortality,195, 196 including increasing mortality risk among colon cancer patients.197-199  
Tobacco smoking remains, so far, the predominant factor in the aetiology of COPD; other factors 
include exposure to air pollution, occupational hazards and infections.200 Auto-immunity may also 
have an indirect contribution: pulmonary damage caused by tobacco smoking or other environmental 
toxins can produce auto-immunological reactions that ultimately lead to the development of COPD.201 
There is evidence that women are more likely to have unfavourable clinical expression and adverse 
outcomes from COPD than men, 202, 203 while lower socio-economic position can contribute towards 
earlier mortality among patients with COPD.204  
Common risk factors for developing cardio-vascular diseases include tobacco smoking, obesity and an 
abnormal level of cholesterol and other lipids in the blood.205 The prevalence of,206 and mortality 
from,207 cardio-vascular conditions tends to be higher in men than women. Mortality from cardio-
vascular conditions is also associated with lower socio-economic position208 and with lifestyle factors 
such physical activity.209  Cardio-vascular conditions have been shown to increase cancer-related and 
all-cause mortality among colorectal cancer patients. 48, 116  
 
Methods and materials 
The data used for this study were National Cancer Registry data for England linked with electronic 
health records (Hospital Episode Statistics). The study population was patients aged 15-90 years who 
had been diagnosed with colon cancer in England between 2009 and 2013, and who had a recording 
of either diabetes, COPD or the cardio-vascular conditions in the Hospital Episode Statistics data in the 
six years prior to cancer diagnosis. Analyses were conducted separately according to whether patients 
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had diabetes, chronic obstructive pulmonary disease or cardio-vascular comorbidities, and the sex of 
the patient.  These sub-groups of patients studied ranged in size from approximately 4,600 to 9,200 
patients.   
The first objective of the study was to estimate the socio-economic inequalities in ninety-day mortality 
among each of the sub-groups of patients – i.e. to estimate the difference in predicted mortality 
between the most and least deprived groups of patients. The second objective was to examine 
whether the proxy measures of severity (i.e. time since comorbidity was first recorded and frequency 
and duration of hospital admissions during this time), plus other prognostic factors, influenced the 
magnitude of the inequalities within each sub-group of patients. The proxy measures of comorbidity 
severity were analysed as time-varying covariates, and used to estimate the weight function of their 
effect of on ninety-day mortality using Weighted Cumulative Exposure (WCE) models.210 These models 
have commonly been used in the pharmaco-epidemiology setting, and weight information about 
duration, timing and intensity of an exposure and estimate the effect of this weighted cumulative 
exposure on the outcome of interest, while adjusting for other fixed-effect covariates. The advantage 
of using this approach is that it accounted for the time-varying effect of these exposure measures of 
comorbidity severity on the outcome. Traditional approaches to modelling these measures of 
exposure may require that the exposure variables are summarised, and thus time-varying information, 
which may be relevant to the relationship between the exposure and outcome, is lost.  
 
Main findings 
Socio-economic inequalities in ninety-day mortality varied according to the comorbidity studied and 
sex of the patient.  Initial analyses of each sub-group of patients (adjusting for age and deprivation) 
showed that the widest inequalities were among female patients with COPD: the most deprived 
patients had a 71% increased risk of mortality compared with the least deprived patients (HR: 1.71; 
95%CI: 1.42, 2.07). 
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Accounting for the weighted cumulative effect of the proxy measures of comorbidity exposure 
reduced the magnitude of the socio-economic differences in mortality among all patient groups 
studied. The reduction ranged from 5% to 17%: among female patients with one of the cardio-vascular 
conditions, the hazard ratio of ninety-day mortality of the most versus least deprived patients reduced 
from 1.42 (95% CI: 1.21, 1.67) to 1.37 (1.16, 1.61), while among male patients with COPD the hazard 
ratio of the most versus least deprived patients reduced from 1.25 (1.05, 1.48) to 1.08 (0.91, 1.28).  
This represented a 12% and 68% relative reduction, respectively.   
There was a marked contrast in the results estimating socio-economic differences in ninety-day 
mortality among male and female patients with COPD, which was unexpected. Among the male 
patients, after adjustment for the weighted cumulative exposure measures of comorbidity, 
emergency presentation and the presence of multiple other comorbidities, there was no evidence of 
mortality differences between the most and least deprived patients (HR 1.00; 95% CIs 0.85, 1.19). By 
contrast, the most deprived female patients still had a 40% increased hazard of mortality compared 
with the least deprived group after adjusting for these same factors (HR 1.40; 1.16, 1.69).  
 
The differences between male and female patients with diabetes or cardio-vascular conditions were 
less notable. Following adjustment for prognostic factors, the most deprived groups of patients with 
these conditions still had a 10-20% higher hazard of mortality than the least deprived groups.  
Emergency presentation was strong prognostic factors of ninety-day mortality, regardless of the 
patient’s sex, age, deprivation group or the comorbidity being studied. The presence of additional 




The study showed that accounting for the time living with comorbidity before cancer diagnosis, and 
the frequency and duration of hospital admissions during that time, appeared to reduce the socio-
economic differences in short-term mortality among patients with diabetes, COPD or cardio-vascular 
conditions. These findings suggest a differential pattern of healthcare utilisation between the most 
and least deprived patients, which may be due to varying severity of comorbidity, different healthcare 
seeking behaviours, or varying complexity of healthcare needs, for example, due to the presence of 
multiple comorbidities.   
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Fulfilment of the third objective of this thesis 
 
In this chapter I examined ninety-day mortality among colon cancer patients with diabetes, COPD or 
cardio-vascular conditions. I investigated whether severity of comorbidity may influence socio-
economic inequalities in ninety-day mortality, using time living with comorbidity and the frequency 
and duration of hospital admissions during that time as proxy measures of comorbidity severity.   
Accounting for these proxy measures of comorbidity severity reduced the socio-economic differences 
in ninety-day mortality among patients with these comorbidities. Differences were further reduced 
after adjusting for cancer diagnosis via emergency presentation and the presence of multiple 
additional comorbidities, but the overall reduction varied according to the sex of the patient and the 
main comorbidity being studied.  
Differential healthcare utilisation prior to cancer diagnosis may influence short-term prognosis after 
cancer is diagnosed. Emergency presentation was a strong prognostic factor in ninety-day mortality. 
Exploring the management of pre-existing comorbidities and healthcare utilisation according to 
deprivation group may further disentangle mechanisms behind the inequalities in short-term 
mortality among cancer patients with comorbidity. For example, investigating whether there are 
opportunities for earlier cancer diagnosis among the most deprived patients with pre-existing 
comorbidities that share common risk factors with cancer or are considered in themselves as risk 
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Timing and duration of hospital admissions and time with comorbidity: explanatory factors in 
socioeconomic inequalities in short-term mortality among colon cancer patients with comorbidity? 
A population-based retrospective cohort study 
 
Helen Fowler, Dimitra-Kleio Kipourou, Michal Abrahamowicz, Marie-Eve Beauchamp, Coraline 




The prevalence of additional chronic diseases, or comorbidities, among cancer patients is associated 
with increased levels of socioeconomic deprivation, while the presence of comorbidities can influence 
cancer outcomes. The most deprived colon cancer patients tend to have poorer short-term prognosis 
following diagnosis. This study investigated the influence of time-varying dimensions of comorbidity 
in socioeconomic inequalities in short-term mortality among colon cancer patients. 
 
Methods 
This retrospective cohort study used population-based cancer registry data of patients aged 15-90 
years diagnosed with colon cancer in England between 2009 and 2013, and who had a recording of 
either diabetes, chronic obstructive pulmonary disease (COPD) or cardio-vascular conditions within 
linked Hospital Episode Statistics data in the six years prior to cancer diagnosis.  
Weighted Cumulative Exposure models estimated the time-varying dimensions of timing and duration 
of hospital admissions and time with comorbidity (considered as proxy measures of comorbidity 
severity) on ninety-day mortality among subgroups of patients defined according to comorbidity 




Accounting for the time-varying dimensions of comorbidity reduced the magnitude of socioeconomic 
differences in mortality among each of the patient subgroups. The reduction in the hazard ratio of 
ninety-day mortality (most versus least deprived patients) was smallest among the female patients 
with cardio-vascular conditions (from HR: 1.42; 95%CI: 1.21, 1.67 to HR: 1.37; 1.16, 1.61) and largest 
among male patients with COPD (1.25; 1.05, 1.48 to 1.08; 0.91, 1.28), representing a 12% and 68% 
relative reduction, respectively. Adjusting for emergency diagnosis with colon cancer and the 
presence of other comorbidities reduced differences in mortality further.  
 
Conclusions 
Differential healthcare utilisation prior to cancer diagnosis may contribute towards some of the 
mortality differences between the most and least deprived colon cancer patients with comorbidity. 
However, even after accounting for this and other prognostic factors, differences in mortality among 
these patients remained. Further investigation of healthcare utilisation and availability of resources, 
stage of cancer diagnosis and options for cancer treatment may provide insights into mechanisms 
which lead to poorer short-term prognosis among the most deprived groups of patients with 







The presence of additional long-term health conditions, or comorbidities, can affect cancer 
outcomes.1 Studies investigating cancer outcomes commonly evaluate the patient’s comorbidity 
status using summary metrics of comorbidity. For example, the Charlson Comorbidity Index (CCI)2 
assigns a weighting to each condition present based upon mortality risk and provides the patient with 
an overall comorbidity score. While these metrics offer an overall snapshot of comorbid conditions 
present (and can give an indication of comorbidity severity, based on weightings assigned to 
conditions), they are not informative in respect to the length of time the patient has lived with these 
conditions, and how these conditions may have impacted the patient’s health historically in the time 
before their cancer diagnosis.   
Patient performance status is a measure of health status used in epidemiological research. It is a score 
that defines a patient’s ability to perform certain activities of daily living, and is used by clinicians to 
determine the best treatment options for patients.3 Performance status is considered a prognostic 
factor for many cancers, such as non-small cell lung cancer,4 but is representative of health status at 
a given point in time.   
The existence of socioeconomic inequalities in short-term colon and colorectal cancer outcomes is 
well acknowledged in the scientific literature, the more deprived groups of patients having worse 
outcomes, even after adjusting for age, stage at diagnosis and other prognostic factors.5-8 The more 
deprived groups of patients tend to carry most of the burden of comorbidity or multimorbidity.9-12 It 
has been established that the presence of comorbidity can influence options for care following the 
patient’s cancer diagnosis, for example, it can have an impact on whether a patient receives curative 
cancer treatment.1 Some comorbidities have been linked with complications13 and higher Intensive 
Care Unit (ICU) admission14 among post-operative cancer patients. Comorbidity can also be predictive 
of duration of hospital stay following cancer diagnosis.15  
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The aim of this study was to investigate factors that may influence socioeconomic inequalities in 
ninety-day mortality among colon cancer patients with comorbidity, accounting for the timing and the 
duration of comorbidities and hospital admissions. The study focused on three comorbid conditions, 
selected because of their noticeable prevalence and their general impact on risk of death. Firstly, 
diabetes, which is a known risk factor for the development of colon cancer16 and mortality among 
patients with colon cancer.17-21  Secondly, chronic obstructive pulmonary disease (COPD), which was 
found to be one of the most prevalent conditions of the CCI among colon cancer patients in a 
descriptive study of cancer comorbidity in England.9 Lastly, we investigated the cardio-vascular 
conditions of the CCI (history of myocardial infarction or congestive heart failure, cerebrovascular 
disease and peripheral vascular disease), given that cardio-vascular diseases are a common cause of 
mortality22 and can increase mortality risk among colorectal cancer patients.23, 24 We considered time 
with the comorbidity and timing and duration of hospital admissions while living with the comorbidity 
as proxy measures of comorbidity severity and health status, and our objective was to investigate 
whether these measures, plus other prognostic factors, explain some or all of the inequality in short-





This study uses national cancer registry data linked with hospital admissions records (Hospital Episode 
Statistics,25 ‘HES’), Route to Diagnosis data,26 and national bowel cancer clinical audit data27 (‘NBOCA’ 
– data compiled by clinicians and other health care professionals working with patients in hospitals in 
multi-disciplinary teams). Data were of patients aged between 15-90 years, diagnosed with cancer of 
the colon in England between 2009 and 2013. Patients over the age of 90 years were excluded due to 
a combination of factors: their shorter life expectancy, the association between higher prevalence of 
comorbidity and increased overall mortality among very elderly patients,28 and because treatment 
options among this age group may differ from those of younger patients, particularly among patients 
with comorbidity, due to an increased risk of post-operative complications.29 Information on diagnosis 
date, age at diagnosis, vital status, date of last follow up, patient sex, socioeconomic deprivation group 
(based on patient residential postcode at time of diagnosis, and defined according to the deprivation 
quintiles of the Income domain of the Indices of Multiple Deprivation30) were obtained from registry 
data. The HES data provided information on timing and duration of hospital admissions occurring up 
to six years prior to cancer diagnosis, and information on the presence and timing of health conditions 
(the comorbidities), based upon the diagnostic fields and admission dates within the data. Route to 
Diagnosis data indicated the channel through which the colon cancer had been diagnosed. 
Information on cancer stage at diagnosis in these data was obtained from the clinical audit data and 
registry data. The stage variable was a composite variable based on the TNM classification system31 
and derived using an algorithm prioritising information on stage from multiple sources.32  
The data were in longitudinal format, with each observation representing a one-month interval of the 
time from six-years prior to cancer diagnosis (the comorbidity look-back period) to the three months 
of follow-up after cancer diagnosis. Thus, the exposure and outcome were captured in separate time-
143
intervals within the data. Figure 1 provides an illustration of the design of our study, with three 
examples of patient scenarios.  
Analyses were conducted separately on six sub-groups of patients that were based on patients with 




The outcome of interest in this study was mortality within ninety days from colon cancer diagnosis. 
This was measured as a binary variable, indicating the patient’s vital status (alive or dead) at ninety 
days from the date of diagnosis.  
 
Exposure (proxy measures of comorbidity severity) 
For each of the comorbidities of interest, the time-varying exposure variable captured the duration of 
hospital admissions occurring during each monthly time-interval prior to cancer diagnosis, defined in 
terms of the number of “bed days” (i.e. the total number of days of the hospital admission or spell, 
from the admission date to the discharge date). Thus, based on the time-interval, this variable also 
defined when the comorbidity was first recorded, and the timing of when the hospital admissions 
occurred. Appendix Table 1 provides an illustration of how this variable is defined in our data, based 
on the hypothetical patient scenarios presented in Figure 1. 
 
Other covariates 
In addition to the deprivation group variable, other covariates (all being time-fixed) included age at 
diagnosis, whether or not the patient had been diagnosed with colon cancer via emergency 
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presentation, and whether the patient was also living with additional comorbidities to the one being 
investigated as the main exposure. Depending on main comorbidity being studied, other additional 
comorbidities included: myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rheumatological 
conditions, liver disease, diabetes, hemiplegia or paraplegia, renal disease, obesity or hypertension.   
The assumed causal relationships between the variables, time with comorbidity, and ninety-day 
mortality are depicted in the directed acyclic graph in Appendix Figure 1. The relationships are defined 
at the time of cancer diagnosis. As the most deprived patients tend  to carry a greater burden of 
comorbidity and multiple comorbidity,9 and comorbidity is more prevalent in older patients,12 time 
with comorbidity and the presence of other (multiple) comorbidities were assumed to be associated 
with both deprivation and age. Emergency presentation with colon cancer was also considered to be 
associated with age and deprivation,33  and also a more advanced stage at diagnosis.34   
 
Analysis 
Cross tabulations were used to summarise i) the distribution of patient characteristics and ii) time with 
comorbidity and total duration of time spent in hospital according to the comorbid conditions being 
investigated.  
 
Weighted Cumulative Exposure models 
We used weighted cumulative exposure (WCE) models in order to account for the dimensions of our 
exposure variable representing comorbidity severity (i.e. the time since the comorbidity of interest 
was first recorded, the timing of hospital admissions and the number of bed days spent in hospital 
during the admission). We considered the number of bed days as an indicator of the intensity of the 
comorbidity. WCE models, proposed by Sylvestre and Abrahamowicz,35 weight information about 
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duration, timing and intensity of the exposure, and estimate the effect of this weighted cumulative 
exposure on the outcome of interest, while adjusting for other fixed-effect covariates. In our analyses 
the time-to-event process (from the time of cancer diagnosis to ninety-days following cancer 
diagnosis) was modelled using the Cox proportional hazards model. 
The purpose of using this approach was two-fold. Firstly, it enabled us to estimate the weight function 
of comorbidity severity on ninety-day mortality according to time before cancer diagnosis. Secondly, 
we could estimate the influence of fixed-effect covariates, such as deprivation group, on the hazard 
of ninety-day mortality, after adjusting for the time-varying weight function of comorbidity severity. 
 
We ran three alternative WCE models, incorporating either 1, 2 or 3 interior knots for the spline used 
to estimate the weight function. The best fitting model of the three was selected on the basis of the 
lowest Bayesian Information Criterion (BIC), using the BIC for censored survival models.36 Weight 
functions were right-constrained, i.e. constrained to go to zero on the right, which is applicable to 
exposures remote in time, such as our six-year lookback for information on the measures of 
comorbidity.  
In the first instance, for each comorbidity-sex sub-group of patients, simple Cox proportional hazards 
models were used to estimate the hazard ratio of ninety-day mortality adjusting for deprivation group 
and the non-linear effect of age (“Model 0”).  
The next step was to estimate the weight function of the time-varying measures of comorbidity on 
ninety-day mortality, using weighted cumulative exposure (WCE) models.  
Our first WCE model included the covariates of deprivation and the non-linear effect of age (“Model 
1”), as in Model 0. Subsequent WCE models were then run adding a binary variable indicating whether 
or not the patient had been diagnosed with colon cancer via emergency presentation (“Model 2”), 
then a categorical variable indicating multiple comorbidity – i.e. whether the patient had 0,1 or 2+ 
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other comorbidities (“Model 3”). Interactions between age and emergency presentation, age and the 
multiple comorbidity variable, and deprivation and the multiple comorbidity variable, were tested and 
removed one by one using a backwards elimination approach, based on that which showed the 
weakest evidence of significance (based on p<0.05) in the model according to the Wald test. The only 
interaction term that was retained in the WCE model was that between age and emergency 
presentation for the analysis of male colon cancer patients with diabetes.  
Management of the data and the statistical analyses were conducted using Stata 16 statistical 
software37 and R software version 3.6.3.38 The weighted cumulative exposure modelling was 





Between 2009 and 2013, 54,425 male patients and 47,791 female patients were diagnosed with colon 
cancer in England (Table 1). Diabetes and the cardio-vascular conditions were more prevalent among 
male patients than female patients (13% of males versus 10% of females had diabetes, and 17% males 
compared with 12% of females had at least one of the cardiovascular conditions). The prevalence of 
COPD was slightly higher among female patients (14.7% versus 13.9% of male patients).  
Among all patients diagnosed with colon cancer, the prevalence (%) of diabetes and the cardiovascular 
conditions was low (<3.5%) among the younger age groups and rose with increasing age, while the 
prevalence of COPD according to age group did not follow this pattern. For example, 12% of female 
patients aged 15-29 and 11.4% of female patients aged 30-44 had COPD compared with 10% of female 
patients aged 45-59.  
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The prevalence of each of the three conditions followed a socioeconomic gradient and rose with 
increasing level of deprivation. For both male and female patients, the biggest difference in prevalence 
between the least deprived and most deprived groups was widest among patients with COPD.   
Diabetes and cardio-vascular conditions were more prevalent among male patients diagnosed with 
colon cancer via emergency presentation than among female patients with an emergency 
presentation. Additionally, diabetes, COPD and cardio-vascular conditions were more prevalent 
among male patients who died within ninety days of colon cancer diagnosis than among females.  
 
Distribution of proxy measures of comorbidity severity according to deprivation group 
Number of bed days in hospital 
Depending on the deprivation group, approximately 37%-48% of patients with diabetes, 36%-48% of 
patients with COPD and 23%-30% patients with one or more of the cardiovascular conditions spent 7 
or less bed days in hospital in the six years prior to cancer diagnosis (Figure 2, Appendix Table 2).  
Among the most deprived groups of patients with the comorbidities of interest, 27% of the patients 
with COPD or with diabetes and 38% of the patients with one of more of the cardio-vascular conditions 
had been in hospital for at least 31 bed days during the six year period, versus 17%, 10% and 29% of 
the least deprived patients with diabetes, COPD or the cardio-vascular conditions, respectively.   
  
Time with comorbidity 
Diabetes, COPD or cardio-vascular conditions were first recorded in hospital admissions occurring up 
to one year prior to cancer diagnosis for approximately 40-50% of patients with these conditions in 
each deprivation group. A higher percentage of patients in the most deprived group had been living 
with their respective condition for 5-6 years compared with the least deprived group, for example, 
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13% of the most deprived group versus 10% of the least deprived group with COPD had the condition 
for 5-6 years (Appendix Figure 2). 
 
Frequency of hospital admissions 
The majority of patients in each of the deprivation groups had hospital admissions occurring from 1 
to 3 of the months in the six-year period before cancer diagnosis: approximately 70% of patients with 
diabetes, 83% - 88% of patients with COPD and approximately 67% of patients with one or more of 
the cardio-vascular conditions (Appendix Figure 3).  
 
Weighted cumulative exposure models 
In comparing the weighted cumulative exposure models according to whether the weight function 
was derived from splines with 1, 2 or 3 internal knots, the models considered to be the best fitting – 
i.e. based on the lowest BIC - were those with 1 internal knot (Appendix Table 3).  
 
Weight function of each comorbidity on ninety-day mortality 
The weight function of the exposure measures of diabetes differed between male and female patients 
in terms of magnitude and shape (Appendix Figure 4). The weight function of diabetes on ninety-day 
mortality for male patients fluctuated according to the length of time the condition was present before 
cancer diagnosis. Following adjustment for emergency presentation (models 2 and 3) the weight 
function followed a stable decrease over time for female patients.    
The weight function of COPD for female patients was negative up until approximately 3 years prior to 
cancer diagnosis, suggesting that during this timeframe these measures of COPD exposure could offer 
a protective effect toward the risk of ninety-day colon cancer mortality (Appendix Figure 5). By 
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contrast the weight function of COPD exposure of male patients appeared to suggest exposure had a 
protective effect on the risk of ninety-day mortality up to 3 years before cancer diagnosis.  
For female patients, the weight function of the exposure of cardio-vascular conditions up to 
approximately 4.5 years prior to cancer diagnosis (following adjustment for emergency presentation) 
was negative, thus suggesting that the exposure had a protective effect on the risk of ninety-day 
mortality (Appendix Figure 6). However, for male patients, the weight function of cardio-vascular 
conditions was positive. Given that the confidence intervals of the weight functions estimated for male 
and female patients with COPD and female patients with cardio-vascular conditions span across zero, 
the negative values of the weight function should be interpreted with some caution.   
 
Socioeconomic deprivation and ninety-day mortality 
Our study aimed to investigate socioeconomic inequalities in ninety-day mortality before and after 
estimating, and adjusting for, the weight function of each comorbidity. The hazard ratio of the most 
deprived group of patients compared with the least deprived group of patients, of each comorbidity-
sex patient sub-group and for each of the four models run are summarised in Figure 3. Within each 
sub-group of patients, based on the Cox regression model adjusting for age and deprivation (Model 
0), the most deprived patients had a higher hazard of mortality than the least deprived groups, ranging 
from a 25% increased hazard among the most deprived male patients with COPD (HR 1.25; 95%CIs: 
1.05, 1.48) to a 71% increased hazard among the most deprived female patients with COPD (HR 1.71; 
1.42, 2.07). After adjusting for the time-varying effects of each respective comorbidity in the WCE 
framework (Model 1) the hazard ratio reduced (from that derived from Model 0), this was the case 
regardless of the comorbidity or the sex of the patient. The excess hazard of mortality of the most 
deprived versus least deprived male patients with COPD went from 25% to weak evidence of an 8% 
increased hazard of ninety-day mortality (HR 1.08; 0.91, 1.28, Model 1). By contrast, among female 
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patients with COPD, the most deprived patients still had a 60% increased hazard of mortality 
compared with the least deprived group (HR 1.60; 1.32, 1.92, Model 1).  
There were also differences between the sexes in respect to socioeconomic inequalities in mortality 
among patients with diabetes or cardiovascular conditions. The increased mortality hazard of the most 
versus least deprived patients with diabetes was 31% among male patients while only 18% among 
female patients with diabetes (HR 1.31, 1.08, 1.58 and HR 1.18, 0.95, 1.47, respectively). Among 
patients with cardio-vascular conditions, the most deprived female patients had a 37% increased 
mortality hazard while the most deprived male patients had a 25% increased hazard of mortality 
versus the least deprived patients (HR 1.37; 1.16, 1.61, and HR 1.25; 1.09, 1.44, respectively).  
Further adjustment for emergency presentation (Model 2), and then for the presence of multiple 
other comorbidities (Model 3) brought further reductions to the hazard ratio of the most deprived 
versus least deprived groups of patients in each patient sub-group. The remaining difference in 
mortality between the most and least deprived groups of patients ranged from no evidence of a 
difference among male patients with COPD (HR 1.00; 0.85, 1.19) to a 40% increased hazard among the 
most deprived female patients with COPD (HR 1.40; 1.16, 1.69). 
To further examine the relationship between deprivation and ninety-day mortality among patients 
with diabetes, COPD or cardio-vascular conditions, the mortality hazard between the time of cancer 
diagnosis and 90 days after, according to deprivation group (most and least deprived groups), age at 
cancer diagnosis, emergency cancer diagnosis and the presence of multiple other comorbidities was 
derived from Model 3. These results are represented as the hazard ratio of ninety-day mortality at 
different combinations of these prognostic factors, referenced to the least deprived group aged 70 
years at cancer diagnosis without emergency presentation and without other comorbidities, and 
presented by comorbidity and sex in Figures 4-6.   
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Ninety-day mortality among patients with diabetes 
The deprivation gap in ninety-day mortality – i.e. the additional risk of mortality of the most deprived 
versus least deprived groups of patients - was wider among the male patients with diabetes than 
among the female patients with diabetes, and evidence of inequalities was weaker among female 
patients (Figures 3 and 4). Being diagnosed with cancer via emergency presentation had more of an 
impact on mortality among male patients than female patients. For example, among 50 year old male 
patients with diabetes and diagnosed with cancer as an emergency, the most deprived patients had 
approximately 3.4 times the hazard of ninety-day mortality (HR 3.38; 95%CIs: 1.11, 10.28) compared 
with the reference group (least deprived patients aged 70 at cancer diagnosis without emergency 
presentation and without other comorbidities), while the most deprived 50 year old female patients 
had 2.3 times the mortality hazard of their respective reference group (HR 2.31; 2.29, 2.33). The most 
deprived 70-year-old male patients who had multiple other comorbidities and had been diagnosed 
with colon cancer via emergency presentation had 7.5 times the hazard of ninety-day mortality of the 
reference group of 70-year-old patients (HR 7.52; 4.19, 13.49). Among the most deprived 70-year-old 
female patients, the mortality hazard was 6.8 times that of the reference group (HR 6.81; 3.96, 11.72). 
 
Ninety-day mortality among patients with COPD 
The contrast between male and female colon cancer patients with COPD, in respect to the influence 
that deprivation or having multiple additional comorbidities had on the hazard of ninety-day mortality 
is demonstrated in Figure 5.  Among male patients there was no evidence of a difference in the hazard 
of mortality between the most and least deprived groups, while among female patients there was an 
obvious deprivation gap, regardless of the status of the other prognostic factors.   
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As an example of the increased hazard of mortality from having multiple other comorbidities, the most 
deprived female patients aged 70 years at cancer diagnosis with additional comorbidities had 2.4 
times the mortality hazard within ninety days of diagnosis (HR 2.35; 1.46, 3.27) of their respective 
reference group (reference group as described previously). However, male patients aged 70 with 
multiple other comorbidities had approximately 1.25 times the mortality hazard of their reference 
group (HR 1.27; 1.11, 1.73).  
The hazard of ninety-day mortality following emergency presentation with colon cancer was broadly 
similar among male or female patients but followed a steeper gradient with age among male patients. 
However, where patients also had multiple other comorbidities the differences between the sexes in 
hazard of mortality was quite striking. For example, the most deprived such female patients aged 70 
had approximately 9 times the mortality hazard (HR: 8.97; 5.64, 14.24), while the most deprived such 
male patients aged 70 had approximately 4.6 times the mortality hazard (HR 4.62; 3.01, 7.10) of their 
respective reference groups.  
 
Ninety-day mortality among patients with cardio-vascular conditions 
In comparing the two sexes, socioeconomic inequalities in ninety-day mortality were most 
pronounced among the female colon cancer patients with cardio-vascular conditions (Figure 6). An 
emergency diagnosis of colon cancer had a similar impact on mortality among male and female 
patients: the least deprived patients diagnosed with colon cancer via emergency presentation at age 
70 had approximately 4 times the hazard of ninety-day mortality compared with their respective 
reference group (HR: 3.89; 3.52, 4.31 and HR: 3.97; 3.52, 4.48 for males and females, respectively). 
The presence of two or more additional comorbidities had a bigger influence on ninety-day mortality 
among female patients than male patients. Among patients who had an emergency cancer diagnosis 
and were living with multiple additional comorbidities, the most deprived 70-year-old female patients 
had 6.6 times the hazard of mortality of the reference group (HR: 6.65; 4.40, 10.04), while among the 
153
most deprived 70 year old male patients the hazard was 5 times that of their respective reference 





The findings of our study indicated that accounting for the weight function of time with comorbidity 
and timing and duration of hospital admissions while living with comorbidity reduced socioeconomic 
inequalities in all-cause ninety-day mortality. Depending on the comorbidity-sex sub-group studied, 
the reduction in the inequalities in mortality ranged from 12% to 68%.  After adjusting for these time-
varying measures of comorbidity and other prognostic factors, socioeconomic inequalities in mortality 
persisted among all but one of the sub-groups of patients (the male patients with COPD). The 
magnitude of the inequalities varied according to the respective comorbidity, sex of the patient, and 
the values of other prognostic factors. Among the male patients with COPD there was no evidence to 
suggest a difference in mortality between the most and least deprived groups of patients after 
adjustment for the prognostic factors. By contrast, between the remaining patient groups, the widest 
socioeconomic inequalities were seen among female patients with COPD: as an example to quantify 
these inequalities, the most deprived patients aged 70 years at cancer diagnosis had a 40% increased 
hazard of ninety-day mortality compared with the least deprived group.  
 
The reduction in socioeconomic inequalities in ninety-day mortality that followed the adjustment for 
timing of comorbidity and hospital admissions, suggests healthcare utilisation may explain part of 
these inequalities. Differences in healthcare utilisation between the most and least deprived groups 
of patients could warrant further consideration. Within the sub-groups of patients we studied, a 
higher percentage of patients in the most deprived group had been living with their condition at least 
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five to six years, had been in hospital for ninety or more bed days or had been admitted to hospital 
during at least ten of the months while living with the comorbidity prior to cancer diagnosis, regardless 
of the comorbidity, as compared with the least deprived group (Appendix Table 2).  Moreover, a study 
of the impact of deprivation on patient health care costs in England showed that the health care costs 
of the most deprived patients were higher than that of the less deprived groups, which is reflective of 
more frequent usage and / or an increased burden of disease among the most deprived group.39  
Emergency presentation was a strong prognostic factor of increased ninety-day mortality in this study, 
irrespective of sex or comorbidity, which concurs with other research findings regarding the influence 
of emergency presentation on short-term mortality among patients with colorectal cancer.34 Adjusting 
for emergency presentation in our WCE models further reduced the socioeconomic inequalities in 
mortality within each of the patient sub-groups, indicating that the most deprived patients were more 
adversely impacted following an emergency diagnosis. While stage at diagnosis is a prognostic factor 
in short-term cancer mortality,40 we considered that time with comorbidity may influence the stage 
at which cancer is diagnosed41 and therefore stage at diagnosis is on the causal pathway in the 
relationship between time with comorbidity and ninety-day mortality (Appendix Figure 1). For this 
reason, we did not consider stage as a potential confounder and did not adjust for it in our analyses. 
 
The outcomes of comorbid cancer patients may not only be influenced by the various prognostic 
factors of the cancer, but also the severity of their comorbidity, and the influence the comorbidity has 
on the management of the cancer. Indeed, the most deprived cancer patients with comorbidity may 
be faced with disadvantage over the least deprived patients with comorbidity even before cancer 
diagnosis, as lower socioeconomic position is associated with poorer outcomes with various chronic 
health conditions, including diabetes,42, 43 COPD44 and cardio-vascular conditions.45  
On this basis, our findings in respect to the diminished socioeconomic inequalities in mortality among 
male patients with COPD were unexpected, particularly given their contrast with the findings for 
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female patients with COPD.  There is evidence to support differences between the sexes in terms of 
clinical expression and outcomes of COPD: female patients with COPD may have worse symptoms,46, 
47 worse health-related quality of life47, 48 and higher all-cause or respiratory mortality49 than males. 
While this could be an explanation for poorer all-cause mortality among the female versus male colon 
cancer patients with COPD in our study, it does not explain the sex differences in respect to 
socioeconomic deprivation and mortality. Women may be more vulnerable to the toxic effects of 
tobacco than men50, 51 while tobacco smoking - a known risk factor for COPD52, 53 - is generally more 
prevalent among more deprived groups.54 It would have been useful to have information on smoking 
status in our data, to see if prevalence of smoking differed substantially between male and female 
patients and between deprivation groups of the patients with COPD, and to investigate whether this 
was connected with the socioeconomic inequalities in mortality among the female colon cancer 
patients with COPD.  
In our study, socioeconomic inequalities in all-cause mortality persisted among patients with one of 
the cardio-vascular conditions; these inequalities appeared to be wider within female patients than 
male patients. The results of a study by Stringhini and colleagues showed that behavioural factors 
(smoking, physical activity levels), and physiological factors (inflammatory markers) could partly 
explain an association between low socioeconomic position and cardiovascular disease mortality in 
England,55 but whether this association differed according to sex was not discussed.  
Among patients with diabetes, there was weaker evidence that socioeconomic inequalities in ninety-
day mortality remained once the time-varying measures of comorbidity and other prognostic factors 
had been accounted for, particularly among the female patients. As the healthcare system in the UK 
places focus on managing diabetes within primary care,56 we made the assumption that patients 
requiring hospital care for diabetes represent those patients with complicated diabetes or diabetes 
that cannot be well managed within primary care.57 It is also possible that those presenting to hospital 
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via emergency admission with complications of diabetes, tend to be of a lower socioeconomic 
position. 42, 43    
 
Searching the scientific literature returned few studies investigating similar measures of comorbidity, 
suggesting these measures (and the influence they have on short-term mortality) may not have been 
well-studied. Shack and colleagues investigated different time windows of comorbidity in relation to 
one-year survival from colorectal cancer, among a population-based cohort of patients in the North 
West of England. They concluded that comorbid conditions recorded up to 18 months before the 
cancer diagnosis were more strongly associated with an excess hazard of death within one-year of 
cancer diagnosis than comorbidities recorded up to one year after cancer diagnosis or at any time.24 
However, the timing of comorbidity did not appear to influence the impact it had on all-cause 
mortality among older, early-stage breast cancer patients.58  We found one other study within the 
scientific literature that had used a similar approach to ours for defining or measuring comorbidity. 
This was an Australian study that modelled comorbidity presence, recency, duration and severity (not 
specific to any one primary disease) in respect to the risk of post-hospitalisation mortality and 
readmission, using administrative data. The Australian study concluded that models with four 
measures  of comorbidity (presence, recency, duration and severity) offered a better model-fit than 
those modelling the presence of comorbidity only.59 While that study used Cox regression models to 
investigate post-hospitalisation outcomes based upon these measures of comorbidity, we estimated 
the weight function of presence of and timing and duration of hospital admissions with comorbidity 
on ninety-day mortality using Weighted Cumulative Exposure (WCE) models. Although this is a novel 
approach to investigating cancer comorbidity, it is an established method in the pharmaco-
epidemiology setting and is used to investigate the impact of recency, timing and dose of drugs on 
patient outcomes.35, 60  The design of our study was such that the event of interest (ninety-day 
mortality) could only occur after cancer diagnosis and not during the period in which our time-varying 
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measures of comorbidity occurred. However, using WCE models provided us with the opportunity to 
adjust for the weighted time-varying effect of time with comorbidity, frequency and duration of 
hospital admissions prior to cancer diagnosis when estimating socioeconomic inequalities in ninety-
day mortality among comorbid colon cancer patients.   
 
In this study we were faced with certain limitations that related to our data. To obtain information on 
comorbidity, we were reliant on the patient requiring hospital care and the comorbidities being well-
recorded in the diagnostic fields of the hospital admissions data. Additionally, there was no means of 
verifying the primary reason for hospital admission. We acknowledge the possibility of measurement 
error or misclassification within these data. However, we assume that while some less severe 
conditions, such as obesity, or conditions such as diabetes may be underreported in these data, that 
the more severe conditions are likely to require hospital care and will be captured within the 
diagnostic fields of these data.  
Nonetheless, the findings of this study provide insight into factors influencing socioeconomic 
inequalities in ninety-day mortality among colon cancer patient with diabetes, COPD or cardio-
vascular comorbidities. Time with comorbidity and timing and duration of hospital admissions 
appeared to explain some of these inequalities, as did having an emergency diagnosis of colon cancer. 
Further investigation of differences in patterns in healthcare utilisation according to deprivation group 
could be informative in further disentangling the mechanisms behind inequalities in short-term cancer 
outcomes among cancer patients with comorbidity. For example, identifying opportunities for earlier 
cancer diagnosis among the most deprived patients with pre-existing comorbidities, particularly those 
comorbidities considered as risk factors for developing cancer.    
Further future research to confirm the unexpected findings of this study and to understand the 
mechanisms leading to these findings would be beneficial.   
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Figure 1: Illustration of the exposure and event time of the study, with three hypothetical patient scenarios 
Patient scenarios 
Patient 1: Has hospital admission with comorbidity at the start of the six-year comorbidity lookback period, has three further hospital admissions before cancer diagnosis, 
and dies within ninety days of cancer diagnosis 
Patient 2: Has two hospital admissions with comorbidity in the six-year period before cancer diagnosis and is alive at ninety days following cancer diagnosis 
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Patients with cardio-vascular conditions
COPD: Chronic obstructive pulmonary disease; dep: deprived
Figure 2: Number of bed days in hospital with comorbidity in the six years 







Table 1: Presence of the comorbid conditions of interest among patients diagnosed with colon cancer between 2009 and 2013 in England, by patient characteristics
Patient characteristics
N % male 
patients




n % male 
patients 
with COPD
n % male patients 
with cardio-vascular 
conditions
N % female 
patients








n % female patients
 with cardio-vascular 
conditions
15-29 326 0.6 0 0.0 34 0.4 0 0.0 443 0.9 1 <0.1 53 0.8 1 <0.1
30-44 1,299 2.4 29 0.4 95 1.3 16 0.2 1,367 2.9 46 1.0 156 2.2 10 0.2
45-59 6,328 11.6 473 6.8 514 6.8 323 3.5 5,643 11.8 277 6.0 557 7.9 136 2.4
60-74 24,150 44.4 3,041 43.5 2,955 39.0 3,107 33.7 18,016 37.7 1,624 35.1 2,527 36.0 1,252 22.4
75-90 22,322 41.0 3,451 49.3 3,980 52.5 5,772 62.6 22,322 46.7 2,676 57.9 3,730 53.1 4,201 75.0
Least deprived 12,149 22.3 1,305 18.7 1,308 17.3 1,798 19.5 10,262 21.5 758 16.4 1,201 17.1 993 17.7
2 12,136 22.3 1,458 20.8 1,485 19.6 1,902 20.6 10,487 21.9 848 18.3 1,319 18.8 1,135 20.3
3 11,296 20.8 1,442 20.6 1,484 19.6 1,908 20.7 10,295 21.5 976 21.1 1,452 20.7 1,171 20.9
4 10,483 19.3 1,480 21.2 1,667 22.0 1,915 20.8 9,457 19.8 1,078 23.3 1,600 22.8 1,257 22.4
Most deprived 8,361 15.4 1,309 18.7 1,634 21.6 1,695 18.4 7,290 15.3 964 20.8 1,451 20.7 1,044 18.6
Yes 14,191 26.1 2,084 29.8 2,581 34.1 3,443 37.4 13,937 29.2 1,593 34.5 2,535 36.1 2,611 46.6
No 40,234 73.9 4,910 70.2 4,997 65.9 5,775 62.6 33,854 70.8 3,031 65.5 4,488 63.9 2,989 53.4
Yes 7,608 14.0 1,174 16.8 1,450 19.1 2,140 23.2 7,105 14.9 913 19.7 1,324 18.9 1,686 30.1
No 46,817 86.0 5,820 83.2 6,128 80.9 7,078 76.8 40,686 85.1 3,711 80.3 5,699 81.1 3,914 69.9
1 4,663 8.6 612 8.8 687 9.1 721 7.8 3,618 7.6 317 6.9 552 7.9 325 5.8
2 9,910 18.2 1,344 19.2 1,361 18.0 1,652 17.9 9,066 19.0 865 18.7 1,380 19.6 962 17.2
3 9,289 17.1 1,177 16.8 1,207 15.9 1,430 15.5 8,207 17.2 835 18.1 1,126 16.0 860 15.4
4 11,972 22.0 1,541 22.0 1,599 21.1 1,862 20.2 10,244 21.4 978 21.2 1,455 20.7 1,094 19.5
Missing 18,591 34.2 2,320 33.2 2,724 35.9 3,553 38.5 16,656 34.9 1,629 35.2 2,510 35.7 2,359 42.1
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Patients with cardio-vascular conditions
HR of patients aged 70 at cancer diagnosis (least deprived = 1)
Model 0: age and deprivation; Model 1: (WCE) age and deprivation; Model 2: Model 1 + EP; Model 3: Model 2 + other comorbidities
Abbreviations - COPD: Chronic obstructive pulmonary disease; WCE: weighted cumulative exposure; EP: emergency presentation
Figure 3: Adjusted hazard ratios (HR) of ninety-day mortality:
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40 45 50 55 60 65 70 75 80 85
Age at cancer diagnosis
Male patients with diabetes
Note: Hazard ratio reference is the least deprived group of patients at age 70 without emergency presentation and without other comorbidities
Figure 4: Hazard ratio of ninety-day mortality by age at cancer diagnosis
According to least or most deprived group, emergency presentation (EP), and presence of 2 or more other comorbidities
Least deprived 2+ other comorbidities EP EP, 2+ other comorbidities
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40 45 50 55 60 65 70 75 80 85
Age at cancer diagnosis
Male patients with COPD
Note: Hazard ratio reference is the least deprived group of patients at age 70 without emergency presentation and without other comorbidities
Figure 5: Hazard ratio of ninety-day mortality by age at cancer diagnosis
According to least or most deprived group, emergency presentation (EP), and presence of 2 or more other comorbidities
Least deprived 2+ other comorbidities EP EP, 2+ other comorbidities
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40 45 50 55 60 65 70 75 80 85
Age at cancer diagnosis
Male patients with cardio-vascular conditions
Note: Hazard ratio reference is the least deprived group of patients at age 70 without emergency presentation and without other comorbidities
Figure 6: Hazard ratio of ninety-day mortality by age at cancer diagnosis
According to least or most deprived group, emergency presentation (EP), and presence of 2 or more other comorbidities
Least deprived 2+ other comorbidities EP EP, 2+ other comorbidities
Most deprived 2+ other comorbidities EP EP, 2+ other comorbidities
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Appendix Table 1: Data format example
Patient id Interval start (month number) Interval end (month number) Exposure (number of bed days) Outcome (ninety-day mortality)
1 0 1 4 0
1 1 2 0 0
1 2 3 0 0
1 … … 0 0
1 15 16 3 0
1 … … 0 0
1 26 27 8 0
1 … … 0 0
1 54 55 15 0
1 … … 0 0
1 72 73 0 0
1 73 74 0 1
2 0 1 0 0
2 … … 0 0
2 12 13 5 0
2 … … 0 0
2 23 24 2 0
2 … … 0 0
2 72 73 0 0
2 73 74 0 0
2 74 75 0 0
3 0 1 0 0
3 … … 0 0
3 33 34 10 0
3 … … 0 0
3 56 57 20 0
3 … … 0 0













Appendix Figure 1: Directed acyclic graph (DAG) depicting the assumed causal relationships between deprivation and other prognostic factors, 
time with a comorbidity and ninety-day mortality. 
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Appendix Table 2: Distribution of time living with comorbidity and frequency and duration of hospital admissions, by patient deprivation group
n % n % n % n % n %
0-0.5 years 826 40.0 925 40.1 942 39.0 986 38.5 850 37.4
0.5-1 year 133 6.4 150 6.5 172 7.1 168 6.6 157 6.9
1-2 years 254 12.3 258 11.2 286 11.8 297 11.6 265 11.7
2-3 years 211 10.2 246 10.7 250 10.3 249 9.7 248 10.9
3-4 years 189 9.2 227 9.8 246 10.2 269 10.5 227 10.0
4-5 years 212 10.3 236 10.2 245 10.1 273 10.7 229 10.1
5-6 years 238 11.5 264 11.4 277 11.5 316 12.4 297 13.1
0-0.5 years 1,114 44.4 1,144 40.8 1,158 39.4 1,278 39.1 1,165 37.8
0.5-1 year 153 6.1 173 6.2 208 7.1 208 6.4 211 6.8
1-2 years 276 11.0 333 11.9 304 10.4 358 11.0 362 11.7
2-3 years 252 10.0 308 11.0 330 11.2 348 10.7 305 9.9
3-4 years 235 9.4 283 10.1 306 10.4 353 10.8 296 9.6
4-5 years 222 8.8 277 9.9 291 9.9 333 10.2 354 11.5
5-6 years 257 10.2 286 10.2 339 11.5 389 11.9 392 12.7
0-0.5 years 970 34.8 1,063 35.0 1,068 34.7 1,137 35.8 948 34.6
0.5-1 year 242 8.7 237 7.8 304 9.9 278 8.8 236 8.6
1-2 years 379 13.6 436 14.4 431 14.0 440 13.9 375 13.7
2-3 years 323 11.6 364 12.0 359 11.7 345 10.9 327 11.9
3-4 years 299 10.7 371 12.2 321 10.4 359 11.3 267 9.7
4-5 years 296 10.6 290 9.5 271 8.8 308 9.7 287 10.5
5-6 years 282 10.1 276 9.1 325 10.6 305 9.6 299 10.9
1-3 1,461 70.8 1,607 69.7 1,684 69.6 1,738 67.9 1,541 67.8
4-6 405 19.6 450 19.5 487 20.1 526 20.6 469 20.6
7-9 126 6.1 159 6.9 150 6.2 174 6.8 143 6.3
10+ 71 3.4 90 3.9 97 4.0 120 4.7 120 5.3
1-3 2,216 88.3 2,426 86.5 2,511 85.5 2,782 85.2 2,546 82.5
4-6 227 9.0 296 10.6 308 10.5 351 10.7 354 11.5
7-9 50 2.0 55 2.0 82 2.8 86 2.6 107 3.5
10+ 16 0.6 27 1.0 35 1.2 48 1.5 78 2.5
1-3 1,871 67.0 1,980 65.2 2,073 67.3 2,154 67.9 1,816 66.3
4-6 646 23.1 727 23.9 693 22.5 658 20.7 587 21.4
7-9 163 5.8 214 7.0 196 6.4 232 7.3 207 7.6
10+ 111 4.0 116 3.8 117 3.8 128 4.0 129 4.7
1-7 987 47.8 1,083 47.0 1,025 42.4 1,065 41.6 840 37.0
8-14 355 17.2 348 15.1 417 17.2 427 16.7 383 16.8
15-30 335 16.2 377 16.3 460 19.0 468 18.3 443 19.5
31-89 314 15.2 390 16.9 394 16.3 456 17.8 445 19.6
90+ 72 3.5 108 4.7 122 5.0 142 5.6 162 7.1
1-7 1,192 47.5 1,208 43.1 1,254 42.7 1,289 39.5 1,102 35.7
8-14 417 16.6 473 16.9 465 15.8 577 17.7 499 16.2
15-30 466 18.6 541 19.3 597 20.3 653 20.0 654 21.2
31-89 363 14.5 486 17.3 492 16.8 600 18.4 629 20.4
90+ 71 2.8 96 3.4 128 4.4 148 4.5 201 6.5
1-7 833 29.8 844 27.8 805 26.1 806 25.4 615 22.5
8-14 459 16.4 496 16.3 534 17.3 527 16.6 439 16.0
15-30 687 24.6 694 22.9 723 23.5 728 23.0 637 23.3
31-89 643 23.0 785 25.8 756 24.6 844 26.6 791 28.9
90+ 169 6.1 218 7.2 261 8.5 267 8.4 257 9.4
Cardio-vascular conditions
Number of months with a hospital admission
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Patients with cardio-vascular conditions
COPD: Chronic obstructive pulmonary disease; dep: deprived
Appendix Figure 2: Time with comorbidity in the six years prior
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Patients with cardio-vascular conditions
COPD: Chronic obstructive pulmonary disease; dep: deprived
Appendix Figure 3: Number of months with a hospital admission with comorbidity






Appendix Table 3: BIC by WCE model and number of internal knots
1 2 3 1 2 3 1 2 3
Model 1 20,194.43 20,200.61 20,208.06 25,175.26 25,179.11 25,185.92 38,141.05 38,146.51 38,154.74
Model 2 19,880.07 19,884.85 19,888.93 24,757.57 24,764.39 24,766.82 37,419.22 37,422.69 37,421.26
Model 3 19,875.90 19,881.82 19,885.54 24,759.03 24,765.91 24,768.39 37,435.60 37,439.60 37,438.31
Model 1 14,962.74 14,964.93 14,971.97 22,692.38 22,694.77 22,701.79 28,356.25 28,359.66 28,366.93
Model 2 14,678.36 14,684.67 14,690.60 22,291.58 22,298.13 22,304.02 27,795.82 27,801.40 27,806.36
Model 3 14,658.37 14,664.90 14,670.90 22,250.75 22,257.82 22,264.13 27,789.51 27,795.84 27,800.93
Females
Diabetes COPD Cardio-vascular conditions















Weight function of diabetes on ninety−day mortality: 
 Model 1 (age and deprivation)
























Weight function of diabetes on ninety−day mortality: 
 Model 2 (Model 1 + emergency presentation)






















Weight function of diabetes on ninety−day mortality: 
 Model 3 (Model 2 + other comorbidities)
























Weight function of COPD on ninety−day mortality: 
 Model 1 (age and deprivation)
























Weight function of COPD on ninety−day mortality: 
 Model 2 (Model 1 + emergency presentation)






















Weight function of COPD on ninety−day mortality: 
 Model 3 (Model 2 + other comorbidities)
























Weight function of cardio−vascular conditions on ninety−day mortality: 
 Model 1 (age and deprivation)
























Weight function of cardio−vascular conditions on ninety−day mortality: 
 Model 2 (Model 1 + emergency presentation)






















Weight function of cardio−vascular conditions on ninety−day mortality: 
 Model 3 (Model 2 + other comorbidities)
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Chapter 6 – Discussion and conclusions  
 
Introduction 
In this thesis I have investigated different aspects of comorbidity to better understand its role in socio-
economic inequalities in short-term mortality among colon cancer patients in England. I firstly used a 
summary measure of patient comorbidity (Charlson comorbidity score) to examine comorbidity as 
one of several prognostic factors in ninety-day mortality. I described comorbidity prevalence among 
patients with cancer of the colon, rectum or lung or with Hodgkin lymphoma, and examined 
comorbidity prevalence and multiple comorbidity prevalence according to socio-economic 
deprivation. To better understand how well information on comorbidity is captured from hospital 
admissions data I compared prevalence information derived from these data with that from other 
data sources of chronic disease prevalence. Lastly, I investigated the influence of time living with 
specific comorbid conditions prior to cancer diagnosis, and the frequency and duration of hospital 
admissions during this time, on socio-economic inequalities in ninety-day mortality.  
In this chapter I discuss each of the research questions of this thesis in turn, summarising the findings 
and putting them in the context of the existing literature. I then discuss the strengths and limitations 
of my research. Finally, I discuss the implications of my research findings on healthcare policy and 
practice and epidemiological research, and offer suggestions for further research.  
 
Prognostic factors in socio-economic inequalities in ninety-day mortality among colon 
cancer patients 
The first research question of this thesis (Research Paper 1)101 aimed to quantify socio-economic 
inequalities in ninety-day mortality among patients with colon cancer, and investigate how various 
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prognostic factors (age and stage at diagnosis, comorbidity, receipt of surgery and presentation for 
surgery) influence the magnitude of these inequalities.   
When I estimated the average predicted probability of death within ninety-days at the deprivation 
group level, based on the average probability of death of all patients in each group, the most deprived 
group of patients had a 5-7% higher prediction of death than the least deprived group (depending on 
the sex of the patient). Further analyses suggested the differential distribution of prognostic factors 
may explain some of the mortality differences between these groups, with stage and treatment being 
the strongest contributors to the inequalities.  
When investigating the magnitude of the inequalities according to the conditional probability of death 
(i.e. conditional on specified values of prognostic factors), inequalities were widest among patients 
receiving an emergency surgery, having an advanced stage of diagnosis or having the highest Charlson 
comorbidity score (3 or more). Putting this into context, the difference in the predicted deaths of the 
most versus least deprived groups was less than 1% among 60 year old male patients with a stage 1 
diagnosis (irrespective of comorbidity score or surgery received) but as much as 12% among 80 year 
old male or female patients with a stage 4 diagnosis and the highest comorbidity score who received 
a major emergency surgery.  
There were inequalities in predicted deaths among patients with the highest comorbidity score even 
for patients with a more favourable, early stage diagnosis who received elective surgery (up to a 2.5% 
difference in predicted deaths between the most and least deprived such patients). This suggests that 
there may be aspects of living with or managing comorbidity and multiple comorbidity that more 
adversely impact the short-term prognosis of the most deprived patients.  
 
Evidence of socio-economic inequalities in the outcomes of colon or colorectal cancer patients are 
widely reported in the scientific literature9-12, 57, 211-213 and support the findings of my study. Many 
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studies have reported on the association between socio-economic position and short-term outcomes, 
the size of this association varying according to the outcome and the characteristics of the patients 
studied. For example, among post-operative colorectal cancer patients in England, the most deprived 
patients had over 30% increased odds of dying within thirty days compared to the least deprived 
patients.57 By comparison, among colorectal cancer patients in Granada, Spain, the difference in one-
year net-survival (i.e. survival from cancer, after adjusting for expected mortality from other causes) 
between the most and least deprived patients was 10% among men and 4% among women.212  
My findings also concur with the evidence from these studies that having a higher burden of 
comorbidity,9, 57 a more advanced stage of diagnosis,57, 212, 213 being of older age,9, 213 and having an 
emergency presentation for surgery9, 57 are associated with poorer patient outcomes.   
A strength of my study was that it provided a detailed examination of socio-economic inequalities and 
how they varied according to different combinations of values of the prognostic factors. This 
highlighted where vulnerabilities among the most deprived patients lay, and less favourable scenarios 
for the short-term prognosis of these patients. I was not able to find any other published studies that 
had explored these inequalities in such a way.   
Studies specifically investigating the contribution of comorbidity to inequalities in short-term 
outcomes of colon or colorectal cancer patients are few. Two studies published by Frederiksen and 
colleagues reported that adding comorbidity to models adjusted for age, sex, year of operation, 
alcohol consumption, tobacco smoking and Body Mass Index reduced socio-economic differences in 
mortality outcomes (thirty-day postoperative mortality56 or all-cause mortality52). A study in the 
Netherlands reported similar findings.93  
Based on the findings of my study and the available evidence in the scientific literature, the most 
deprived patients have poorer short-term prognosis following cancer diagnosis, and comorbidity may 
play a part in this. Looking at comorbidity in more detail – particularly as pre-existing comorbidities 
can influence stage at diagnosis214, 215 and options for treatment13, 111 - may improve our understanding 
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of why the most deprived patients with comorbidity fare worse than the least deprived patients with 
comorbidity.    
 
The prevalence of comorbidity among cancer patients in England 
The second research question of this thesis (Research Paper 2)127 aimed to describe comorbidity 
prevalence among population-based England cancer registry cohorts of patients with cancer of the 
colon, rectum, lung or with Hodgkin’s lymphoma. I estimated the prevalence of fourteen conditions 
and the associations between sociodemographic factors and the presence of these conditions among 
these four cohorts of patients.   
Half of the patients in the colon cancer patient cohort had at least one comorbidity, with hypertension, 
COPD and diabetes being the most common of the fourteen comorbidities studied (age-sex adjusted 
prevalence of these conditions: 17%, 11% and 6%, respectively). The study showed that increased 
levels of deprivation were associated with the presence of all of the comorbidities studied except one 
(rheumatological conditions) among colon cancer patients, and that the most deprived patients had a 
higher probability of having multiple comorbidities. The majority (70-90%) of colon cancer patients 
who had conditions such as COPD, diabetes or cardio-vascular conditions (e.g. cerebrovascular 
disease, congestive heart failure and peripheral vascular disease) also had other comorbidities, 
suggesting many of these patients may have complex healthcare needs.  
 
My study builds on existing studies of cancer comorbidity prevalence that have reported on the 
prevalence of conditions among cancer patient cohorts,48, 116 or provided prevalence estimates 
according to factors such as patient age and sex.117 Information in the scientific literature on socio-
economic position and comorbidity among cancer patients is more sparse, although a study of cancer 
patients in the Netherlands reported an association between low socio-economic position and an 
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increased risk of having cardio-vascular diseases, COPD or diabetes among colorectal cancer 
patients.93 Many of the studies that have investigated socio-economic position and comorbidity 
prevalence are more generally focused on multimorbidity14, 15, 64, 216 (i.e. the presence of two or more 
chronic conditions) within the general population, rather than on comorbidity in the context of a 
primary disease such as cancer. These studies reported that having multimorbidity was more common 
among people of lower socio-economic position. Looking at chronic diseases in isolation, a recent 
study using UK data (Whitehall II study linked with Hospital Episode Statistics) reported associations 
between higher levels of deprivation and conditions such as diabetes, heart failure, chronic 
obstructive bronchitis, renal failure and liver disease.217 These associations and that reported in 
another study of COPD prevalence in England218 were of a similar magnitude to those reported for the 
colon cancer patients in my study.  
Many of the comorbid colon cancer patients in my study had not just one but multiple comorbidities, 
and therefore were living with at least three chronic conditions, including cancer. The likelihood of 
this rose with increasing deprivation and with age. In addition to the implications this may have on 
the prognosis of these patients at the time of their cancer diagnosis, this also factors into a broader 
public health issue: the ageing of the population and the rising prevalence of chronic diseases and 
multimorbidity.3, 219 Kingston and colleagues predicted that the percentage of the population aged 65 
years and older living with four or more health conditions is projected to rise from 10% to 17% 
between 2015 and 2035.219 This highlights the importance of healthcare systems that are able to 
manage the simultaneous care of patients with multiple health conditions, and adapt to an increasing 
demand on resources.220 Furthermore, interventions to mitigate the rise in prevalence of chronic 
diseases (for example, focusing on behavioural and lifestyle risk factors for developing chronic 
diseases), or interventions to limit the progression of existing conditions and support behavioural self-
management of these conditions, may help reduce the prevalence of multimorbidity and the 
utilisation of healthcare services.   
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Administrative hospital admissions data as a source of information on chronic disease 
prevalence 
 
The third research question of the thesis aimed to investigate hospital admissions data in England as 
a source of information on chronic disease prevalence, by examining how information on the 
prevalence of thirteen chronic diseases captured from this source compared with prevalence 
information available from other data sources.  
In the first instance, I used hospital admissions data to calculate the crude prevalence of each of the 
thirteen conditions among an England cancer registry cohort of colorectal cancer patients and 
compared this with the prevalence among other colorectal cancer patient cohorts reported in the 
scientific literature. This provided an opportunity to investigate commonly used sources of data on 
comorbidity among cancer patients. The majority of studies retrieved from the literature search had 
used administrative data sources to capture information on comorbidity, and patterns in respect to 
the most prevalent of the thirteen conditions among colorectal cancer patients were consistent 
among these data sources. Studies of comorbidity among cancer patients in the United States used 
Medicare claims data to derive information on comorbidity from hospital records and primary care 
data, which was limited to patients aged 65 years and over. Given the association between increasing 
age and comorbidity prevalence,115, 127 it is anticipated that the prevalence of many of the conditions 
may be higher among this older group of patients than among cohorts of patients that included 
younger adults. This study also highlighted differences between countries in approaches to obtaining 
information on cancer comorbidity from healthcare administrative data. Within a universal healthcare 
system in England, the Hospital Episode Statistics data is collated for all patients admitted to public 
(National Health Service, NHS) hospitals in the country. These data can be accessed via application to 
NHS England and can be linked with cancer registration data. In the United States, information on 
patient hospital records is sourced through health insurance claims (either via public programs such 
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as Medicare or via private insurers) or via a medical record review.221  Medicare represents the 
broadest population-based healthcare administrative data within the United States, representing 
approximately 97% of patients aged 65 years and over.222  As discussed earlier in this thesis, after 
reviewing and evaluating the methods used to define comorbidity among cancer patients in 
epidemiological studies, Sarfati and colleagues concluded that the different approaches used have 
varying advantages and disadvantages, but there is no one approach that offers a gold standard to 
measuring comorbidity among cancer patients.104 The variety of methods used to measure 
comorbidity may pose a limitation when amassing evidence-based research upon which to base 
healthcare policy decisions aimed at improving outcomes of cancer patients with comorbidity. Further 
inconsistency in the methods of deriving information on comorbidity and differing characteristics of 
populations upon which the evidence is based may present a further challenge. There has been a call 
for transparency with - and validation of - algorithms used to identify patients with different health 
states from routinely collected administrative data, in order to demonstrate accuracy and consistency 
with the use of these data for this purpose.223, 224     
 
The second objective of the study was to compare the age-sex adjusted prevalence among the England 
cancer registry cohorts of colorectal cancer, lung cancer and Hodgkin lymphoma patients with the 
reported national prevalence of these conditions among adults in England. National prevalence 
information, where available, was commonly sourced from data that is taken from a sample of the 
population rather than being population-based. Data sources included the Health Survey for England 
(HSE) or the Quality of Outcomes Framework (QOF). These data sources may be subject to biases: 
survey information may be liable to recall bias or non-response bias and General Practices are offered 
financial incentives for reporting information on specific conditions through the QOF (reporting bias). 
National prevalence information was only available for six of the thirteen conditions of interest. The 
findings suggested that the prevalence of certain conditions (e.g. obesity and diabetes) may be 
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underestimated from hospital admissions data. Certain conditions sharing common risk factors with 
cancer, such as COPD, were shown to be more prevalent among the England cancer registry cohorts 
than among the general population. This was anticipated, but it highlights the problem of comorbidity 
among cancer patients and more generally, multimorbidity. My findings also showed that the 
reporting of the prevalence of specific diseases among the general population can be very limited or 
vary between data sources. Wider disease registration and collection of population-based information 
on the diagnoses of common chronic conditions would provide a resource with which to monitor 
changes in incidence and prevalence of these conditions over time, and provide further data resources 
for epidemiological research into patient outcomes.   
 
Timing and duration of hospital admissions and time with comorbidity as explanatory 
factors in socio-economic inequalities in ninety-day mortality 
 
The fourth research question of this thesis aimed to investigate socio-economic inequalities in ninety-
day mortality among colon cancer patients with comorbidity; specifically, with diabetes, COPD or 
cardio-vascular conditions (congestive heart failure, myocardial infarction, peripheral vascular 
disease, or cerebrovascular disease). It also aimed to examine whether time-varying exposure 
measures of comorbidity (time since a comorbidity was first reported and the duration and timing of 
hospital admissions during this time), plus other prognostic factors, influence socio-economic 
inequalities in ninety-day mortality.  
 
This study represented a novel approach to exploring the influence of comorbidity on cancer patient 
outcomes. I used weighted cumulative exposure models to account for the effect of the time-varying 
measures of comorbidity on ninety-day mortality. This method, proposed by Sylvestre and 
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Abrahamowicz,210 is commonly used in the pharma-epidemiology setting to account for the timing, 
duration and intensity of drug exposure. Using a more traditional approach to investigate time with 
comorbidity and time in hospital as exposures on the outcome of ninety-day mortality would have 
meant summarising these exposure variables and thus removing time-varying information that may 
be relevant to the association between these exposures and the outcome.  
 
There were inequalities in short-term mortality among each of the subgroups of colon cancer patients 
with the same pre-existing comorbidity: the most deprived patients with diabetes, COPD or cardio-
vascular conditions had an increased hazard of ninety-day mortality compared with the least deprived 
patients (after adjusting for age and deprivation). After accounting for the time-varying exposure 
measures of comorbidity, the differences in mortality between the most and least deprived patients 
reduced within each patient subgroup. The relative reduction ranged from 12% among female 
patients with one of the cardio-vascular conditions to 68% among male patients with COPD. This 
finding suggested that, among patients with these pre-existing comorbidities, healthcare utilisation 
prior to cancer diagnosis may be an explanatory factor in some of the socio-economic disparities in 
ninety-day mortality after cancer diagnosis. There is evidence to suggest differential patterns in 
healthcare utilisation between the most and least deprived groups in England. The most deprived 
groups tend to have more frequent usage or greater need for care due to an increased burden of 
disease.225 Indeed, among each of the subgroups of patients I studied, the percentage of the most 
deprived patients who had lived with the comorbidity in question up to six years and had spent at 
least 90 days in hospital prior to cancer diagnosis was higher than that of the least deprived patients.  
 
Among patients with COPD, there was an unexpected contrast in findings between male and female 
patients in respect to socio-economic differences in all-cause ninety-day mortality. After accounting 
for the time-varying exposure of COPD, and adjusting for age, emergency presentation and the 
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presence of other comorbidities, there was no evidence to suggest that the most deprived male 
patients had a higher hazard of mortality than the least deprived male patients. By contrast, the 
mortality differences between the two deprivation groups persisted among the female patients.  
At the onset, socio-economic differences in ninety-day mortality were lower among the male sub-
group of patients with COPD: the most deprived patients had a 25% increased age-adjusted hazard of 
mortality versus the least deprived patients, while among the female sub-group the age-adjusted 
mortality hazard of the most deprived patients was 71% higher than that of the least deprived 
patients. After accounting for the time-varying exposure measures of COPD, there was only weak 
evidence of an 8% increased hazard of mortality among the most versus least deprived male patients, 
while among the most deprived female patients there was a 60% increased hazard. There is evidence 
males have a stronger social gradient in mortality from COPD than females,226  suggesting that these 
findings relate more to the mechanisms between the existence of COPD and the colon cancer 
diagnosis (and beyond) than to the presence of COPD alone. The presence of pre-existing comorbidity 
can influence the stage at which cancer is diagnosed. For example, cancer may be diagnosed at an 
earlier stage based upon increased contact with healthcare professionals due to the comorbidity, or 
diagnosis may be delayed where the symptoms of cancer are masked by, or attributed to, the 
comorbidity.214, 227 The presence of COPD has been shown to increase the odds of being diagnosed 
with some cancers at a more advanced stage.228 There is little information within the scientific 
literature in respect to socio-economic position and the relationship between healthcare utilisation 
with COPD and stage of colon cancer diagnosis. It would be useful to investigate this further, to 
understand if this relationship differs between the most and least deprived patients with COPD, and 
whether this differs by sex.   
 
Although females tend to have worse COPD outcomes than males,202, 229 the reasons behind the 
persistent socio-economic differences in mortality among the female sub-group of patients with COPD 
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are less clear. Women have a greater vulnerability towards the adverse effects of tobacco smoking 
than men.230, 231 As smoking prevalence is associated with higher levels of socio-economic 
deprivation,232 the reason for the mortality differences could be related to smoking status, assuming 
that i) smoking is more prevalent among female than male patients and ii) among the female patients 
with COPD, smoking is more prevalent amongst the most deprived patients. Having access to data on 
the smoking status of the patients in this study would have been beneficial, to investigate this more 
fully.  
Another aspect to consider is whether the male and female COPD patient sub-groups studied are 
equally representative of COPD patients. My analyses focused on colon cancer patients who had COPD 
recorded in their hospital records up to six years prior to their cancer diagnosis. COPD is a condition 
that tends to be underdiagnosed, 233, 234 and there is some suggestion that certain clinical guidelines 
and criteria for the diagnosis of COPD may lead to overdiagnosis of COPD in older men and missed 
diagnosis of COPD in younger women.235 An implication of this could be over- and under- 
representation of COPD patients in the male and female sub-groups of colon cancer patients I studied, 
respectively.  A further implication may be differential severity of disease, where younger female 
patients may have had more severe disease by the time COPD was diagnosed.235 There is a possibility 
of  selection bias among the sub-groups of patients I studied, which may have contributed to the 
unexpected contrast in findings between male and female patients with COPD.  
 
Emergency presentation was a strong prognostic factor in ninety-day mortality among patients with 
diabetes, COPD or cardio-vascular conditions. Adjusting for emergency presentation with colon cancer 
and for the presence of multiple comorbidities (factors that are associated with increased levels of 
deprivation)127, 236  further reduced the differences in ninety-day mortality between the most and least 
deprived patients within each of the comorbidity subgroups. However, even after adjusting for these 
factors the inequalities in ninety-day mortality generally persisted, indicating that other factors appear 
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to be playing a role in these inequalities. Further investigation of healthcare utilisation prior to cancer 
diagnosis, according to deprivation group, may provide some insights into the mechanisms that lead 
to poorer short-term cancer prognosis among the most deprived patients with comorbidity. One 
dimension of this may be the mechanisms between socio-economic position, comorbidity, stage at 
diagnosis and receipt of treatment.  
 
Strengths and Limitations  
 
The research conducted for this thesis used population-based cancer registry data, representing a 
robust and reliable source of information on patients diagnosed with cancer in England. I used multiple 
linked datasets to supplement the registry data and enhance the range of information available for 
the cancer patients I studied. These linked data allowed me to obtain information on variables such 
as presence and timing of comorbidity, stage at diagnosis, surgery received, timing of surgery, 
presentation for surgery, and the length and frequency of hospital admissions prior to cancer 
diagnosis.  
Comorbidity was the focus of my thesis, and I used the diagnostic fields of hospital admissions data to 
derive information on comorbidity recorded in the six years prior to diagnosis. I have acknowledged 
limitations of these data for this purpose in earlier chapters of this thesis, including the possibility of 
measurement error or misclassification arising when the diagnostic fields are coded from medical 
notes made by clinicians.237 Nonetheless, the external validity of the algorithm we developed to 
extract information on comorbidity was shown to be over 86 percent. 76 My research into sources of 
information on cancer comorbidity highlighted that routine administrative data such as primary and 
secondary care records are commonly used as a source of information on cancer comorbidity. These 
data offer many benefits for epidemiological research, such as being low in cost, accessible, providing 
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information on a wide range of diseases and offering generalisability due to the large populations they 
cover.131  
In the analyses I conducted for the first research question of this thesis (Chapter 3), I had to deal with 
the problem of missing information for stage at diagnosis among approximately 30 percent of the 
cohort of colon cancer patients. However, as stage appeared to be missing under the Missing at 
Random mechanism, it was possible to undertake multiple imputation of these data and avoid the 
biases associated with a complete case analysis.238 Missing at Random is the mechanism whereby the 
propensity for information to be missing is not related to the missing data but is related to some of 
the observed data.238 A challenge that I faced with this process was that the analysis model I developed 
to address my research question was not compatible with imputation models used in traditional 
approaches to multiple imputation. This was because the analysis model included interactions 
between stage and other covariates (which could not be included in an imputation model) and age at 
diagnosis was modelled using a cubic spline to investigate the non-linear effect of age on the outcome 
of ninety-day mortality. To overcome this problem I used the Substantive Model Compatible Fully 
Conditional Specification approach to multiple imputation, which has been shown to produce 
consistent estimates for analysis models which include non-linear covariate effects or interactions.239 
A further benefit of this was that it provided me with an opportunity to broaden my experience with 
the use of multiple imputation.  
 
My research used the Income Deprivation domain of the England Indices of Multiple Deprivation (IMD) 
2010 as a measure of socio-economic position. This is an ecological measure of deprivation at the 
small area level, and provides an approximate summary of income deprivation of individuals living 
within each area. It reflects a mixture of individual and contextual deprivation, and can highlight areas 
in which disadvantage may be concentrated.240 However, it does not fully represent the income 




The aim of my thesis was to investigate the role of comorbidity in socio-economic inequalities in 
ninety-day mortality among colon cancer patients. A limitation of the data I used for this research is 
that it did not provide information on detrimental lifestyle or behavioural factors that are more 
prevalent among the most deprived groups, are risk factors for some of the chronic conditions I 
studied as comorbidities (e.g. COPD or diabetes) and are associated with early mortality. Examples of 
such factors include tobacco smoking status, alcohol consumption, poor dietary habits and lack of 
physical activity. In my research the outcome of interest was all-cause ninety-day mortality, meaning 
that comorbid patients could have died from complications of their comorbidity or other reasons, 
rather than directly due to their cancer. Lifestyle factors such as tobacco smoking and poor diet are 
unlikely to confound the relationship between socio-economic position and all-cause ninety-day 
mortality, as it can be argued that they are on the causal pathway. For example, increased deprivation 
levels lead to increased prevalence of smoking, while smoking is associated with increased risk of 
mortality.  
 
The relationship between socio-economic position and increased short-term mortality following colon 
cancer diagnosis is complex, given that many prognostic factors in short-term mortality are also 
associated with socio-economic position, such as later stage at diagnosis,213 diagnosis via emergency 
presentation242 and increased comorbidity burden.127 An additional dimension to this relationship is 
provided by other variables associated with socio-economic position that can influence cancer 
diagnosis and prognosis. For example, the level of social support available to a patient or their beliefs 
about cancer risk or screening have been shown to be associated with lower uptake in routine cancer 
screening among people of lower socio-economic position.243 Barriers to presentation with cancer 
symptoms, such as lack of recognition of common symptoms or difficulties travelling to medical 
appointments, are more common among people living in more deprived areas.244 Furthermore, 
patient socio-economic position can influence clinical management decisions of physicians.245    
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My research considered comorbidities that had existed up to six years prior to cancer diagnosis, while 
patient deprivation group was based upon residential postcode at the time of cancer diagnosis. My 
research showed that the more deprived patients were more likely to have comorbidity.127 It is 
possible that the presence of pre-existing health conditions could influence the deprivation group 
patients are assigned to at cancer diagnosis. For example, a long-term health condition may prevent 
or limit the ability to undertake employment, which in turn could impact upon level of income and 
area of residence. However, as the presence of many common conditions is associated with lower 
socio-economic position,218, 246, 247 this scenario may be more likely to arise among people who are 
already experiencing some income deprivation, suggesting the effect on socio-economic position may 
be small. Another aspect of living with a long-term health condition that could influence income 
deprivation is the cost of treatment for the condition. Receiving treatment for a health condition is 
unlikely to have a substantial impact on income deprivation in England, where there is government-
funded universal healthcare free at the point of use. However, in countries where universal public 
healthcare is not available, medical debt (i.e. problems paying medical bills) from treatment for 
chronic health conditions can in some instances cause financial hardship.248 There is some evidence 
within the United States that medical debt may impact upon ability to access needed care,249 
suggesting that in such scenarios medical debt (and financial hardship) could be a potential mediator 
in the relationship between pre-existing health conditions and cancer.   
 
As my research investigated the influence of pre-existing comorbidity on ninety-day mortality 
following colon cancer diagnosis, it would have been useful to have information on other measures of 
patient health status. One such example would be patient performance status, which is a measure of 
health status represented by a score within a scale that defines a patient’s ability to perform certain 
activities of daily living (Appendix Table 4).250  
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The data I used were data of patients diagnosed with cancer between 2009 until 2013, thus my 
research is based on patients diagnosed with cancer between 7 and 11 years ago. While these do not 
represent the most recent data, other studies of cancer outcomes including patients with more recent 
diagnoses of cancer are still reporting the existence of socio-economic inequalities.251, 252  The findings 
of my research are therefore still applicable to the current time.   
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Implications of this research 
 
Health policy and practice 
 
Socio-economic position, multimorbidity and healthcare utilisation 
The findings of research highlighted the greater burden of comorbidity among the most deprived 
patients. I investigated pre-existing comorbidities recorded up to six years prior to cancer diagnosis, 
which meant that patients could have been living with these conditions for some time prior to being 
diagnosed with cancer. Within the context of existing evidence, these finding suggest that, even 
before the time of cancer diagnosis, the most deprived patients with comorbidity may already have 
complex healthcare needs as compared with the least deprived patients, particularly those patients 
with multiple comorbidities.  
Low socio-economic position is associated with an increased risk of adverse outcomes from several of 
the chronic conditions I studied as comorbidities.  For example, COPD patients of lower educational 
attainment and household income tended to have a greater risk of more severe disease, poorer lung 
function and physical functional limitations,253 while low socio-economic position is associated with 
an increased risk of cardiovascular disease mortality,254 a higher risk of readmission to hospital 
following a previous admission related to heart failure,255 and a higher rate of hospitalisation for COPD 
complications.256  
Furthermore, having multiple chronic conditions, or multimorbidity, is associated with a variety of 
outcomes including increased mortality and poorer quality of life,257, 258 poor functional status and 
adverse drug events.259 Patients with multimorbidity tend to have higher rates of healthcare 
utilisation.260-263 For example, patients with multimorbidity may have up to 2.5 times the GP 
consultations or hospital admissions of patients without multimorbidity.264 Moreover, a socio-
economic gradient has been reported in respect to healthcare utilisation among multimorbid 
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patients,225 with the most deprived having a larger number of healthcare consultations, hospital 
admissions,  longer hospital stays265-267 and unplanned admissions.268 General practitioners managing 
multimorbid patients in deprived areas of Scotland reported the needs of their patients as complicated 
and challenging, particularly where patients were dealing with difficult social and financial problems 
in addition to their health.269   
There is evidence within some healthcare systems that organisational interventions can improve 
outcomes among multimorbid patients.270 For example, a study conducted in the United States 
showed that coordination of care between primary care physicians, nurses and social workers 
involving a set of defined intervention activities for chronically ill older patients (home visits, 
formulation of a risk reduction plan, maintaining contact with the patient for monitoring purposes) 
led to a reduction in healthcare utilisation.271 Organisational interventions aimed at management of 
particular risk factors (such as healthcare utilisation) or areas where patients face challenges have 
been reported as being the most effective.270 Implementation of interventions offering broader-based 
support to patients with multimorbidity in deprived areas may help improve outcomes of the most 
deprived cancer patients with comorbidity or multiple comorbidities.  
 
Socio-economic position and stage of cancer diagnosis among patients with pre-existing comorbidities 
While low socio-economic position has been linked with increased comorbidity burden among cancer 
patients,93, 127 it is also associated with advanced stage of cancer at diagnosis.213 The relationship 
between comorbidity and cancer stage is complex: the presence of comorbidity may delay diagnosis 
due to masking cancer symptoms or interfering with diagnostic investigations128 or alternatively, result 
in an earlier diagnosis because of more frequent healthcare-seeking with the comorbidity.214, 227 
Studies in England have shown that the management of certain conditions, such as hypertension, may 
provide an opportunity for potential cancer symptoms to be discussed by patients or discovered by 
doctors and lead to an earlier cancer diagnosis.128, 272 Another study of patients with one of nine 
196
different types of cancer (breast, colon, rectum, liver, stomach, ovary, uterus, bladder or kidney) 
reported evidence that having diabetes with complications increased the odds for an early stage of 
cancer diagnosis by approximately 24% but also increased the odds of unknown stage by 
approximately 30%.228  
 
Diabetes is a known risk factor for developing colorectal cancers.31 In the United States, several studies 
have been conducted in the last two decades that investigate uptake of colorectal cancer screening 
among people with diabetes. Results of these studies have been mixed: one found that people with 
diabetes were not much more likely to receive screening than people without diabetes,273 while one 
reported that women with diabetes had 14% higher odds of receiving colorectal cancer screening than 
the women without.274 Another study in the United States reported that 39% of adults with diabetes 
were not up to date with the guideline-recommended colorectal cancer screening.275 Similarly, a 
recent study in England found that approximately 40% of adults with type 2 diabetes were not up-to-
date with their biennial colorectal cancer screening invitation.276  
The bowel screening programme in England is currently aimed at men and women aged 50-74 years. 
Uptake of colorectal cancer screening in England tends to be socially graded,277 for example, a 43% 
versus 57% uptake was reported among the most versus least deprived groups between 2010 and 
2015.278 Earlier research concluded that factors such as lack of social support and beliefs about cancer 
risk and screening may influence this social gradient.243 To address this, initiatives such as 
implementation of a colorectal health promotion campaign and targeted screening programme may 
be a practical step in aiming to detect colorectal cancer earlier among high risk groups or people within 
the screening age range living in deprived areas. 
 
Management of patients with multiple chronic diseases in the healthcare system 
Healthcare systems such as the National Health Service have historically tended to be based around 
single disease management, with highly specialized secondary care services.  As a result, patients with 
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multiple chronic conditions and more complex healthcare needs often receive duplicative and 
fragmented care.63, 279 In a study published in 2013, Hughes and colleagues reviewed five clinical 
guidelines of the UK’s National Institute of Health and Clinical Excellence (NICE) – an advisory body in 
the domain of health, public health and social care. They chose guidelines for five conditions that are 
common comorbidities. Their research found that comorbidity was inconsistently accounted for in 
these guidelines, ranging from being discussed extensively to not being mentioned at all.280 
Furthermore, patient centred care was discussed only in a generic context with limited 
recommendations for clinicians.280 
The consensus of opinion in the scientific literature advocates for a change in focus from treating 
single diseases to person-centred approaches to enable more effective management of people with 
multimorbidity.4, 64, 69, 279-282 A more optimal health care delivery would include integration and 
coordination across conditions as well as between clinicians and settings,69 and take factors such as 
patient age and socio-economic position into account.264 More recently in the UK there have been 
plans to move towards a more integrated care approach within the NHS. The NHS Five Year Forward 
View published in 2014 pledged to pledged to reduce barriers in the provision of care between 
different healthcare providers, for example, by delivering some services in specialist centres organised 
to support people with multiple health conditions as well as those with single diseases.283  
Given that certain chronic conditions share common risk factors with cancer, including older age, 
specialist centres that provide a multi-disciplinary approach to treating cancer alongside specific 
comorbidities may improve patient outcomes. For example, the common co-existence of cancer and 
cardiovascular diseases,284 and the complexities of managing both conditions at the same time,285 has 
led to the establishment of ‘cardio-oncology’ services in some NHS hospitals in England.  
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The impact of COVID-19 on cancer patients, diagnostic services and cancer care 
The COVID-19 epidemic in the United Kingdom has impacted the healthcare system and the delivery 
of cancer care.  At the time when the United Kingdom went into lockdown in March 2020, the 
healthcare provided by the National Health Service switched to being almost entirely focused on 
caring for patients with COVID-19. One impact of this has been some delays in patients being 
diagnosed with cancer. Because of measures put in place to restrict the spread of coronavirus, less 
face-to-face primary care consultations were taking place, and fewer urgent referrals to specialists for 
investigation of cancer symptoms (the “2-Week-Wait” referral pathway) were being made.286 The 
impact of delays in colorectal cancer diagnosis via the 2-week-wait pathway over a three-month 
lockdown has been predicted as a 10-16% reduction in 10-year net survival (depending on age group), 
equating to 981 lives lost.287 A further implication of the impact of COVID-19 on the healthcare system 
was that elective surgeries were suspended,288 which delayed many cancer surgeries. It has been 
predicted that a six-month delay in surgery for cancer of the colon or rectosigmoid junction would 
reduce 5-year net survival by up to 5% among patients with a stage 1 diagnosis and up to 30% among 
patients with a stage 3 diagnosis, depending on the age of the patient.289 
Cancer patients are vulnerable to COVID-19 infection as they are in an immunosuppressive state due 
to their malignancy and anticancer treatments.290 Moreover, cancer patients with comorbidity may 
also be at a greater risk of complications with COVID-19 due to their additional disease(s). COVID-19 
infection has led to increased COPD severity and mortality among people with COPD,291 while diabetes 
is a risk factor for poorer prognosis following infection with COVID-19.292 To date there is limited 
research on the impact of deprivation on the outcomes of cancer patients with a COVID-19 infection. 
However, more generally, an article currently under peer review reports a 2% increase in the COVID-
19 mortality rate for each percentage point increase in the proportion of the population in England 
experiencing income deprivation.293  
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The scientific evidence on the influence of the COVID-19 pandemic on cancer patient outcomes 
continues to grow. It is not yet known if the most deprived cancer patients have been more adversely 
impacted by the COVID-19 pandemic than the less deprived patients. However, the most deprived 
cancer patients with comorbidity and multiple comorbidities are likely to be among the groups most 
vulnerable to adverse outcomes following COVID-19 infection. The challenge for healthcare providers 




Points for consideration by health policy makers and health service managers  
The findings of this research may be useful to health policy makers and health service managers, 
specifically when drafting guidelines or policy focused on mitigating inequalities in access to health 
care and inequalities in health outcomes. Table 6.1 summarises points for consideration.   
 
Table 6-1 Points for consideration by health policy makers and health service managers  
Finding For consideration 
Higher prevalence of 
comorbidity and multiple 
comorbidity among the 
most deprived cancer 
patients 
Clinical guidelines include clear advice on dealing with common comorbidities, 
and on managing common concomitant conditions in parallel. 
 
Multi-disciplinary approach for the management of cancer with other chronic 
conditions, to improve outcomes among multimorbid cancer patients. 
Targeted interventions to reduce prevalence of chronic disease / 
development of further chronic diseases among at-risk patients living in 
deprived areas, for example, smoking cessation programmes. 
Support for patients with chronic health conditions who are living with mental 
health conditions or facing social challenges that may compromise their ability 
to manage their (physical) health (e.g. supporting patients in tandem with 
Adult Social Care teams).  
Stage at diagnosis and 
surgical treatment received 
may contribute towards 
socio-economic 
inequalities in short-term 
mortality among colon 
cancer patients  
Targeted screening for those clinically at risk of developing colorectal cancer / 
with existing chronic conditions / from deprived areas, to facilitate earlier 
cancer diagnosis and improved prognosis 
Targeted health promotion campaigns to raise awareness of bowel cancer 
health and cancer symptoms  
Policy focused on ensuring equality in access to health care, specifically in 
regard to:  
 Access to specialised clinicians / surgeons  
 Support provided following cancer diagnosis and in preparation for 
treatment 





inequalities in short term 
mortality following colon 
cancer diagnosis 
Healthcare usage of the most deprived patients with pre-existing chronic 
diseases provides opportunity for early discussion of cancer symptoms, and 






Benefit of wider registration of common chronic diseases in England 
A finding of my research was that there was limited publicly available information on the English 
national prevalence of several of the chronic conditions I studied, either from government sources or 
within the scientific literature. Moreover, certain comorbidities that I studied, such as diabetes, may 
be underreported in hospital admissions data - a commonly used source of information on 
comorbidity. The World Health Organisation advocates for patient registries in disease management, 
to facilitate the provision of the necessary continuity of care for chronic diseases.294 Registries also 
facilitate public reporting and retrospective or prospective research,295 and have been shown to 
improve patient outcomes and processes of care.295-297  
When conducting epidemiological studies of comorbidity among cancer patients, it would be 
beneficial to have access to data from population-based disease registries to capture information on 
co-existent diseases among patients. This would provide a comprehensive source of information on 
specific chronic conditions and provide details that it may not be possible to verify from administrative 
data (for example, date of diagnosis). These data can also be used to validate the prevalence 
information captured in administrative data sources. Wider registration of common chronic diseases 
and accessibility to the data collated would facilitate more detailed epidemiological investigations into 




Next steps and suggested further research 
 
The findings of my research suggested that healthcare utilisation prior to cancer diagnosis may have 
contributed toward socio-economic differences in ninety-day mortality among patients with pre-
existing diabetes, COPD or cardio-vascular comorbidities. Further research into patterns in hospital 
healthcare utilisation with these and other pre-existing comorbidities, according to deprivation group 
and stage of cancer diagnosis, may help to unravel the mechanisms behind these findings. In 
particular, it would be useful to ascertain whether there are differential patterns in healthcare 
utilisation and in availability of resources, whether time spent in hospital with pre-existing conditions 
is influential in the stage at which cancer is diagnosed and the treatment received following cancer 
diagnosis, and whether this differs according to deprivation group.    
 
My research focused on physical comorbidities among cancer patients. Research to investigate the 
influence of mental comorbidities, either alone or in combination with physical comorbidities, may 
help to further disentangle the role of comorbidity in socio-economic inequalities in cancer outcomes. 
Studies of patients in Scotland highlighted that mental-physical multimorbidity was common,264 
associated with socio-economic deprivation,64 and that this combination of co-existing conditions 
presented the biggest burden to the most deprived patients in terms of managing their own health.269 
 
Further research examining longer-term outcomes of cancer patients may also be insightful in better 
understanding the mechanism between comorbidity, socio-economic position and cancer prognosis. 
While socio-economic inequalities in mortality tend to be more evident in the short-term after 
cancer diagnosis12 it would be interesting to understand whether these inequalities persist longer-





The role of comorbidity in socio-economic inequalities in short-term mortality among colon cancer 
patients is complex. Using cancer registry data linked with other population-based data sources I was 
able to examine different dimensions of comorbidity and its relationship to socio-economic position 
and short-term mortality among colon cancer patients.  
My research emphasised the increased burden of comorbidity among the most deprived cancer 
patients. I have shown an association between increased levels of deprivation and the prevalence of 
most of the comorbid conditions I studied, and the prevalence of multiple comorbidity. This study 
added to the existing scientific literature by exploring the associations between sociodemographic 
factors and the prevalence of specific comorbidities among four large population-based cohorts of 
cancer patients in England.  
The results of my research showed that the most deprived colon cancer patients consistently had 
poorer short-term mortality then the least deprived patients, even after adjusting for patient age, 
stage at diagnosis, Charlson comorbidity score and receipt and presentation for surgical treatment.  
Inequalities in ninety-day mortality were evident among patients with the same levels of comorbidity. 
Among patients with the higher Charlson comorbidity score the magnitude of the inequalities was 
influenced by the status of other prognostic factors, widening with advanced stage, age and receiving 
emergency surgery. This suggested that some (potentially unmeasured) aspect of living with or 
managing comorbidity or the cancer was leading to more adverse short-term outcomes for the most 
deprived patients.  
Exploring this further by examining comorbidity at a more granular level, my findings suggested that 
accounting for time with a specific comorbidity and differential patterns in healthcare utilisation prior 
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to cancer diagnosis reduced some of the differences in ninety-day mortality between the most and 
least deprived groups of colon cancer patients with diabetes, COPD or cardio-vascular conditions.  This 
may possibly reflect greater comorbidity severity or more complex healthcare needs among the most 
deprived patients. However, even after accounting for the presence of comorbidity and other 
dimensions of living with a comorbidity prior to cancer diagnosis, the socio-economic inequalities in 
ninety-day mortality among comorbid patients persisted. These findings suggested other factors, 
rather than the direct influence of comorbidity, may be contributing towards these inequalities.  
The growing prevalence of multimorbidity and the burden of comorbidity among cancer patients 
highlights the need for healthcare systems designed and equipped to manage multiple chronic 
conditions simultaneously. Undertaking a multi-disciplinary approach to treating cancer alongside 
other chronic diseases may improve treatment options and outcomes of the most deprived patients, 
who are those most likely to be living with comorbidity or multiple comorbidity.  
Further investigation of hospital healthcare utilisation according to patient deprivation group may 
provide insights into opportunities to improve outcomes of the more deprived groups living with 
chronic diseases who go on to develop colon cancer. Mechanisms to be explored include the interplay 
between deprivation, pre-existing chronic disease(s), stage at cancer diagnosis and options for 
treatment of cancer. One example of this would be targeted colorectal cancer screening of at-risk and 
disadvantaged groups seeking healthcare for specific chronic diseases, to facilitate earlier stage cancer 
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Appendix Table 1: The prevalence (%) of thirteen comorbid conditions among colorectal cancer patient cohorts identified from the scientific literature
Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported
Liver disease
Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
1.4%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years Mild liver disease: 0.6%
Moderate / severe liver 
disease: <0.1%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data












Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
Mild liver disease: 1.6%
Moderate / severe liver 
disease: 0.9%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
Mild liver disease: 0.3%
Moderate / severe liver 
disease: 0.2%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 




Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
17.8%
Frederiksen et al. 2009 Denmark Retrospective 
cohort
Colorectal 2001-2004 Patients diagnosed with 
adenocarcinoma of the colon or 
rectum in Denmark
Hospital records and files of the 
Register of Medicinal Product 
Statistics, which contains 
information on the sales of 
pharmaceutical products in 
Denmark
8,763 Median age 69 years, 
interquartile range 61-76 
years
8.0%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years Diabetes (without chronic 
complication): 2.7%
Diabetes with chronic 
complications: 0.2%




Colorectal 2007 Patients of Mayo Clinic Medical records 100 Range not reported, mean 
71.6 (+/-9.4) years
19.0%
Ahmadi et al. 2014 Iran Prospective 
cohort
Colorectal 2006-2011 Patients from 10 gastrointestinal 
clinics
Blood test for Type 2 Diabetes at 
time of enrollment
1,127 Range not reported, mean 
53.4 (+/-14.3) years
8.7% (95%CI: 7.0-10.7%)
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data










Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported




Colorectal 2005-2011 Patients treated at a Cancer 
Centre
Diabetes treatment information in 
patient oncology consult notes
1,304 24-98 years, median 71.2 
years
21.2%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
Diabetes (without end-organ 
damage): 16.1%
Diabetes (with end-organ 
damage): 1.0%
Cuthbert et al. 2018 Alberta, Canada Cohort Colorectal 2004-2015 Patients recorded in cancer 
registry data
Inpatient hospital data and 
physician billing claims
12,265 Range not reported, mean 
71.6 (+/-9.4) years
14.0%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis




Diabetes with complications: 
4.9%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded > 6 
months prior to cancer diagnosis) 




Haydon et al. 2006 Australia Prospective 
cohort
Colorectal 1990-2002 Melbourne Collaborative Cohort 
Study participants diagnosed with 
colorectal cancer between 
recruitment and August 2002
Body measurements at time of 
recruitment to study
526 42-79 years, median 66.8 
years
Body mass index >30: 24%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 0.4%
Yang et al. 2012 United States 
(California, 
Connecticut, Detroit, 
Hawaii, Iowa, New 
Mexico, Seattle, 






Colon 1999 - 2004 Patients recorded in cancer 
registry data
Medicare claims from 12 months 
before to 3 months after cancer 
diagnosis
36,079 66+ years 4.3%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 1.9%
Rectal: 1.8%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis




Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
3.2%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 1.0%
224
Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 1.8%
Rectal: 1.4%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
0.6%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
1.7%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 








Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 0.8%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data











Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
0.3%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
0.5%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 




Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
10.3%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 2.9%
Ahmadi et al. 2014 Iran Prospective 
cohort
Colorectal 2006-2011 Patients from 10 gastrointestinal 
clinics
Test for hypertension at time of 
enrollment
1,127 Range not reported, mean 
53.4 (+/-14.3) years
13.4% (95%CI: 11.1-15.8%)
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 5.1%
Rectal: 3.8%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
2.3%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis




Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 








Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 20.0%
Yang et al. 2012 United States 
(California, 
Connecticut, Detroit, 
Hawaii, Iowa, New 
Mexico, Seattle, 






Colon 1999 - 2004 Patients recorded in cancer 
registry data (SEER)
Medicare claims from 12 months 
before to 3 months after cancer 
diagnosis
36,079 66+ years 76.0%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Primary hypertension
Colon: 16.6%
Rectal: 12.9%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis




Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
Chronic renal failure: 2.4%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 1.6%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Chronic renal disease
Colon: 4.6%
Rectal: 3.5%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
4.1%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
Moderate or severe renal 
disease: 5.5%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 





Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 2.6%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 5.8%
Rectal: 4.7%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
3.0%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
2.6%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 
1,061 24-97 years, mean 69.8 (+/- 
12.7) years
6.3%
Chronic Obstructive Pulmonary Disease
Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
20.9%
Frederiksen et al. 2009 Denmark Retrospective 
cohort
Colorectal 2001-2004 Patients diagnosed with 
adenocarcinoma of the colon or 
rectum in Denmark
Hospital records and files of the 
Register of Medicinal Product 
Statistics, which contains 
information on the sales of 
pharmaceutical products in 
Denmark
8,763 Median age 69 years, 
interquartile range 61-76 
years
11.0%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years Chronic pulmonary disease: 
7.9%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Chronic pulmonary disease
Colon: 6.3%
Rectal: 5.7%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
Chronic pulmonary disease: 
14.4%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
12.1%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 




Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis




Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 3.7%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 5.8%
Rectal: 3.3%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
4.5%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
10.8%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 





Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
6.7%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 1.7%
Sarfati et al. 2014 New Zealand Retrospective 
cohort
Colon and rectal July 2006 - June 2008 Patients recorded in cancer 
registry data




25+ years Colon: 3.5%
Rectal: 2.3%




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
3.8%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
5.3%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 





Gross et al. 2006 United States Retrospective 
cohort
Colorectal 1993 - 1999 Patients with stage 1 - 3 
colorectal cancer, recorded in 
cancer registry data (SEER)
Medicare (inpatient, outpatient and 
physician) claims data from 2 years 
prior to 60 days after cancer 
diagnosis
29,733 67-99 years, mean 77.8 
years
2.4%




Colorectal 1997-2004 Patients recorded in cancer 
registry data
Hospital admissions 18 to 6 months 
prior to cancer diagnosis
29,563 15-99 years 0.8%
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Condition Location of study Study type Colon or colorectal 
cancer
Timeframe of cancer 
diagnosis
Study population Source of information on 
comorbidity
N Patient age Prevalence reported




Colorectal 2000-2014 Patients recorded in cancer 
registry data
Hospital electronic health record - 
report closest to date of cancer 
diagnosis
2,670 Range not reported, mean 
71 (+/- 12) years
0.6%
Mehta et al. 2018 Texas, United States Retrospective 
cohort
Colorectal 2005 - 2011 Patients recorded in cancer 
registry data (SEER)
Medicare (inpatient and outpatient) 
claims data from 1 year to 30 days 
prior to cancer diagnosis
16,693 65+ years, mean 77.2 (+/- 
7.3) years
Connective tissue disease / 
rheumatologic disease: 1.8%
Luque-Fernandez et al. 
2020
Girona and Granada, 
Spain
Cross-sectional Colorectal 2011 Patients recorded in cancer 
registry data
Spanish Primary Care Clinical 
database (conditions recorded 
within 6 months cancer diagnosis 
excluded) 




Appendix Table 2: The reported prevalence of thirteen health conditions in England or the United Kingdom
Condition Reported prevalence Population Country Year(s) Data / Source Obtained from
Liver Disease
Liver disease Only incidence information available: 
Age-standardised rate of hospital admissions 
due to liver disease: 131.2 per 100,000 persons
(England) England 2016 - 2017 Hospital Episode Statistics
(Office for National Statistics 2011 
census, mid year population estimates)








Type 1 or Type 2 Diabetes 5% People aged 20-79 years (UK) UK 2015 OECD Health at a Glance 2017
(Data obtained from International 
Diabetes Federation Atlas, prevalence 



















Obesity 24.0% men, 24.4% women People aged 16+ years (England) England 2004 Health Survey for England Zaninotto et al (2009)
Dementia
Dementia 4.3% People aged 65+ years (England) England Six-monthly trends 
reported:
Sept 2015 to Sept 
2017
GP practice data / Quality and 
Outcomes Framework
PHE: "Recorded prevalence" using 







Dementia Estimated 767,000 (95% uncertainty interval 
735,000 to 797,000): 
(i.e. approximately 1.3% of this population)




Condition Reported prevalence Population Country Year(s) Data / Source Obtained from
Cerebrovascular Disease (CVD)








Hypertension 23.60% People aged 16+ years (England) England 2014 Quality and Outcomes Framework and 
Health Survey for England
National Cardivascular Intelligence 












Chronic kidney disease 6.1% [95% credible intervals: 5.3, 7.0] 
(estimated)
People aged 16+ years (England) England 2009-2011 Health Survey for England (HSE), 2011 
Census, and 2011 Office for National 






Moderate to severe chronic 
kidney disease
5.50% (England and Wales) England and Wales April 2015 - June 
2016
Clinical Practice Research Datalink National CKD Audit (QMUL / LSHTM 
/ UCL / Informatica)
Stages 3-5 chronic kidney 
disease
4.30% People aged 18 + years (England) England 2009-2010 Quality and Outcomes Framework NHS publication: Chronic Kidney 















MI / Heart attack Only incidence information available: 
198k heart attack hospital visits 2015-2017
(England) UK 2015-17 Hospital Episode Statistics British Heart Foundation (BHF) 
website 
(CVD Statistics - BHF UK Factsheet)
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Condition Reported prevalence Population Country Year(s) Data / Source Obtained from
MI Only event rate information available:
(standardised to European standard 
population)
Men: 154 per 100,000 population (95%CI 153 
to 155)
Women: 66 per 100,000 population (95%CI 
65.3 to 66.7)
(England) England 2010 Hospital Episode Statistics Smolina et al (2012)
Chronic Obstructive Pulmonary Disease (COPD)
COPD 2.57% (total population)
4.56% (people aged ≥35 years) 
(England) England 2016 Royal College of General Practitioners 
Research and Surveillance Network 
(RCGP RSC) database
Rayner et al (2017)
COPD 3.50% People aged >15 years (England) England 2001 Health Survey for England Nacul et al (2011)
Congestive Heart Failure (CHF)
CHF 1.40% (UK) UK 2014 Clinical Practice Research Datalink and 
Hospital Episode Statistics
Conrad et al (2018)








Symptomatic peripheral arterial 
disease 3.4% (2000) and 2.4% (2014)
(UK)
UK 2000 and 2014
The Health Improvement Network 
database Cea-Soriano et al (2018)











Systemic lupus erythematosus 97.04/100,000 person years (95% CI: 94.18 to 
99.9)
(UK) UK 1999-2012 Clinical Practice Research Datalink Rees et al (2014)
Polymyalgia rheumatica Point prevalence 0.87% (2011) People aged 40+ years (UK) UK 2011 Clinical Practice Research Datalink Partington et al (2018)
Abbreviations: CKD - Chronic kidney disease; CVD - Cardiovascular disease; GP - General Practice; LSHTM - London School of Hygiene and Tropical Medicine; NHS - National Health Service;
OECD - Organisation for Economic Co-operation and Development; PHE - Public Health England; QMUL - Queen Mary University London; UCL - University College London; UK - United Kingdom
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Condition Crude Adjusted (95% CI) Crude Adjusted (95% CI) Crude Adjusted (95% CI)
Liver disease 1.94 1.84 (1.66, 2.02) 2.26 2.45 (2.12, 2.78) 1.33 1.34 (1.07, 1.61)
Diabetes 10.64 5.30 (5.08, 5.52) 11.23 5.40 (5.08, 5.72) 5.71 5.36 (4.83, 5.88)
Obesity 2.49 2.27 (2.07, 2.46) 2.26 2.27 (1.94, 2.59) 2.41 2.51 (2.13, 2.89)
Dementia 1.89 0.50 (0.47, 0.53) 2.64 0.69 (0.66, 0.71) 0.43 0.40 (0.26, 0.55)
Hemiplegia or paraplegia 0.96 0.50 (0.43, 0.58) 1.60 1.04 (0.85, 1.23) 0.53 0.51 (0.34, 0.68)
Cerebrovascular disease 4.59 1.58 (1.50, 1.66) 7.58 3.49 (3.20, 3.78) 2.02 1.83 (1.53, 2.13)
Hypertension 38.98 16.60 (16.30, 16.90) 42.70 18.69 (18.18, 19.19) 16.01 15.20 (14.31, 16.10)
Renal disease 4.63 1.53 (1.45, 1.62) 6.02 2.10 (1.91, 2.29) 2.45 2.24 (1.90, 2.57)
Myocardial infarction 3.71 1.26 (1.20, 1.32) 5.86 2.46 (2.28, 2.64) 1.67 1.49 (1.22, 1.76)
Chronic obstructive pulmonary disease 13.20 9.96 (9.54, 10.37) 33.66 24.59 (23.61, 25.58) 10.34 10.21 (9.47, 10.95)
Congestive heart failure 4.52 1.43 (1.36, 1.50) 6.73 2.55 (2.34, 2.75) 1.79 1.57 (1.30, 1.85)
Peripheral vascular disease 3.48 1.17 (1.10, 1.24) 7.99 2.97 (2.79, 3.15) 1.47 1.30 (1.05, 1.55)
Rheumatological conditions 2.01 1.00 (0.90, 1.09) 3.49 2.11 (1.86, 2.35) 2.32 2.40 (2.03, 2.76)
Abbreviations: CI - confidence interval
Colorectal Lung Hodgkin Lymphoma
Cancer
Appendix Table 3: The crude and age-sex adjusted prevalence (%) of thirteen condition health conditions among patients diagnosed with colorectal cancer, lung cancer or 
Hodgkin Lymphoma in England between 2009-2013
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Appendix Table 4 - Performance Status Scales (the Zubrod Scale and the Karnofsky Scale) 
 
Two commonly used Performance Status scales are the Zubrod Scale and the Karnofsky 
scale.  
Zubrod Scale Karnofsky Scale 
0 Normal activity 100 Normal; no evidence of disease 
90 Able to perform normal activities 
with only minor symptoms 
1 Symptomatic and ambulatory; 
cares for self 
80 Normal activity with effort; 
some symptoms 
70 Able to care for self but unable to 
do normal activities 
2 Ambulatory >50% of time; 
occasional assistance 
60 Requires occasional assistance; 
cares for most needs 
3 Ambulatory ≤50% of time; 
nursing care needed 
50 Requires considerable assistance 
40 Disabled; requires special assistance 
30 Severely disabled 




Source: West and Jin (2015), JAMA Oncology  
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Appendix Figure 1: Flow diagram to show the process followed by the stage algorithm to 
derive the overall grouped TNM stage at diagnosis variable, based upon individual 
components of tumour (T), nodes (N) and metastases (M) 
 
  M 
T = 1 or 2 
M = 1 
N = 1 or 2 M = 0 
N = 0 T = 3 or 4 
Stage = 4 
Stage missing 
Stage = 1 
Stage = 2 












Source: Benitez-Majano et al. (2016) British Journal of Cancer 
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Appendix A: The domains of the England Indices of Multiple Deprivation (IMD) 2010 
 
The seven domains of the England IMD 2010 (and their respective weights)80: 
 Income Deprivation (22.5%) 
 Employment Deprivation (22.5%) 
 Health Deprivation and Disability (13.5%) 
 Education, Skills and Training Deprivation (13.5%) 
 Barriers to Housing and Services (9.3%) 
 Crime (9.3%) 
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